SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions December patent applications/inventions, industry category 12/11

20110318264 - Methods and compositions for diagnosis and treatment of cancer: The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of colorectal, in particular colonic, and gastric tumor tissues and colorectal, in particular colonic, and gastric tissues, and which represent targets for therapy or diagnosis of such tumor diseases in a subject.... Agent:

20110318265 - Coupled identification and treatment of cancer: Provided are methods to treat cancer in which a patient is identified as having gallium-avid cancer by use of a gallium scan or other means, and is then treated with a pharmaceutically acceptable gallium composition.... Agent:

20110318266 - Phthalimide derivative metabotropic glutamate r4 ligands: Disclosed are mGluR4 positive allosteric modulator ligands of general formula (I) and radiolabeled derivates, their use as therapeutic agents for the treatment of central nervous system disorders modulated by mGluR4 and as ligands for the labeling and diagnostic imaging of mGluR4 in mammals.... Agent:

20110318270 - Drug identification protocol for type 2 diabetes based on gene expression signatures: It relates generally to the field of drug identification and evaluation and therapeutic optimization. More particularly, it provides a protocol for identifying compounds useful in the treatment of TNFα associated diabetes or a condition associated with diabetes based on a signature of genomic or proteomic expression. Diagnostic and prognostic protocols... Agent: Verva Pharmaceuticals Ltd

20110318268 - Herpes simplex virus (hsv) with modified tropism, uses and process of preparation thereof: A modified Herpes Simplex Virus (HSV), which has a portion of gD (glycoprotein D) of the glycoproteic envelope deleted and a heterologous single chain antibody inserted in place of such deleted portion; the modified HSV is capable of infecting cells through receptor HER2/ErbB2 but not through receptors HVEM/HveA and nectin1/HveC;... Agent:

20110318269 - Method for screening phage display libraries against each other: The present invention relates to a method for screening phage display libraries against each other. In particular, the invention relates to a method for screening at least two phage display libraries against each other to identify and/or select one or more interacting binding partners or binding molecules making up such... Agent: Nextera As

20110318267 - Ph-responsive nanostructures: The present invention relates to compositions comprising stimuli-responsive materials which can be used for delivery of agents. Materials are provided that can respond to changes in a surrounding environment, including changes in ion concentration. For example, one or more properties of the material may be affected by a change in... Agent: President And Fellows Of Harvard College

20110318271 - Arginase inhibitors for the treatment of depression: The subjects of the current invention are compounds, which exhibit arginase inhibiting activity (including difluoromethylornithine (DFMO) and L-norvaline, but not limited to them), and which can be used as therapeutically active agents for the treatment and prevention of depression and/or depression-related conditions. Other subjects of the present invention are the... Agent: University Of Tartu

20110318272 - Pesticidal mixtures giving synergistic pesticidal effects: Compositions and methods are provided for synergistic pesticidal mixtures comprising a first pesticidal composition and a second pesticidal composition, wherein the pesticidal activity of the mixture exhibits synergistic effects compared with the expected effects of the mixtures based on the sum of the activity of the first pesticidal composition alone... Agent: Arysta Lifescience Corporation

20110318275 - Multifunctional contrast agent using biocompatible polymer and preparation method: The present invention relates to a biocompatible contrast agent and a method of its preparation. More particularly, the present invention relates to a multifunctional contrast agent manufactured by prepairing a novel polysuccinimide-based polymer by introducing an alkanolamine group to the main group of the polysuccinimide in addition to a biocompatible... Agent: Korea Research Institute Of Chemical Technology

20110318273 - Fluorescent contrast agents: The invention relates to contrast agents for imaging of diseases associated with inflammations. More specifically the invention provides optical imaging contrast agents for imaging of activated leukocytes and methods for imaging of such. The contrast agent changes its fluorescent properties upon reaction with oxidants produced by the activated leukocytes.... Agent: Ge Healthcare As

20110318274 - Variant of mite allergen and uses thereof: The present invention relates to a new variant of the group 2 allergen from the house dust mite Dermatophagoides pteronyssinus, named Der p 2 variant, and uses thereof. The new variant exhibits cDNA and protein sequence diversity from other known Der p 2 variants.... Agent:

20110318276 - Aerosol composition with enhanced dispersion effects: A stable, high VOC, single phase, non-aqueous liquid aerosol composition having enhanced dispersion based on reduced particle size and increased evaporation rate to result in improved active ingredient dispersion, slower settling in air and less residue on surfaces. The composition includes at least one hydrocarbon propellant, at least one active... Agent: S.c. Johnson & Son, Inc.

20110318278 - Foamable suspension gel: The present subject matter provides foamable suspension gels that foam after release from a container. The foamable suspension gels contain at least one pharmaceutically active agent that is sparingly soluble to insoluble in water, a second pharmaceutically active agent, and optionally a third active agent.... Agent: Stiefel Research Australia Pty Ltd

20110318277 - Tacrolimus compositions for aerosol administration: The present disclosure relates generally to highly concentrated macrolide solutions for aerosol administration, and related methods of producing and administering the same. In one aspect, provided herein is a receptacle containing a highly concentrated solution of a macrolide compound such as tacrolimus, where the solution exhibits long-term stability in a... Agent: Apt Pharmaceuticals, Inc. University Of Maryland, Baltimore

20110318279 - Polymeric masticatory masses for cosmetic products: The invention relates to novel masticatory masses for oral hygiene, made from foamed synthetic polymers, a method for production and use thereof.... Agent: Bayermaterialsecience Ag

20110318280 - Polymeric anti-microbial agents: Polymeric anti-microbial agents produced by substituting the nitrogen atoms in the backbone of ethylenimine polymers, for example, substitution with aralkyl groups, are provided. The agents are believed to have low human toxicity while being effective against a variety of pathogens and are useful in applications involving human contact, such as... Agent:

20110318281 - Lactobacillus salivarius sg-m6 for improving oral bacterial groups and health care compositions thereof: This invention provides to a strain of Lactobacillus salivarius SG-M6 with deposit number of CGMCC NO. 3505 and a fermentation product thereof. The present invention also provides a health composition for improving oral bacteria population, which comprises the Lactobacillus salivarius SG-M6 or the fermentation product thereof. The health care composition... Agent: Syngen Biotech Co., Ltd.

20110318282 - Composition and method for reducing demineralization of teeth: A human oral care composition, includes safe and effective amounts of the fluoride ion and stabilized chlorine dioxide, that may take the form of a paste, gel, rinse, spray, powder, varnish or similar that reduces demineralization and promotes remineralization of teeth. The method includes the topical application of the composition... Agent: Micropure, Inc.

20110318283 - Use of antibacterial compounds for the oral cavity hygiene: h

20110318284 - Novel sirtuin 6 activating peptides and cosmetic or pharmaceutical composition containing them: The present invention relates to sirtuin 6 activating peptides, derived from highly conserved regions of human SIRT proteins, and to a cosmetic or pharmaceutical composition comprising at least one sirtuin 6 activating peptide in a physiologically acceptable medium. The invention further relates to the utilization of a cosmetic composition to... Agent: Isp Investments Inc.

20110318285 - Personal care composition additive for application on keratin substrates to provide long lasting benefits: The present invention relates to a personal care composition additive for use on keratin substrates in order to provide long lasting benefits to the keratin substrate such as in conditioning systems, such as 2/1 shampoo's, leave-on and rinse off conditioners, for hair and skin, or for imparting greater water resistance... Agent: Hercules Incorporated

20110318286 - Spf enhanced extended color bulk powders and methods of making thereof: This application discloses, among other things, extended color bulk powders and partially and dispersions and methods of making thereof. Fully and partially extended color powders and fully and partially extended color dispersions can be used in cosmetic and makeup products, personal care products, and pharmaceutical products.... Agent: Us Cosmetics Corporation

20110318287 - Anti-fungal nail polish: A premium, colored, acrylic nail polish or lacquer combined with at least one FDA-approved antifungal agent for the purpose of providing an attractive nail coating with antifungal properties.... Agent: Alde Associates, LLC

20110318288 - Cosmetic composition for skin whitening comprising the extract of magnolia sieboldii as active ingredient: Disclosed herein is a skin-whitening cosmetic composition comprising an extract of Magnolia sieboldii as an active ingredient. The Magnolia sieboldii extract has an excellent effect of inhibiting tyrosinase activity and melanin production, and the cosmetic composition comprising the Magnolia sieboldii extract as an active ingredient has an excellent skin-whitening effect.... Agent: Coreana Cosmetics Co., Ltd.

20110318290 - Compounds and methods for inhibiting axillary malodour: Enzymes mediating in the release of compounds characteristic of human malodour and in particular axillary malodour, and compounds that inhibit said enzymes having the general formula (I)... Agent: Givaudan Sa

20110318289 - Methods and compositions for reducing body odor: The invention relates to biocontrol bacteria and related methods and compositions for control of body malodor-causing bacterial species or the production of odor-causing substances by such organisms.... Agent: Novozymes Biologicals, Inc.

20110318291 - Trehalose-containing topical drying composition and method of using same: e

20110318292 - Environmentally benign plasticizers based on derivatives of acetone: Compounds derived from acetone are provided. Particularly, the compounds are derivatives of hydroxyacetone, including dimers of both 1-hydroxyacetone and 1,3-dihydroxyacetone. The hydroxy moieties on the core hydroxyacetone molecule serves as an attachment point for a variety of moieties (e.g., ethers, esters, phosphorous containing, or nitrogen containing) that are selected to... Agent: Boston Polymer LLC

20110318295 - Oil-in-water emulsion-type hair cosmetic: m

20110318294 - Phosphorous-containing surfactants as polymeric cationic compound deposition aids: Personal care products exhibiting superior conditioning and/or color fastness can be obtained by use of mixtures of certain phosphate esters and polyquats.... Agent: Croda, Inc.

20110318293 - Hair preparation comprising royal jelly: Agent for changing the color and/or permanently changing the shape of keratinic fibers, wherein the agent contains in a cosmetic carrier at least one color- and/or shape-changing component as well as an animal-based care agent, in particular royal jelly, in combination with a polyalkoxylated fatty substance. The agents are suitable... Agent:

20110318296 - Solid air freshener: The present invention relates to a solid air freshener comprising the following components: i) a total amount of polyethylene glycols in the range of from 30 to 80 Wt.-%, wherein the weight average molecular weight Mw of the total amount of polyethylene glycols present in the solid air freshener is... Agent: Symrise Gmbh & Co. Kg

20110318297 - Single protein nanocapsules for protein delivery with long-term effect: A protein nanocapsule having a single-protein core and a thin polymer shell anchored covalently to the protein core.... Agent: The Regents Of The University Of California

20110318298 - Viral infection therapeutic drug containing polyalkyleneimine: Methods for administering a polyalkyleneimine to treat or prevent a viral infection, inactivate a virus, inhibit viral adsorption to a cell, and inhibit viral invasion of a cell are presented.... Agent: Nippon Shokubai Co., Ltd.

20110318302 - Cancer treatment: The invention relates to the treatment of cancer, e.g. kidney cancer, using chemotherapeutic agents and immunocytokines, in particular immunocytokines which bind to the Extra Domain-A (ED-A) isoform of fibronectin.... Agent:

20110318299 - Composition for accelerating nerve repair: The present invention discloses a composition for accelerating nerve repair. The composition comprises platelet-rich fibrin, a growth factor and a cytokine. The composition may further comprise a tissue with a stem cell or a neural tube to be a scaffold for promoting nerve generation. The platelet-rich fibrin is obtained from... Agent: Taipei Medical University

20110318304 - Detection of epha3 as a marker of the presence of a solid tumor: The invention provides methods and compositions for detecting non-hematopoietic, non-tumor EphA3-expressing cells in cancer patients and for monitoring the prognosis of patients using EphA3.... Agent:

20110318303 - Il-10 and methods of treating ocular and other diseases: Disclosed herein TPV1 is a method of treating ocular and systemic conditions by administering IL-10 and TPV134R polypeptides.... Agent: Allergan, Inc.

20110318301 - Il-17a/f heterologous polypeptides and therapeutic uses thereof: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present... Agent:

20110318300 - User of interleukin-1 conjugates in the treatment of diabetes: The invention provides compositions, pharmaceutical compositions and vaccines for the treatment, amelioration and/or prophylaxis of diabetes, preferably of type II diabetes. The compositions, pharmaceutical compositions and vaccines of the invention comprise a core particle and an antigen, wherein said antigen comprises an interleukin-1 (IL-1) molecule. When administered to an animal,... Agent: Cytos Biotechnology Ag

20110318305 - Substituted pyridine and pyrimidine derivatives and their use in treating viral infections: The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R1, X, Y, Z, R2, R3, R4, R5, R6, R7, R8, R9, R18, R19 and n is selected independently and... Agent:

20110318306 - Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology: The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers... Agent: Ibc Pharmaceuticals, Inc.

20110318308 - Lipocalin-type prostaglandin d2 synthase as a biomarker for lung cancer progression and prognosis: A PGD(2) receptor (DP) deficiency enhances tumor progression accompanied by abnormal vascular expansion. In tumors, angiogenic endothelial cells highly express DP receptor, and its deficiency accelerates vascular leakage and angiogenesis. Administration of a synthetic DP agonist, BW245C, markedly suppresses tumor growth as well as tumor hyperpermeability in WT mice, but... Agent: Winthrop-university Hospital

20110318307 - Xiap therapy: The invention features methods, compositions and kits for the treatment of retinal degenerative disorders.... Agent:

20110318318 - Anti-apoptotic fusion proteins: The present invention relates to a fusion protein comprising a protein transduction domain capable of introducing the fusion protein into a mammalian cell and an anti-apoptotic protein comprising the amino acid of the sequence of SEQ ID NO:1 or an anti-apoptotically active variant or fragment thereof. The invention also relates... Agent:

20110318316 - Chinese hamster apoptosis-related genes: Provided is an isolated polypeptide comprising a Cricetulus griseus sequence capable of mediating apoptosis of a cell, the sequence being selected from a FAIM sequence shown as SEQ ID NO: 1; a FADD sequence shown as SEQ ID NO: 2; a PDCD6 sequence shown as SEQ ID NO: 3; and... Agent: Agency For Science, Technology And Research

20110318317 - Chinese hamster apoptosis-related genes: Provided is an isolated polypeptide comprising a Cricetulus griseus sequence capable of mediating apoptosis of a cell, the sequence being selected from a FAIM sequence shown as SEQ ID NO: 1; a FADD sequence shown as SEQ ID NO: 2; a PDCD6 sequence shown as SEQ ID NO: 3; and... Agent: Agency For Science, Technology And Research

20110318309 - Equol-producing bacterium and use thereof: The present invention is directed to a microorganism having an ability of converting daidzein to equol in 24 hours of 50% or higher; a food/beverage or pharmaceutical composition containing the microorganism; an equol production method employing the microorganism; and a nucleic acid fragment which can specifically detect the microorganism.... Agent: Kabushiki Kaisha Yakult Honsha

20110318310 - Method for enhancing stem cell trafficking: Consumption of blue-green algae, or extracts thereof, enhances trafficking or homing of stem cells in animals by inducing a transient increase in the population of stem cells present in the animal's circulatory system. The animal may be healthy or suffering some disease or physiological condition.... Agent: Desert Lake Technologies, LLC

20110318311 - Tumor-selective e1a and e1b mutants: Modified E1a regulatory sequences are provided, wherein at least one Pea3 binding site, or a functional portion thereof, is deleted. Also provided are modified E1a sequences that selectively express particular isoforms. Also provided is an E1b-19K clone insertion site. These modified sequences can be used individually, or in combination with... Agent: The Regents Of The University Of California

20110318314 - Mesenchymal stem cells and uses therefor: Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.... Agent:

20110318315 - Mesenchymal stem cells and uses therefor: Methods of treating graft versus host disease, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.... Agent:

20110318313 - Modulation of splenocytes in cell therapy for traumatic brain injury: The invention provides methods for treating traumatic brain injury. The invention is generally directed to treating traumatic brain injury by administering cells that have one or more of the following effects in an injured subject: interact with splenocytes, preserve splenic mass, increase proliferation of CD4+ and CD8+ T-cells, increase IL-4... Agent: Abt Holding Company

20110318312 - Rejuvenation or preservation of germ cells: Certain embodiments disclosed herein include, but are not limited to, at least one of compositions, methods, devices, systems, kits, or products regarding rejuvenation or preservation of germ cells or gametes. Certain embodiments disclosed herein include, but are not limited to, methods of modifying germ cells or gametes, or methods of... Agent: Searete LLC, A Limited Liability Corporation Of The State Of Delaware

20110318319 - Activation and aggregation of human platelets and formation of platelet gels by nanosecond pulsed electric fields: Methods for forming activated platelet gels using nsPEF's and applying the activated gels to wounds, such as heart tissue after myocardial infarction. The platelets are activated by applying at least one nsPEF with a duration between about 10 picoseconds to 1 microsecond and electrical field strengths between about 10 kV/cm... Agent: Old Dominion University

20110318321 - Controlled release pharmaceutical or food formulation and process for its preparation: The present invention relates to a controlled release pharmaceutical or food formulation comprising at least one active pharmaceutical or food ingredient dispersed in a mixture of a glycogen with a polysaccharide, and the process for its preparation. The invention also relates to a slow release system represented by a mixture... Agent: Aziende Chim.riun.ang.franc.a.c.r.a.f. S.p.a.

20110318320 - Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women: The present invention relates to nutritional supplements to be administered to, or to be taken by, women desiring to become pregnant, and pregnant and nursing women. The nutritional supplements of this invention have a unique blend of vitamins, minerals, lycopene, co-enzyme Q10, DHA, docusate (such as docusate sodium), folic acid,... Agent:

20110318322 - Conjugates of a lysosomal enzyme moiety and a water soluble polymer: Conjugates of a lysosomal enzyme moiety and one or more non-peptidic water soluble polymers are provided. Typically, the non-peptidic water soluble polymer is a poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising such conjugates, methods of making the conjugates, and methods of administering the... Agent: Nektar Therapeutics

20110318324 - Methods and compositions for cns delivery of b-galactocerebrosidase: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an B-Galactocerebrosidase protein, salt, and a polysorbate surfactant for the treatment... Agent: Shire Human Genetic Therapies, Inc.

20110318323 - Methods and compositions for cns delivery of iduronate-2-sulfatase: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the... Agent: Shire Human Genetic Therapies, Inc.

20110318326 - Compositions and methods: The invention relates to a method for alleviating the inhibition of neurite outgrowth from a neurone, wherein said neurone comprises a Nogo receptor, said method comprising contacting said neurone with a composition capable of causing phosphorylation of a Nogo receptor, wherein said composition comprises protein kinase A or casein kinase.... Agent: Medical Research Council

20110318325 - Inositol pyrophosphates determine exocytotic capacity: The invention provides reagents and methods for treating type II diabetes, as well as methods for identifying compounds for treating type II diabetes.... Agent: Biocrine Ab

20110318328 - Specific lysis of staphylococcal pathogens by bacteriophage phi11 endolysin: The Staphylococcus aureus bacteriophage phi11 endolysin has two peptidoglycan hydrolase domains (endopeptidase and amidase) and a SH3b cell wall-binding domain. In turbidity reduction assays, the purified protein can lyse untreated staphylococcal mastitis-causing pathogens, S. aureus and coagulase negative staphylococci (S. chronogenes, S. epidermis, S. hyicus, S. simulans, S. warneri, and... Agent:

20110318327 - Treatment of sanfilippo syndrome type b: Among other things, the present invention provides methods and compositions of treating Sanfilippo syndrome type B (Sanfilippo B) by, e.g., intrathecal (IT) administration of a Naglu protein. A suitable Naglu protein can be a recombinant, gene-activated or natural protein. In some embodiments, a suitable Naglu protein is a recombinant Naglu... Agent: Shire Human Genetic Therapies, Inc.

20110318329 - Method of treatment or prophylaxis: The present invention is directed to methods and agents that are useful in the prevention and amelioration of signs and symptoms associated with neuropathic conditions. More particularly, the present invention discloses the use of angiotensin II receptor 2 (AT2 receptor) antagonists for the treatment, prophylaxis, reversal and/or symptomatic relief of... Agent:

20110318330 - Medicinal products for the treatment of blood coagulation disorders: A virally safe, thrombin-free factor-Xla concentrate or a coagulation factor concentrate which contains factor XIa as an active pharmaceutical ingredient and which is obtained by fractionation of plasma or serum or by genetic engineering and is suitable for the treatment of coagulation disorders attributable to diminished and/or delayed thrombin formation.... Agent: Bio-products & Bio-engineering Ag

20110318332 - Immunoglobulin g composition: The invention relates to an immunoglobulin G composition comprising mannitol, glycine and a nonionic detergent, in which the immunoglobulin G concentration is 100 g/l±20 g/l.... Agent: Laboratoire Francais Du Fractionnement Et Des Biotechnologies

20110318331 - Nanoparticles and use thereof: A novel nanoparticle and use thereof were provided in the present invention. In particular, the nanoparticle is used for delivering therapeutic component, such as oligonucleotide and hydrophobic drug.... Agent: Kaohsiung Medical University

20110318333 - Novel non-toxic composition and method of using such for treating a degenerative or an immune system-related disease: There is provided a non-toxic composition and method of using such for treating a degenerative or an immune-related disease. The non-toxic composition comprises a sprouted grain composition comprising digestive enzymes, a clustered water composition, and a substantially undenatured whey protein composition.... Agent:

20110318339 - Anti-dll4 antibodies and uses thereof: Provided herein are anti-DLL4 antibodies and methods of using anti-DLL4 antibodies as therapeutic agents in diseases or disorders associated with DLL4.... Agent:

20110318340 - Deglycosylated antibodies: The present invention provides an antibody, or antibody fragment, with modified glycosylation for use in treating or preventing a disease or condition, where the antibody or fragment: (a) suppresses an inflammatory condition forming part of the disease or condition to be treated or prevented; and/or (b) displays increased efficacy and/or... Agent: Hansa Medical Ab

20110318341 - Frizzled-binding agents and uses thereof: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or... Agent:

20110318337 - Humaneered anti-factor b antibody: This invention relates to humaneered anti-factor B antibodies and antigen-binding fragments thereof with reduced immunogenicity. The humaneered anti-factor B antibodies and antigen-binding fragments thereof are derived from murine monoclonal antibody 1379, which binds factor B in the third short consensus repeat (“SCR”) domain and selectively inhibits activation of the alternative... Agent:

20110318336 - Identification and treatment of aggressive lung cancer tumors: This invention relates to the identification and treatment of aggressive lung cancer tumors in patients. More particularly, it provides a method of identifying patients with non-small cell lung carcinoma (NSCLC) who have an aggressive node-negative (N0) tumor and a likelihood of a poor overall survival. The method comprises the step... Agent: George Mason Intellectual Properties, Inc.

20110318335 - Methods and products for treating proliferative diseases: Methods and products for treating proliferative diseases, and wounds, using as a pharmacon an autophagy inhibitor, a glycolytic inhibitor, and/or an agent able to alter cellular production of reactive oxygen, or combination thereof, optionally in combination with one or more chemotherapeutic agents. In some embodiments, the invention combines a 4-aminoquinoline,... Agent: The Regents Of The University Of Colorado

20110318342 - Methods of using il-1 antagonists to treat autoinflammatory disease: Methods of treating, inhibiting, or ameliorating an autoinflammatory disorder, disease, or condition in a subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the autoinflammatory disorder, disease, or condition is treated, inhibited, or ameliorated. The IL-1 antagonist is... Agent: Regeneron Pharmaceuticals, Inc.

20110318343 - Stable liquid pharmaceutical formulation of igg antibodies: This invention is directed to a stable liquid pharmaceutical formulation comprising a high concentration, e.g. 50 mg/ml or more, of antibody in about 20-60 mM succinate buffer or 30-70 mM histidine buffer, having pH from about pH 5.5 to about pH 6.5, about 0.01-0.1% polysorbate, and a tonicity modifier that... Agent: Abbott Biotherapeutics Corp.

20110318338 - Targeting pax2 for the treatment of breast cancer: The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating... Agent: Phigenix, Inc.

20110318334 - Taxane analogs for the treatment of brain cancer: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application... Agent: Tapestry Pharmaceuticals, Inc.

20110318344 - Tumor treatment: The patent discloses the use of Hepatocellular Carcinoma Related Protein 1 (HCRP1) as a marker for the efficiency of an anti-EGFR antibody treatment of a tumour patient. If a tumour biopsy sample of the tumour patient reveals an HCRP1 protein or mRNA amount equal to or above the amount in... Agent: Medizinische Universitaet Wien

20110318346 - Alpha b-crystallin as a therapy for ischemia or inflammation: The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods... Agent:

20110318345 - Nasal delivery: substances and the nasal administration thereof, in particular as one of a liquid, as a suspension or solution, or a powder, to the nasal airway of a subject, in particular the posterior region of the nasal airway, and in particular the upper posterior region of the nasal airway, which includes... Agent: Optinose As

20110318347 - Amino acid sequences targeting human cd4, cxcr4, ccr5, tlr4, alphav integrin, beta3-integrin, beta1-integrin, human alpha2-integrin, cd81, sr-bi, claudin-1, claudin-6 and claudin-9, respectively, and neutralizing viral entry: The present invention relates to amino acid sequences that are directed against (as defined herein) human cellular receptors for viruses and/or bacteria such as e.g. Nanobodies specifically recognizing hCD4, hCXCR4, hCCR5. hTLR4, human alphaV integrin, human beta3 integrin, human beta1 integrin, human alpha2 integrin, hCD81, hSR-B1, hClaudin-1, hClaudin-6 and hClaudin-9,... Agent: Ablynx N.v.

20110318348 - Induction of mucosal immune responses by mucosal delivery pentabody complex (mdpc): The subject invention provides, for example, a novel approach to specifically induce intranasal and/or oral mucosal as well as humoral antibody response by administrating a mucosal delivery pentabody complex (MDPC). The MDPC is a complex formed by mixing a target antigen and a mucosal delivery pentabody (MDP) that has a... Agent: Dow Agrosciences LLC

20110318350 - Antibodies that bind both il-17a and il-17f and methods of using the same: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same... Agent: Zymogenetics, Inc.

20110318349 - Dual variable domain immunoglobulins and uses thereof: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.... Agent: Abbott Laboratories

20110318351 - Novel methods of cancer diagnosis and therapy targeted against a cancer stem line: Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment.... Agent:

20110318356 - Antibodies against tissue factor pathway inhibitor: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.... Agent: Novo Nordisk A/s

20110318352 - Compositions and methods for the treatment of viral infections: The invention provides compositions, kits and methods utilizing polypeptides having a viral alpha-helix heptad repeat domain in a stabilized a-helical structure (herein also referred to as SAH). The compositions are useful for treating and/or preventing viral infections. The invention is based, at least in part, on the result provided herein... Agent: Dana Farber Cancer Institute, Inc.

20110318354 - Cytokine receptor zcytor17 multimers: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and... Agent: Zymogenetics, Inc.

20110318353 - Humanized il-25 antibodies: The present invention relates to target binding members (e.g., antibodies) that bind a specified epitope of human IL-25. The invention also relates to target binding members (e.g., antibodies) that comprise one or more humanized antibody VL domain sequences and bind IL-25. The invention further relates to compositions comprising target binding... Agent:

20110318358 - Immunotherapy for clearing pathological tau conformers: The present invention relates to methods of treating and preventing Alzheimer's Disease or other tauopathies in a subject by administering a tau protein, its immunogenic epitopes, or antibodies recognizing the tau protein or its immunogenic epitopes under conditions effective to treat or prevent Alzheimer's Disease of other tauopathies. Also disclosed... Agent: New York University

20110318357 - Methods and compositions based on shiga toxin type 2 protein: The invention is based on the discovery of the epitope in the Stx2 protein for the 11 E1O antibody. The invention features compositions containing non-full length Stx2 polypeptides that include the 11 E1O monoclonal antibody epitope. The invention also features methods of producing anti-Stx2 antibodies specific for the 11 E1O... Agent: The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.

20110318355 - Mutant proteins of the f protein of piv-5 and piv-2: The present application concerns mutant proteins of the fusion protein (F protein) of the parainfluenza virus (PIV) which are currently indexed as type 5 PIV (PIV-5 or PIV5) and type 2 PIV (PIV-2 or PIV2). The present application concerns products deriving therefrom, such as: nucleic acids, vectors, cells, fusion inhibitors... Agent: Universite Claude Bernard De Lyon 1

20110318359 - Method for reducing blood pressure using inhibitors of plasma kallikrein: The present invention relates to methods of reducing blood pressure in a subject by administering a plasma kallikrein inhibitor.... Agent:

20110318360 - Anti-lipid antibodies: The present invention relates, in general, to anti-lipid antibodies and, in particular, to methods of inhibiting HIV-I infection using anti-lipid (e.g. anti-phospholipid) antibodies.... Agent: Duke University

20110318361 - Anticancer drug comprising inhibitor of tmprss4: The present invention relates to an anticancer agent containing a TMPRSS4 (transmembrane protease, serine 4) inhibitor as an effective ingredient, more precisely an anticancer agent containing an inhibitor of TMPRSS4 activity as an effective ingredient. The anticancer agent of the present invention can be used effectively for the treatment of... Agent:

20110318362 - Novel card proteins involved in cell death regulation: The present invention provides NB-ARC and CARD-containing proteins (NACs), nucleic acid molecules encoding NACs and antibodies specific for at least one NAC. The invention further provides chimeric NAC proteins. The invention also provides screening assays for identifying an agent that can effectively alter the association of a NAC with a... Agent: Sanford-burnham Medical Research Institute

20110318364 - nonapeptide with anti-tumour activity: The present invention relates to peptides or peptide like molecules and their uses in therapy, in particular as anti-tumour agents.... Agent: Lytix Biopharma As

20110318363 - Specific tt virus sequences and chimeric tt virus host cell dna molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity: Described are single-stranded new sequences of TT viruses, rearranged TTV sequences and hybrid molecules of a specific TT virus sequence and host cell DNA that are capable of replicating autonomously for use in diagnosis, prevention and treatment of diseases like cancer and autoimmunity. In addition, it relates to the use... Agent: Deutsches Krebsforschungszentrum

20110318368 - Anti-human alpha9 integrin antibody and use thereof: The present invention relates to an anti-human α9 integrin antibody. More particularly, the present invention relates to: a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody that specifically recognize human α9 integrin; a hybridoma cell that produces the monoclonal antibody; a method for producing the monoclonal... Agent: Gene Techno Science Co., Ltd.

20110318366 - Biologic compounds: The present invention relates to amino acid sequences that are directed against TRAIL cell surface receptor 2 (herein also “DR5”), as well as to compounds or constructs thereof, and in particular proteins and polypeptides and nucleotides that encode them (referred to herein in their entirety as “NB agents”) and fragments... Agent: Novartis Ag

20110318365 - Methods for treatment of degenerative disease associated with apoptosis: A method for treating a degenerative disease or neurodegenerative disease in a mammalian subject is provided. The method provides administering VEGF-B polypeptide or functional variant or mimetic thereof in an amount effective to reduce or eliminate the degenerative disease in the mammalian subject without having any substantial angiogenic effect across... Agent: The United States Of America, As Represented By The Secretary, Department Of Health And Human

20110318367 - Novel targets for treatment of hypercholesterolemia: In certain embodiments this invention this invention pertains to the discovery that inhibition of myosin light chain interacting protein (Mylip) can mitigate one or more symptoms of hypercholesterolemia. Methods of treating hypercholesterolemia and methods of screening for agents to treat hypercholesterolemia are provided.... Agent: The Regents Of The University Of California

20110318369 - Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease: An isolated molecule which comprises an antibody specifically bindable with a binding affinity below 20 nanomolar, preferably below 10 nanomolar, to a human major histocompatibility complex (MHC) class I being complexed with a HLA-restricted antigen and optionally further comprises an identifiable or therapeutic moiety conjugated to the antibody.... Agent: Technion Research & Development

20110318370 - Cxcl4l1 as a biomarker of pancreatic cancer: The invention relates to the use of CXCL4L1 as a biomarker of pancreatic cancer in a patient. More particularly, the invention relates to a method for detecting a pancreatic cancer and/or pancreatic metastasis in a patient, said method comprising determining the expression level of the CXCL4L1 gene in a biological... Agent:

20110318371 - Novel serpentine transmembrane antigens expressed in human cancers and uses thereof: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigens of the Prostate). Four... Agent:

20110318375 - Immunomodulatory therapeutic agents: A group of peptides has been isolated from the serum of domesticated mammals and then identified through the use of mass spectrometry. These peptides are byproducts of fibrinogen activation and the complement cascade. The peptides of greatest activity are the activated forms of fibrinopeptide A and fibrinopeptide B {activated by... Agent:

20110318373 - Immunosuppression modulating compounds: The present invention provides immunosuppression compounds capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signaling induced by PD-1, PD-L1, or PD-L2 and therapies using... Agent: Aurigene Discovery Technologies Limited

20110318372 - Indoleamine 2,3-dioxygenase based immunotherapy: The present invention relates to the field of prophylaxis and therapy of cancer. In particular there is provided a protein Indoleamine 2,3-dioxygenase (IDO) or peptide fragments here of that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to the use of DO or peptides derived here from... Agent: Herlev Hospital

20110318374 - Spanx-b polypeptides and their use: It is disclosed herein that SPANX-B is uniquely expressed in a number of human tumors and that SPANX-B is an immunogenic antigen that is recognized by human T cells inducing helper CD4+ and cytolytic CD8+ T cell responses. Specific SPANX-B polypeptides and polynucleotides are disclosed that can be used to... Agent: The United States Of America, As Represented By The Secretary, Department Of Health And Human

20110318376 - Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins: The present invention is directed to self-folding, soluble, stable RSV G and F polypeptides that contain a neutralizing epitope. Fusion proteins and immunogenic conjugates containing the RSV G and F polypeptides, along with recombinant transgenes and vectors, and host cells suitable for expression of such genetic constructs are also disclosed.... Agent: University Of Rochester

20110318377 - Methylated tat polypeptides and methods of use thereof: The present invention provides isolated methylated Tat peptides; and compositions comprising the peptides. The present invention further provides isolated antibodies specific for a Lys-51-methylated Tat polypeptide. Also provided are methods of identifying agents that inhibit Lys-51 methylation of a Tat polypeptide. The present invention further provides methods of treating an... Agent:

20110318378 - Peptides presenting an epitope of a domain of factor h binding protein and methods of use: Polypeptides that can elicit antibodies that are bactericidal for different fHbp variant strains of N. meningitidis, and methods of use, are provided.... Agent:

20110318379 - Vaccine for porcine post-weaning diarrhea caused by enterotoxigenic escherichia coli: Vaccines and methods for making and using the same. An example vaccine may be a vaccine against enterotoxigenic Escherichia coli. The vaccine may include an Escherichia coli strain. The Escherichia coli strain may produce K88 fimbria and a fusion protein including a mutant LT enterotoxin linked with a STb enterotoxin.... Agent: South Dakota State University

20110318380 - Mhc multimers in cancer vaccines and immune monitoring: The present invention relates to MHC-peptide complexes and uses thereof in the diagnosis of, treatment of or vaccination against a disease in an individual. More specifically the invention discloses MHC complexes comprising cancer antigenic peptides and uses there of.... Agent: Dako Denmark A/s

20110318381 - Process for the preparation and use of a bivalent vaccine against morphine-heroine addiction: The structural design, preparative methods and chemical composition of two structural formulations of bivalent vaccines against morphine-heroin addiction (morphine-6-hemisuccinyl-EDC-TFCS-tetanus toxoid and 3-O-carboxymethylmorphine-EDC-TFCS-tetanus toxoid), are disclosed. These vaccines are suitable for human use in which they are capable of triggering the synthesis of polyclonal antibodies against morphine opiate and its structural... Agent: Instituto Nacional De Psiquiatria Ramon De La Fuente Muniz

20110318382 - Immunomodulatory agents and methods of use: An antisense oligonucleotide compound, composition, vaccine and methods for treating a variety of conditions characterized by up-regulation of IL-10 in a mammalian subject are disclosed. The compound (i) is composed of morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5′ exocyclic carbon of... Agent: Avi Biopharma, Inc.

20110318383 - Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease: The present invention relates to a novel, isolated and purified hemorrhagic feline calicivirus FCV-DD1. The invention further embraces monovalent and multivalent vaccines containing the new FCV-DD1 strain. In addition, the invention encompasses methods of protecting felines against infection or preventing disease caused by feline calicivirus alone or in addition to... Agent:

20110318384 - Vector for treatment vaccine for stable and constitutive high-expression cervical cancer and recombinant lactobacillus transformed by the same: An expression vector constitutively expressing a high level of the human papillomavirus (HPV) antigen protein is provided. Also, a recombinant lactic acid bacteria, transformed with the expression vector and expressing the HPV antigen protein on the surface thereof, and a composition comprising the recombinant lactic acid bacteria are provided. The... Agent:

20110318385 - Engineered botulinum neurotoxin c1 with selective substrate specificity: An isolated polypeptide comprising a botulinum neurotoxin C1 light chain having a modified amino acid sequence relative to the sequence of a wild-type botulinum neurotoxin C1 light chain is disclosed. The modified botulinum neurotoxin C1 light chain is capable of selectively cleaving syntaxin protein, but has substantially reduced or no... Agent: Wisconsin Alumni Research Foundation

20110318386 - Bacillus isolates and methods of their use to protect against plant pathogens: Methods of inducing systemic acquired resistance to infection in a plant by applying a composition comprising a Bacillus control agent to said plant wherein said plant is capable of producing defense proteins.... Agent: Montana State University

20110318387 - Immunization method using cancer cells: The present invention provides a method for immunizing a laboratory animal, which comprises the following steps: (1) transplanting cancer cells having a metastatic potential and capable of expressing an antigen into the laboratory animal; and (2) allowing the cancer cells to be engrafted in the laboratory animal to thereby immunize... Agent:

20110318388 - S1p receptors modulators and their use thereof: The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response.... Agent: Akaal Pharma Pty Ltd

20110318390 - Bioactive dose having a rapid release coating or rapid release layer containing a material for modulating ph of a bodily fluid to help or hinder absorption of a bioactive: A bioactive dose for delivering a bioactive agent to a mammal includes a solid bioactive dosage unit containing at least one bioactive agent and a rapid release coating provided on at least one outer surface of the solid bioactive dosage unit. The rapid release coating contains a material having a... Agent:

20110318391 - Bioactive dose having containing a material for modulating ph of a bodily fluid to help or hinder absorption of a bioactive: A bioactive dose for delivering a bioactive agent to a mammal, includes a solid bioactive dosage unit containing at least one bioactive agent and a rapid release coating provided on at least one outer surface of the solid bioactive dosage unit, the rapid release coating containing a material having a... Agent:

20110318392 - Drug coating providing high drug loading and methods for providing the same: The present invention is directed to aqueous drug coatings that include at least one insoluble drug, wherein the drug accounts for about 85 wt % to about 97 wt % of the drug coatings. A drug coating according to the present invention may include only one insoluble drug, two or... Agent:

20110318389 - Human pancreatic beta cell lines for diagnostic of diabetes: The present invention relates to a method for preparing commercial scale quantities of human functional Betacells and to the establishment of cell lines. It also relates to a method of diagnosis using Beta cell tumors or cells derived thereof. The method comprises sub-transplantation procedure to enrich the graft in proliferating... Agent: Sarl Endocells

20110318394 - Multi-linked star-shaped polymers and synthetic methods therfor: The invention describes new synthetic medical adhesives and antifouling coatings which exploit the key components of natural marine mussel adhesive proteins.... Agent: Knc Ner Acquisition Sub, Inc.

20110318395 - Polyhydroxyalkanoate medical textiles and fibers: Absorbable polyester fibers, braids, and surgical meshes with prolonged strength retention have been developed. These devices are preferably derived from biocompatible copolymers or homopolymers of 4-hydroxybutyrate. These devices provide a wider range of in vivo strength retention properties than are currently available, and could offer additional benefits such as anti-adhesion... Agent: Telpha, Inc.

20110318393 - Substituted pyrazole compounds: Provided are substituted pyrazole compounds which are useful as protein kinase inhibitors, compositions comprising the compounds, and methods of use thereof. The protein kinase inhibitors are particularly for inhibition of Aurora A (Aurora-2) protein kinase and are useful in the treatment of diseases associated with protein kinases, especially diseases associated... Agent: Miikana Therapeutics, Inc.

20110318398 - Cosmetic composition comprising molecular encapsulated fermented extract of rhus javanica l. as an active ingredient: The present invention relates to a cosmetic composition comprising a composite prepared by molecularly encapsulating a fermented sumac (Rhus javanica L.) extract with a cyclodextrin derivative as an active ingredient. More particularly, the present invention relates to a skin-whitening or antioxidant composition comprising a composite prepared by molecularly encapsulating a... Agent: Korea Natural Science Co., Ltd.

20110318396 - Dermatological/cosmetic compositions comprising a retinoid and benzoyl peroxide: Dermatological/cosmetic compositions contain, in a physiologically acceptable medium, at least one retinoid, dispersed benzoyl peroxide and a gelling system comprising at least two categories of compounds.... Agent: Galderma Research & Development

20110318399 - Emulsified cosmetic composition: Disclosed is an emulsified cosmetic which is not sticky, has a long-lasting moisturizing effect, and can realize an excellent shiny sensation after application. Specifically disclosed is an emulsified cosmetic characterized by comprising (A) 0.1 to 15% by mass of a plate-like powder, (B) 0.1 to 30% by mass of an... Agent:

20110318397 - Method for preparing high purity ginsenoside rd using lactobacillus casei and cosmetic composition for anti-wrinkle comprising the high purity ginsenoside rd: The present invention relates to a method for preparing high-purity ginsenoside Rd using Lactobacillus casei, more particularly to a method for preparing high-purity ginsenoside Rd using Lactobacillus casei and an anti-wrinkle cosmetic composition comprising the high-purity ginsenoside Rd as an active ingredient. Since the method of the present invention is... Agent: Korea Natual Scienceco., Ltd.

20110318400 - Skin care product: The invention relates to a skin-care product comprising at least one component selected from the group of heat shock protein from alfalfa and heat shock protein hydrolysate from alfalfa. The invention further relates to the use of shock protein from alfalfa or hydrolysate thereof for slowing down the aging of... Agent: Alfa Biogene International B.v.

20110318401 - Treatment of leg ulcers using placenta derived collagen biofabric: The present invention provides a method of treating a leg ulcer comprising contacting the leg ulcer with a collagen biofabric. The leg ulcer may be a venous, arterial, diabetic or decubitus (pressure) ulcer. The invention further provides kits comprising one or more pieces of collagen biofabric for the treatment of... Agent:

20110318402 - Tricalcium phosphates, their composites, implants incorporating them, and methods for their production: Methods for the synthesis of tricalcium phosphates are presented, as well as a series of specific reaction parameters that can be adjusted to tailor, in specific ways, properties in the tricalcium phosphate precursor precipitate. Particulate tricalcium phosphate compositions having an average crystal size of about 250 nm or less are... Agent: Angstrom Medica

20110318403 - Preparation and use of pouteria lucuma extract: A method of preparing Pouteria lucuma extract was developed which comprises extracting oil from the nut. The lucuma nut oil (LNO) was effective to induce cell migration, enhance tissue regeneration and enhance wound healing. The lucuma nut oil provides an agent that is useful for therapeutic or cosmetic maintenance of... Agent: Rutgers, The State University Of New Jersey

20110318404 - Wound dressing, methods and apparatus for making same and storage and use thereof: Provided is a wound dressing prepared from whole blood that is clotted ex vivo to form a sheet of clotted blood that is applied onto the skin over a sight of skin injury.... Agent:

20110318405 - Chemical combination and method for increasing delivery of coenzyme q10: The present invention relates to a chemical combination and method for increasing delivery of Coenzyme Q10. The chemical combination comprises Coenzyme Q10 mixed with at least one chemical. The at least one chemical includes cyclic terpene containing essential oil(s) that permit unprecedented levels of Coenzyme Q10 to be made available... Agent:

20110318409 - Fractions of wheat germ ferment: The invention concerns wheat germ ferment, its biologically active fractions, the process for their production, the pharmaceutical preparations containing them and their uses.... Agent:

20110318408 - Hla class i a2 tumor associated antigen peptides and vaccine compositions: A composition or vaccine composition comprising at least one peptide that has less than 600 contiguous amino acids having 100% identity to a native sequence of CEA, HER2/neu, MAGE2, MAGE3, or p53, the peptide further comprising at least one epitope selected from Table 6.... Agent:

20110318407 - Inactivated dengue virus vaccine with aluminium-free adjuvant: The present disclosure provides immunogenic compositions for the prevention and/or treatment of disease caused by dengue virus.... Agent:

20110318406 - Lecithin carrier vesicles and methods of making the same: A hydrated lecithin carrier vesicle composition includes a lecithin-derived membrane-forming lipid vesicle in conditioned water for incorporation of an active ingredient to form a dispersed composition. A method of making the hydrated lecithin carrier vesicle includes using lecithin having not more than about 80% w/w phosphatidylcholine in the presence of... Agent:

20110318410 - Rare earth metal compounds, methods of making, and methods of using the same: Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the... Agent: Spectrum Pharmaceuticals, Inc.

20110318411 - Multi-layered orally disintegrating tablet and the manufacture thereof: The present invention features a tablet containing a first layer and a second layer, wherein: (i) the first layer includes a pharmaceutically active agent and the composition of the first layer is different from the composition of the second layer; (ii) the tablet has a density less than about 0.8... Agent:

20110318413 - Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof: The present invention relates to an extended release formulation comprising darifenacin or pharmaceutically acceptable salts thereof and one or more release controlling hydrophobic materials optionally coated with combination of one or more release controlling hydrophobic materials and one or more release controlling hydrophilic materials; wherein said formulation provides controlled release... Agent: Micro Labs Limited

20110318412 - Low dose doxepin formulations, including buccal, sublingual and fastmelt formulations, and uses of the same to treat insomnia: The invention disclosed herein generally relates to low-dose oral doxepin pharmaceutical formulations and the use of these formulations to promote sleep.... Agent: Somaxon Pharmaceuticals, Inc.

20110318414 - Regenerative tissue grafts and methods of making same: A graft containing a scaffold that includes a matrix in which are positioned mesenchymal progenitor cells (MPCs) has the capacity to substantially improve wound healing, including wounds resulting from injury to nerve, bone and vascular tissue. MPCs can be harvested from debrided muscle tissue following orthopaedic trauma. The traumatized muscle-derived... Agent:

20110318415 - Hollow gold nanospheres (haunss) and haunss-loaded microspheres useful in drug delivery: A near-infrared mediated drug delivery system comprising a plurality of microspheres made of polymeric material, each sphere containing a plurality of hollow gold nanospheres together with drug product, wherein upon NIR irradiation, the drug product is released from the microsphere.... Agent:

20110318416 - Bioresorbable polymer matrices and methods of making and using the same: A bioerodible composition for delivery of a bioactive agent is the reaction product of a reaction mixture which includes an oxidized dextran solution, and a mixture of solids containing a dihydrazide, a bioactive agent, and optionally a pH adjusting agent in an amount sufficient to achieve a pH of the... Agent: Royer Biomedical, Inc.

20110318418 - Compositions of 5-ethyl-2--pyrimidine: This invention relates to the field of pharmaceutical chemistry and, more specifically, to pharmaceutical formulations as well as to intermediates used to prepare such formulations and to methods for manufacturing such formulations.... Agent: Metabolex, Inc.

20110318420 - Fulvestrant nanosphere/microsphere and preparative method and use thereof: Fulvestrant nanosphere/microsphere and preparation method and use thereof are provided in the present invention. The carrier material of the fulvestrant nanosphere/microsphere is methoxy ended polyethylene glycol-polylactic acid block copolymer. The nanosphere/microsphere is prepared by solvent-nonsolvent method, in-liquid drying method and/or spray drying method, and has the features of high drug... Agent: Xi'an Libang Pharmaceutical Technology Co., Ltd.

20110318419 - Graft materials containing bioactive substances, and methods for their manufacture: Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibroblast Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix... Agent:

20110318417 - Highly pure cinacalcet or a pharmaceutically acceptable salt thereof: Provided herein are impurities of cinacalcet, (R)-α-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-(5,6,7,8-tetrahydronaphthalene)methaneamine (tetrahydro cinacalcet impurity), (R)-α-Methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethaneamine-N-oxide (cinacalcet N-oxide impurity) and (R)-α-methyl-N-[3-[3-(trifluoromethyl)phenyl]methyl]-1-naphthalenemethaneamine (benzylamine impurity); and processes for preparation and isolation thereof. Provided further herein is a highly pure cinacalcet or a pharmaceutically acceptable salt thereof substantially free of impurities, processes for the preparation thereof, and pharmaceutical... Agent: Actavis Group Ptc Ehf

20110318421 - Surface functionalized ceramic nanoparticles: The present disclosure is directed to surface functionalized ceramic nanoparticles. The method for producing the surface functionalized ceramic nanoparticles generally includes at least four distinct steps: 1) synthesis of an amphiphilic surfactant having the desired surface functionality, 2) formation of mixed solvent microstructured solution with the surfactant, 3) synthesis of... Agent:

20110318422 - Targeted active agent delivery system based on calcium phosphate nanoparticles: Calcium phosphate nanoparticle active agent conjugates are described. Specifically, anticancer agent conjugates are prepared which are suitable for targeted active agent delivery to tumor cells and lymphatics for the treatment of cancer and the treatment or prevention of cancer metastasis.... Agent:

20110318423 - Methods and apparatus for creating particle derivatives of hdl with reduced lipid content: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to... Agent: Hdl Therapeutics

20110318424 - Methods for prolonging viability of cone cells using modulators of the mammalian target of rapamycine (mtor): The present invention is directed to the use of modulators of the mammalian target of rapamycine (mTOR) pathway, glucose and/or glucose enhancers for treating retinal disorders and, in particular, for prolonging the viability of cone cells.... Agent: President And Fellows Of Harvard College

20110318426 - Antibacterial agent and method of using the same: An antibacterial agent of the present invention contains a metal-containing compound containing a metal other than aluminum, and a phosphorus-adsorbing material. A method of using an antibacterial agent of the present invention is a method for improving an antibacterial property of a metal-containing compound containing a metal other than aluminum,... Agent: Kaneka Corporation

20110318425 - Treatment of interstitial cystitis using (6ar, 10ar)- delta-8-tetrahdraocannabinol-11-oic acids: The present invention relates to non-psychoactive derivatives of tetrahydrocannabinol, which are useful in treating interstitial cystitis and relieving symptoms thereof. The invention uses (6aR,10aR)-Δ8-tetrahydrocannabinol-11-oic acids (hereinafter referred to as (6aR,10aR)-Δ8-THC-11-oic acid), as well as pharmaceutical compositions containing the (6aR,10aR)-Δ8-THC-11-oic acids, for treatment of interstitial cystitis in a mammal. The invention... Agent:

20110318427 - Fungicidal compositions based on copper salts: e

20110318428 - Treatment solution for treating wounds, in particular for liquid wound treatment: The invention relates to a treatment solution for treating wounds, preferably for liquid wound treatment of acute and chronic wounds, made of an aqueous solution including zinc, iron, and acid, wherein the per liter proportion of zinc is 10 to 100 mg, the proportion of iron is 6.5 to 60... Agent:

20110318430 - Tumor therapy with antitumor agents in combination with sindbis virus-based vectors: A method for treating malignant tumors with Sindbis viral based vectors in combination with antitumor agents and pharmaceutical formulations for use in such treatment.... Agent: New York University

20110318429 - Uses of an immunomodulatory protein (gmi) from ganoderma microsporum: The invention provides a method for inhibiting EGF receptor activity comprising contacting an EGF receptor with an immunomodulatory protein (GMI) from Ganoderma microsporum, or a recombinant thereof. Also provided is a method for treating invasion and metastasis of cancer cells, comprising administering an effective amount of an immunomodulatory protein (GMI)... Agent: Mycomagic Biotechnology Co., Ltd.

20110318431 - Pharmaceutical compositions and methods of treating neurological insults: A pharmaceutical composition containing a magnesium salt and an osmotic hypertonic agent, like a mannitol, is disclosed. Also disclosed are methods of treating individuals who have suffered a neurological insult, such as traumatic brain injury.... Agent: Endogenx

20110318432 - Compositions for the treatment of gastro-esofageal reflux disease (gerd): Oral pharmaceutical, nutraceutical, health foods and medical device compositions based on polysaccharides from Opuntia Ficus Indica cladodes in combination with other active substances are useful for the prevention or treatment of GERD (Gastro-Esophageal Reflux Disease), gastric esophagitis and related diseases (e.g. dyspepsia, esophagitis, esofageal tumour, gastro-intestinal symptoms, chronic pharyngitis, Barrett's... Agent: Bionap S.r.l.

20110318433 - Soothing pharmaceutical or cosmetic composition comprising a peptide that activates hmg-coa reductase: a

20110318434 - Acne vulgaris treatment regimen: An improved method, formulation and kit for the treatment of acne vulgaris are disclosed. The formulation is effective in inhibiting or killing the Proprionibacterium microorganism without utilizing antibiotics A preferred formulation alleviates the four pathogenic factors involved in the development of acne a) the putative pathogen of acne, Proprionibacterium acnes,... Agent:

20110318435 - Composition comprising longan arillus extract or combined extract comprising the same for treating neurodegenerative disease: This disclosure relates to a composition for prevention or treatment of neurodegenerative disease comprising longan arillus extract, or combined extract comprising longan arillus. The composition exhibits remarkably excellent prevention or treatment effect of neurodegenerative disease by containing longan arillus extract or combined extract comprising longan arillus, and particularly, it may... Agent: Korea Institute Of Science And Technology

20110318436 - Herbal solid formulation and process for preparing the same: Disclosed is a herbal solid formulation of Allium sativum extracts essentially free of excipients and preservatives and process for preparing the same.... Agent: Himalaya Global Holdings Ltd

20110318437 - Combinations of herb extracts having synergistic antioxidant effect, and methods relating thereto: The present invention comprises mixtures of herb extracts, namely a mixture of the herb ginger and the herb sophora, which which mixture exerts synergistic antioxidant effect. Skin care preparations incorporating such herb extract mixtures, and their methods of preparation and use, are also claimed.... Agent: The Dial Corporation

20110318438 - Pharmacologically effective composition of herbs for treatment on symptoms of influenza and colds: A pharmacologically effective composition of herbs is provided for symptom relieving for influenza and colds. The composition that is antiviral, antibacterial and does not contain any undesirable stimulants such as caffeine.... Agent:

20110318439 - Plant extracts from acronychia species and their use: The invention relates to plant extracts and bioactive molecules derived from the plant genus Acronychia and their use as antioxidants, antibacterials, anthelmintic, anti-inflammatories, cancer chemopreventatives, food additives and fragrance components in pharmaceuticals, nutraceuticals, foods and cosmetics.... Agent: Ecobiotics Ltd

20110311442 - Direct cellular energy delivery system: A lipid vesicle comprising a phospholipid which is a stable vesicle former and at least one unstable vesicle forming member, wherein the unstable vesicle forming member is selected from the group consisting of a polar lipid which is not a stable vesicle former, a PEG, a raft former and a... Agent: University Of Louisville Research Foundation, Inc.

20110311443 - Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient: The invention relates to a method for treating a cancerous and/or an inflammatory disease in a patient, comprising internally administering to the patient an effective amount of a pharmaceutical preparation blocking the biological activity of at least one protein cluster (CMP) or group of CMPs containing at least CD26 and/or... Agent: Klaus Tschira Stiftung Ggmbh

20110311444 - Imaging diagnostic agent and extracorporeal diagnostic agent for incurable neurological diseases: (wherein R1a and R1b are each independently a hydrogen atom, alkyl, acetyl, or methoxycarbonyl; R2s are each independently a fluorine atom, CHF2—, CF3—, CHF2O—, or CF3O—; R3s are each independently a hydrogen atom or a fluorine atom; A is alkyl, cyano, carboxyl, alkoxycarbonyl, or R4—(CH2)m—; R4 is hydroxy, carboxy, cyano,... Agent:

20110311445 - Diagnosis and treatment of myeloid and lymphoid cell cancers: Disclosed is a method of diagnosing and treating myeloproliferative or lymphoproliferative cell disorders, such as cancer, with chlorotoxin and/or derivatives, analogs or fragments thereof, which are effective to bind to an inhibit abnormal myeloid or lymphoid cell growth.... Agent: Morphotek, Inc.

20110311446 - Peptides that specifically bind hgf receptor (cmet) and uses thereof: A polypeptide or multimeric polypeptide construct having the ability to bind to cMet or a complex comprising cMet and HGF, and methods for use are disclosed.... Agent: Dyax Corp.

20110311447 - Compounds comprising 4-benzoylpiperidine as a sigma-1-selective ligand: Bipiperidinyl compounds and salts thereof are disclosed. The compounds include high affinity ligands for σ1 receptors. Some compounds are also highly selective for σ1 receptor compared to σ2 receptor. Compounds can comprise radioisotopes, including 18F or 11C. Radiolabeled compounds can be used as probes for imaging distribution of σ1 receptor... Agent: Washington University

20110311453 - Alloyed semiconductor quantum dots and concentration-gradient alloyed quantum dots, series comprising the same and methods related thereto: An alloyed semiconductor quantum dot comprising an alloy of at least two semiconductors, wherein the quantum dot has a homogeneous composition and is characterized by a band gap energy that is non-linearly related to the molar ratio of the at least two semiconductors; a series of alloyed semiconductor quantum dots... Agent: Indiana University Research And Technology Corporation

20110311449 - Antibodies: The present invention provides antibodies which bind to CXC chemokine receptor 4 (CXCR4) and which do not induce significant apoptosis of CXCR4 expressing cells. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.... Agent: Affitech Research As

20110311448 - Antibody to rage and uses for in vivo imaging or for targeting therapy: This invention discloses an antibody which is raised to a peptide, the sequence of which is: N-R-N-G-K-E-T-K-S-N-Y-R-V-R-V-Y-Q-I-P, N-R-R-G-K-E-V-K-S-N-Y-R-V-R-V-Y-Q-I-P, S-R-N-G-K-E-T-K-S-N-Y-R-V-Q-V-Y-Q-I-P, N-R-R-G-K-E-V-K-S-N-Y-R-V-R-V-Y-Q-I-C, or Ac-N-R-R-G-K-E-V-K-S-N-Y-R-V-R-V-Y-Q-I-C-amide. This antibody can be labeled with an imageable marker or linked to an agent. This antibody can be a monoclonal antibody. The invention also includes a method for... Agent:

20110311452 - Inflammation targeting particles: Opsonizable micro- or nanoparticles, that contain at least one active agent, such as an imaging or therapeutic agent; that have a positive surface charge and that do not contain on their surface targeting ligands, such as antibodies, peptides or aptamers, can be used to treating and/or monitoring a condition associated... Agent: Board Of Regents Of The University Of Texas System

20110311454 - Molecules with extended half-lives, compositions and uses thereof: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant... Agent: Medimmune, LLC

20110311450 - Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against KRTCAP3, FAM26F, MGC52498, FAM70A or TMEM154 antigens, which are differentially expressed in cancer, and diagnostic and therapeutic usages. This invention further relates to... Agent:

20110311451 - Synthesis of polymer conjugates of indolocarbazole compounds: The present invention relates to a process for the preparation of polymer conjugates of iπdolocarbazole compounds, in particular of polymer conjugates of K-252a and derivatives thereof, by a synthetic route which results in a highly pure product, with a high product yield. In a further aspect the present invention relates... Agent: Creabilis S.a.

20110311455 - Encapsulated agent guided imaging and therapies: A nano-capsule construct for imaging and therapeutic uses and method for production are provided. One nano-probe embodiment based on genome-depleted plant brome mosaic virus (BMV) whose interior is doped with indocyanine green (ICG), an FDA-approved near infrared fluorescent dye, is used to illustrate the invention. The material encapsulated in viral... Agent: The Regents Of The University Of California

20110311456 - Marker alloy: A marker alloy foreign implant made of a biodegradable metallic material and having the composition MgxYbyMz wherein x is equal to 10-60 atomic percent; y is equal to 40-90 atomic percent; z is equal to 0-10 atomic percent; M is one or more element selected from the group consisting of... Agent: Biotronik Vi Patent Ag

20110311457 - Methods for imaging vascular inflammation using improved nanoparticle contrast agents: The present invention also provides methods and compositions for imaging and evaluating, e.g., blood flow or inflammation in a subject. Such evaluations are important in a number of clinical diagnoses, including assessing organ damage associated with angina pectoris, heart attack, stroke, cancer, atherosclerosis, and the like, as well as assessing... Agent: Nanoscan Imaging, LLC

20110311459 - Alkaloid aminoester derivatives and medicinal composition thereof: The present invention relates to alkaloid aminoester compounds which act as muscarinic receptor antagonists, processes for the preparation of such a compound, compositions which contain such a compound, and therapeutic uses of such a compound.... Agent: Chiesi Farmaceutici S.p.a.

20110311458 - Alkaloid aminoester derivatives and medicinal compositions thereof: The present invention relates to alkaloid aminoester compounds which act as muscarinic receptor antagonists, processes for their preparation, compositions comprising them, and therapeutic uses thereof.... Agent: Chiesi Farmaceutici S.p.a.

20110311460 - Aerosol odor eliminating compositions containing alkylene glycol(s): Aerosol odor eliminating compositions are described which are aqueous based and include at least one alkylene glycol, at least one surfactant wherein one or more of the at least one surfactant has an HLB of about 7 to about 20, compressed gas propellant, at least one fragrance, a buffering system... Agent: S. C. Johnson & Son, Inc.

20110311461 - Alkaloid aminoester derivatives and medicinal composition thereof: The present invention relates to alkaloid aminoester compounds which act as muscarinic receptor antagonists, processes for their preparation, compositions comprising them, and therapeutic uses thereof.... Agent: Chiesi Farmaceutici S.p.a.

20110311462 - Compositions for treatment of ear disorders and methods of use thereof: The present invention relates to compositions and methods useful for the treatment of ear disorders, administered to a treated ear in the form of a foam or a mousse. Administering a medicament in such forms will increase the residence time of the medicament in the ear canal, provide relatively uniform... Agent: Otic Pharma Ltd.

20110311463 - Hair spray and hair mousse with natural ingredients: A naturally occurring film forming material for a hair spray or mousse, rather than a synthetic resin. A preferred naturally occurring film forming material is a polysaccharide, which is a sugar polymer with an INCI name of LEVAN. The film forming material may be mixed with any of a naturally... Agent:

20110311464 - Teeth whitening material and teeth whitening method: The present invention relates to a tooth bleaching material containing peroxyglutaric acid and/or peroxypolyacrylic acid as a bleaching ingredient, as well as a method of bleaching teeth which includes the step of applying the tooth bleaching material in the form of a dilute solution or without dilution onto surfaces of... Agent:

20110311466 - Novel 4-(azacycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and in cosmetics: e

20110311465 - Oxidizing composition for the treatment of keratin fibers:

20110311467 - Longwearing, transfer resistant cosmetic compositions having a unique creamy texture and feel: The present invention is directed to a long wearing, transfer resistant cosmetic composition which is waterproof, comfortable and has a unique creamy texture and feel containing: (a) a reaction product of (i) at least one polyamine and (ii) at least one oil soluble high carbon polar modified polymer; (b) water;... Agent: L'oreal S.a.

20110311468 - Guar gum containing compounds: Disclosed is a method of reducing the appearance of coloring streaks in a composition that has a colorant comprising adding a guar gum containing compound to said composition.... Agent: Mary Kay Inc.

20110311469 - Alcohol as sandalwood odorant: The present invention relates to certain derivatives of 2-ethyl-4-(2′,2′-dimethyl-3′-alkyl-3′-cyclopenten-1′-yl)-4-penten-1-ol. These compounds possess very interesting perfuming ingredients due to their unusual combination of sandalwood and floral notes. The present invention also concerns the use of such compounds in the perfumery industry as well as the compositions or articles containing such compounds.... Agent:

20110311470 - Compositions for a powder having an aqueous phase: In an embodiment of the present invention, there is provided a personal care composition having: a) at least one hydrophilic binder chosen from a sodium starch glycolate cross-linked with a phosphate ester group; b) at least one hydrophobic powder filler; and c) water, wherein the composition is in loose powder... Agent: L'or&#xc9 Al S.a.

20110311471 - Clear leave-on hair care composition comprising aminosilicone and its solvent: Disclosed is a hair care composition comprising: a specific aminosilicone; a solvent for the aminosilicone; wherein the composition is for leave-on use; and wherein the composition has a turbidity of 2.0 NTU or less. The compositions of the present invention provide improved dry conditioning benefits such as reduced friction.... Agent:

20110311472 - Application of mrna for use as a therapeutic against tumour diseases: The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The... Agent: Curevac Gmbh

20110311473 - Methods of treating cognitive impairment: The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3... Agent: University Of South Florida

20110311478 - Combinatorial methods for treating cellular proliferative disorders and immune deficiencies using salicinium: The present invention provides novel immunotherapeutic compositions and methods useful for treating or preventing microbial infections, weakened immune systems, diseases in which cells have become obligately anerobic and cellular proliferative disorders including cancer. The immunotherapeutics herein use benzaldehyde derivatives, precursors and intermediaries alone or in combination with additional therapeutic agents... Agent:

20110311480 - Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Bristol-myers Squibb Company

20110311477 - Infusion treatment methods and compositions using salicinium for treating cellular proliferative disorders and immune deficiencies: The present invention provides novel immunotherapeutic compositions and methods useful for treating or preventing microbial infections, weakened immune systems, diseases in which cells have become obligately anaerobic and cellular proliferative disorders including cancer. The immunotherapeutics herein use benzaldehyde derivatives, precursors and intermediaries alone or in combination with additional therapeutic agents... Agent:

20110311475 - Means and method for the treatment of antibody deficiency diseases based on il-21 and il-21 variants: The present invention relates to an lnterleukin-21 (IL-21) variant which is capable of increasing the secretion of IgG and/or IgA antibodies in B cells and/or is capable of binding the IL-2 receptor complex and/or the IL-4 receptor complex, comprising stretches of amino acids of lnterleukin-4 (IL-4) or lnterleukin-2 (IL-2) in... Agent:

20110311476 - Methods for treating an immune deficiency or enhancing immune function using salicinium, non-limited in terms of treatment indication, but encompassing methods for treating cancer and microbial, bacterial, viral, fungal; non-limited in terms of delivery m: The present invention provides novel immunotherapeutic compositions and methods useful for treating or preventing microbial infections, weakened immune systems, diseases in which cells have become obligately anaerobic and cellular proliferative disorders including cancer. The immunotherapeutics herein use benzaldehyde derivatives, precursors and intermediaries alone or in combination with additional therapeutic agents... Agent:

20110311479 - Modulators of indoleamine 2,3-dioxygenase and methods of using the same: The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.... Agent: Incyte Corporation, A Delaware Corporation

20110311474 - Novel tricyclic compounds: e

20110311481 - Methods and compositions for contributing to the treatment of cancers: Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of chemotherapeutic agent(s) (e.g., cisplatin and/or cyclophosphamide).... Agent: Spectrum Pharmaceuticals, Inc.

20110311485 - 1,2,4-oxadiazole derivatives and their therapeutic use: The present disclosure relates to 1, 2, 4 oxadiazole derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the S1P1 receptors.... Agent: Almirall S.a.

20110311483 - Crth2 modulators: Compounds of Formulae I-1 to I-9 are disclosed, which are modulators of CRTH2, particularly antagonists of CRTH2, that are useful for treating various disorders, including asthma and respiratory disorders.... Agent: Ironwood Pharmaceuticals, Inc.

20110311482 - Hepatitis c virus inhibitors: m

20110311484 - Strains of xenotropic murine leukemia-related virus and methods for detection thereof: Provided are novel strains of Xenotropic Murine Leukemia Virus-Related Virus (XMRV), or polynucleotides or polypeptides thereof. Identified herein are nucleic acid changes or amino acid changes identified in XMRV strains isolated from subjects. Also provided are methods of detecting such XMRV strains based at least in part on the identified... Agent: Whittemore Peterson Institute For Neuro-immune Disease

20110311486 - 1,2,4-oxadiazole benzoic acid compositions: Novel 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising an 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith.... Agent: Ptc Therapeutics, Inc.

20110311487 - Delivery of therapeutic agents to the bone: This invention relates to compositions and methods of delivering therapeutic agents to bone. More specifically, the invention relates to endowing a large molecule vectors i.e., adeno virus, retrovirus, liposomes, micelles, natural and synthetic polymers, or combinations thereof, with the ability to target bone tissue in vivo and with improved stability... Agent: Saint Louis University

20110311488 - Modified bacterial cell: We describe modified bacterial cells that are defective in gene expression and their use in the treatment of bacterial infections of animals and plants and the inhibition of bacterial biofilm formation.... Agent: University Court Of The University Of Edingburgh

20110311489 - Optically-based stimulation of target cells and modifications thereto: Stimulation of target cells using light, e.g., in vivo or in vitro, is implemented using a variety of methods and devices. One example involves a vector for delivering a light-activated molecule comprising a nucleic acid sequence that codes for light-activated molecule. The light-activated molecule includes a modification to a location... Agent:

20110311498 - Generation of patient-specific differentiated cell types by epigenetic induction: Disclosure of a mammalian cytoplasmic donor cell line. Disclosure of a patient specific cell line. Disclosure of a method to obtain a mammalian cytoplasmic donor cell line by fusing a differentiated mammalian cell and a functionally enucleated mammalian embryonic cell line. Disclosure of a method to obtain a patient specific... Agent:

20110311499 - Secretion system and methods for its use: The present invention provides reagents and methods for inhibiting bacterial infection and abnormal cell growth, as well as for selection cloning of nucleic acid inserts.... Agent: University Of Washington Through Its Center For Commercialization

20110311500 - Combination bacteriolytic therapy for the treatment of tumors: Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of... Agent: The Johns Hopkins University

20110311502 - Agent for prevention or amelioration of obesity: r

20110311501 - Anti-obesity agent and anti-obesity food: An anti-obesity agent containing, as an active ingredient, a microorganism which belongs to the species Lactobacillus reuteri and is capable of producing lipases having the amino acid sequences respectively depicted in SEQ ID NO: 1, 3 or 5 or amino acid sequences having deletion, substitution or addition of one or... Agent: Nestec Ltd.

20110311503 - Active ingredient combinations having insecticidal and acaricidal properties: The novel active ingredient combinations which consist of the compounds of the formula (I) in combination with further active insecticidal ingredients (II) are very suitable for control of animal pests such as insects and/or unwanted acarids.... Agent: Bayer Cropscience Ag

20110311490 - Recombinant bacteriophages useful for tissue engineering: The invention provides for a composition comprising a genetically engineered bacteriophage capable of guiding cell growth and polarization via signaling peptides and directionally aligned structures. The invention provides for modified bacteriophage and its uses thereof. The present invention also provides for genetically engineered phage capable of guiding cell growth, migration... Agent: The Regents Of The University Of California

20110311497 - Cell suspension preparation technique and device: The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for grafting to a patient. In applying the method and/or in using the device, donor tissue is harvested, subjected to a cell dissociation treatment, cells suitable for grafting back to a... Agent:

20110311495 - Isolated populations of renal stem cells and methods of isolating and using same: Isolated populations of fetal renal stem cells and progenitor cells are provided. Also provided are methods of generating and using these isolated populations of cells.... Agent: Tel Hashomer Medical Research Infrastructure And Services Ltd.

20110311492 - Maintenance/expansion of hsc's: The invention is related to methods for culturing stem cells, more particularly hematopoietic stem cells (HSC). The invention relates to methods for HSC maintenance and/or expansion through the use of soluble factors. The invention is also directed to cells produced by the methods of the invention. The cells are useful,... Agent:

20110311496 - Mesenchymal stem cells and uses therefor: The present technology provides compositions of mesenchymal stem cells for promoting wound healing or fracture healing and methods of promoting wound healing or fracture healing comprising the steps of administering mesenchymal stem cells in an effective amount.... Agent:

20110311493 - Methods for stabilizing a bioprosthetic tissue by chemical modification of antigenic carbohydrates: Methods are provided herein for modifying antigenic carbohydrate epitopes within a xenographic bioprosthetic tissue by oxidation of vicinal diols to form aldehydes or acids and subsequence reductive amination of aldehydes to form stable secondary amines, or amidation or esterification of acids to form stable amides or esters. Advantageously, methods provided... Agent:

20110311494 - Methods of reprogramming renal cells: A method of reprogramming a differentiated renal cell towards a progenitor phenotype is disclosed. The method comprises up-regulating in the differentiated renal cell an expression of at least one pluripotency associated gene and/or at least one renal stem cell associated gene, thereby reprogramming the differentiated renal cell towards a progenitor... Agent: Tel Hashomer Medical Research Infrastructure And Services Ltd.

20110311491 - Treatment of sarcoidosis using placental stem cells: Provided herein are compositions and methods of treating individuals having sarcoidosis or a sarcoidosis-related disease or disorder, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein. Also provided herein are kits comprising said cells or a composition thereof.... Agent: Anthrogenesis Corporation

20110311504 - Coenzyme q10-containing composition for oral ingestion: Disclosed are: a coenzyme Q10 composition for oral ingestion which improves the bioabsorbability of coenzyme Q10 and enables efficient ingestion of coenzyme Q10 and which is highly safe, and a pharmaceutical preparation and a functional food containing the composition for oral ingestion. Combining coenzyme Q10 and a seed processed product... Agent: Mitsubishi Gas Chemical, Company, Inc.

20110311505 - Photosensitive aminoacid-monomer linkage and bioconjugation applications in life sciences and biotechnology: This invention is related to preparation of photosensitive ruthenium based aminoacid monomers and oligomers, aminoacid monomer-protein cross-linking using photo sensitat ion and conjugation on micro and nano-structures by ruthenium-chelate based monomers. Its vast range biotechnolgy applications of multifunctional, biocompatible, stabilE and specific micro and nanobio-conjugates, which will stand-alone or simultaneously... Agent:

20110311506 - Piggybac transposon variants and methods of use: The present invention provides hyperactive piggyBac transposons, in particular hyperactive piggyBac transposons from Trichoplusia ni (cabbage looper moth) that transpose at a higher frequency than wildtype. The invention also features integration defective piggyBac transposons. The piggyBac transposons and transposases can be used in gene transfer systems for stably introducing nucleic... Agent: The Johns Hopkins University

20110311508 - Method of modulating hsf-1: The present invention is directed to methods of modulating HSF1 activity comprising modifying the acetylation of the DNA binding domain of the HSF1.... Agent: Northwestern University

20110311507 - Methods for diagnosing and treating autoimmune disorders: Provided herein are, inter alia, methods of identifying patients who are at risk of developing an autoimmune disorder, and treating patients suffering from autoimmune disorders.... Agent: The General Hospital Corporation

20110311509 - Treatment of ocular diseases: The present invention relates to the use of at least one protease for the manufacture of a medicament for the treatment and/or prevention of ocular diseases related to neoangiogenesis selected from the group consisting of age related macular degeneration (AMD), choroidal neovascularisation, Hippel-Lindau Disease, iris neovascularisation, ischemic proliferative retinopathy, neovascularisation... Agent: Marlyn Nutraceuticals,inc.

20110311510 - Compositions and methods for prion decontamination: The invention relates to compositions and methods for prion degradation, decontamination or disinfection. The composition comprises an oxidizing agent, one or more proteases and a surfactant such as an ionic surfactant/detergent. The method comprises contacting a prion contaminated entity with a prion-degrading composition comprising an effective amount of an oxidizing... Agent:

20110311511 - Crystal structure of pfa-m1 and the pfa-m1 co4 complex: The invention relates to the X-ray crystal structure of PfA-M1 aminopeptidase alone, and in complex with the phosphinate dipeptide analogue hPheP[CH2]Phe. More specifically the present invention provides the structure coordinates of PfA-M1 and PfA-M1 in complex with Co4. The invention also includes the use of the X-ray crystal structures as... Agent:

20110311517 - Antibodies and methods for treating estrogen receptor-associated diseases: Provided herein in certain embodiments are antibodies, antibody fragments, pharmaceutical compositions, methods for modulating the functions of estrogen receptor alpha 36, and methods for preventing and/or treating diseases mediated by estrogen receptor alpha 36.... Agent: Shenogen Pharma Group, Ltd.

20110311516 - Chemically programmed vaccination: Provided herein is a method for chemically programmed vaccination. Methods include inducing a covalent-binding polyclonal antibody response in a subject and programming the polyclonal response with a targeting compound.... Agent: The Scripps Research Institute

20110311512 - Genetic variants underlying human cognition and methods of use thereof as diagnostic and therapeutic targets: Compositions and methods for the detection and treatment of neurological disorders, including ASD, are provided.... Agent:

20110311513 - Methods for treating coagulation disorders: The invention is directed to methods for treating coagulation disorders, in particular, hemophilia. Such methods utilize novel compositions including Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) alone or in combination with other agents and/or treatment modalities.... Agent:

20110311514 - Methods for treating disorders of amino acid metabolism: The invention is directed to methods for treating disorders of amino acid metabolism, in particular, maple sugar urine disease (MSUD). Such methods utilize novel compositions including Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) alone or in combination with other agents and/or treatment modalities.... Agent:

20110311520 - Methods for treatment of allergic asthma: Methods of treatment of allergic asthma with IgE antagonists, including anti-IgE antibodies, IgE variants, peptide antagonists, peptidomimetics and other small molecules, are described.... Agent: Genentech, Inc.

20110311519 - Methods of treatment of bone degenerative diseases: Methods of reducing bone loss and treating degenerative bone diseases such as osteoporosis are disclosed. The methods comprise administration of an agent that inhibits signaling through the IL-17 pathway, such as an antibody or a quinazoline analogue such as halofuginone.... Agent: Washington University

20110311518 - Novel synthetic agonists of tlr9: The invention relates to synthetic chemical compositions that are useful for modulation of Toll-Like Receptor (TLR)-mediated immune responses. In particular, the invention relates to agonists of Toll-Like Receptor 9 (TLR9) that generate unique cytokine and chemokine profiles.... Agent: Idera Pharmaceuticals, Inc.

20110311521 - Novel therapy for anxiety: The present invention relates to a method of modulating, treating or effecting prophylaxis of a subject having anxiety or at risk of developing symptoms of anxiety, said method being characterized in that a therapeutically effective amount of a modulator of chondroitin sulphate proteoglycans is administered to said subject.... Agent:

20110311515 - Pulmonary administration of immunoglobulin single variable domains and constructs thereof: The present invention relates to a method wherein an immunoglobulin single variable domain (such as a Nanobody) and/or construct thereof are absorbed in pulmonary tissue. More particularly, the invention provides systemic delivery of an immunoglobulin single variable domain and/or construct thereof via the pulmonary route.... Agent: Ablynx N.v.

20110311525 - Delivery of a cd40 agonist to a tumor draining lymph node of a subject: The invention relates to the use of a CD40 agonist for treating cancer, a pre-malignant disorder or an infectious disease, wherein a CD40 agonist is locally administered and targeted to a tumor draining lymph node of a subject. Optionally, a CD40 agonist is formulated in a slow-release formulation. Optionally, a... Agent: Academisch Ziekenhuis Leiden H.o.d.n. Lumc

20110311527 - Il23p19 antibody inhibitor for treating ocular and other conditions: Disclosed herein is a method of treating certain ocular and other diseases with an anti-IL-23p19 antibody.... Agent: Allergan, Inc.

20110311531 - Immunotherapy of autoimmune disorders using antibodies which target b-cells: Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal therapies. The antibodies may be bispecific antibodies which may be produced recombinantly as fusion proteins, or as hybrid, polyspecific antibodies.... Agent: Immunomedics, Inc.

20110311524 - Inhibitors of angiopoietin-like 4 protein, combinations, and their use: Modulators of angiopoietin-like 4 protein are provided along with methods for their use in the treatment of diseases and pathological conditions. Combinations of ANGPTL4 antagonists and other therapeutics, e.g., anti-cancer agents, and methods of their use in the treatment of mammals susceptible to or diagnosed with cancer, or with relapse... Agent: Genentech, Inc.

20110311529 - Method for treating a rheumatic disease using a soluble tla4 molecule: The present invention relates to compositions and methods for treating rheumatic diseases, such as psoriasis arthropathica, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.... Agent: Bristol-myers Squibb Company

20110311522 - Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof: The present invention provides monoclonal antibodies that bind specifically to H5 subtype avian influenza virus hemagglutinin (HA) proteins, and can block the binding activity of at least 50% of the known monoclonal antibodies to the H5 subtype avian influenza virus hemagglutinin (HA) protein. The monoclonal antibodies can be used for... Agent: Xiamen University

20110311523 - Platelet derived growth factor receptor supports cytomegalovirus infectivity: The disclosure relates generally to compositions and methods useful for inhibiting the infection and propagation of viral particles, particularly members of the Herpesviridae family, and more particularly to cytomegalovirus (CMV).... Agent: California Pacific Medical Center

20110311526 - Polynucleotide and polypeptide sequences involved in the process of bone remodeling: This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling, variants and derivatives of the polynucleotides and corresponding polypeptides, uses of the polynucleotides, polypeptides, variants and derivatives, and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders.... Agent: Alethia Biotherapeutics Inc.

20110311530 - Truncated baff receptors: The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered 0-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders.... Agent: Biogen Idec Ma Inc.

20110311528 - Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of psoriasis: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, psoriasis.... Agent: Action Medicines

20110311532 - Inhibition of complement and cellular activation: A method of inhibiting Fc mediated platelet activation in a subject induced by administration of a therapeutic antibody or fragment thereof includes administering to the subject an amount of anti-platelet agent effective to inhibit Fc induced platelet activation in the subject.... Agent:

20110311537 - Methods of using il-1 antagonists to treat familial mediterranean fever (fmf): Methods of treating, inhibiting, or ameliorating Familial Mediterranean Fever (FMF) by administering to a subject in need thereof a therapeutically effective amount of an interleukin 1 (IL-1) antagonist, are provided. The IL-1 antagonist can be an antibody or derivative thereof, which is capable of blocking or inhibiting the biological action... Agent: Regeneron Pharmaceuticals, Inc.

20110311535 - Nkg2d-fc for immunotherapy: Methods for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising an NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression... Agent: Dana-farber Cancer Institute, Inc.

20110311536 - Prevention of type 1 diabetes by treg vaccination with an insulin mimetope: The invention involves methods and products for inducing Treg cells for immune suppression in connection with autoimmune disease and transplant rejection.... Agent: Dana-farber Cancer Institute, Inc.

20110311533 - Regulation of protein level: This represents a method for treating/preventing a disease, disorder or condition comprising administration to a subject in need of a therapeutically amount of a chimeric protein comprising PrP or a fragment thereof and a protein of interest, the DNA encoding the chimeric protein, the vector encoding the DNA or host... Agent:

20110311534 - Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders: The present invention provides for chimeric Wnt antagonists comprising a Frz domain component derived from a Frizzled protein, a secreted Frizzled related protein or Ror protein and an Fc immunoglobulin component, and their use in the treatment and diagnostic detection of cellular Wnt signaling and Wnt-mediated disorders, including cancer.... Agent: Genentech, Inc.

20110311538 - Inhibitors of receptor tyrosine kinases and methods of use thereof: The present invention provides moieties that bind to an Ig-like domain, e.g., D4 or D5, of a human receptor tyrosine kinase, e.g., the human Kit RTK or the PDGFR RTK, or the D7 domain of a type V receptor tyrosine kinase wherein the moieties lock the ectodomain of the receptor... Agent: Yale University

20110311539 - Diagnosis and treatment of cancer using cancer-testis antigens: The invention relates to CT polypeptides and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof in methods and compositions for the diagnosis, prognosis and treatment of diseases, such as cancer. More specifically, the invention relates... Agent: Ludwig Institute For Cancer Research Ltd

20110311541 - Mutant proteins of the f protein of piv-5 and piv-2: The present application concerns mutant proteins of the fusion protein (F protein) of the parainfluenza virus (PIV) which are currently indexed as type 5 PIV (PIV-5 or PIV5) and type 2 PIV (PIV-2 or PIV2). The present application concerns products deriving therefrom, such as: nucleic acids, vectors, cells, fusion inhibitors... Agent: Universite Claude Bernard De Lyon 1

20110311542 - Sp35 antibodies and uses thereof: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of... Agent: Biogen Idec Ma Inc.

20110311543 - Tumor antigens bfa5 for prevention and/or treatment of cancer: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of... Agent:

20110311540 - Wisp polypeptides and nucleic acids encoding same: Wnt-1-Induced Secreted Proteins (WISPs) are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to... Agent:

20110311544 - Anti-cd71 monoclonal antibodies and uses thereof for treating malignant tumor cells: The present invention provides novel anti-CD71 monoclonal antibodies, in particular mouse-human chimeric anti-CD71 monoclonal antibodies, advantageously associated to effector cells for triggering ADCC mechanisms. Anti-CD71 antibodies, as well as pharmaceutical compositions containing them, are useful for inhibiting proliferation and/or killing malignant tumour cells, especially metastatic cutaneous and uveal melanoma cells.... Agent: Institut National De La Sante Et De La Recherche Medicale (inserm)

20110311545 - Family of pain producing substances and methods to produce novel analgesic drugs: A method may include treating pain, shock, and/or inflammatory conditions in a subject. A method may include using a therapeutically effective amount of an antibody, a lipoxygenase inhibitor, a cytochrome P-450 enzyme inhibitor, and/or an antioxidant configurable to at least partially treat pain, shock, and/or inflammatory conditions in a subject.... Agent:

20110311546 - Angiopoietin-2 specific binding agents: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.... Agent: Amgen, Inc.

20110311547 - Arthritis treatment: Administration of a monoclonal Ab (mAb) that specifically targets IL-1α is useful to treating articular and extra-articular symptoms of arthritis.... Agent: Xbiotech, Inc.

20110311548 - Use of b lymphocyte stimulator protein antagonists to treat asthma and other allergic and inflammatory conditions of the respiratory system: The invention relates to methods of preventing, treating, and ameliorating asthma, allergen-induced respiratory symptoms, and/or an allergic or inflammatory condition of the lung or respiratory system in a patient by administering B Lymphocyte Stimulator antagonists. In addition, the invention provides a method of reducing total serum IgE levels in a... Agent: Human Genome Sciences, Inc.

20110311549 - Methods for treating conditions associated with masp-2 dependent complement activation: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2... Agent: Omeros Corporation

20110311550 - Agents for hcv treatment: Provided are polypeptides, including antibodies and fragments thereof, useful for preventing or treating new or recurring infection of hepatitis C virus, as well as methods of preventing or treating new or recurring hepatitis C viral infection. Also provided are modified E1 and E2 polypeptides.... Agent: The Scripps Research Institute

20110311551 - Antibodies directed against hepatitis c virus e1e2 complex, compositions of hcv particles, and pharmaceutical compositions: The invention provides new conformational antibodies, and more particular conformational monoclonal antibodies and fragments thereof, that are directed against HCV. Also provided are compositions of particles that are recognized by such antibodies, and pharmaceutical compositions containing these particles. Also described are HCV enveloped subviral particles and purified HCV enveloped complete... Agent:

20110311554 - Compositions and methods for suppressing fibrocytes: The present invention relates to the ability of anti-FcγR antibodies to suppress fibrocytes. Methods and compositions for suppressing fibrocytes are provided. These methods are useful in a variety of applications including treatment and prevention of conditions resulting from fibrosis in the liver, kidney, lung, heart and pericardium, eye, skin, mouth,... Agent:

20110311553 - Effectors of par-2 activation and their use in the modulation of inflammation: The present invention relates to the recognition that PAR-2 receptors amplify the inflammatory response and that effectors of PAR-2 activation can thus be used to modulate the inflammatory response and thereby impart therapeutic benefit to patients. The invention is particularly directed to the use of PAR-2 effectors in the treatment... Agent: Boehringer Ingelheim International Gmbh

20110311552 - Notch1 receptor binding agents and methods of use thereof: Means and methods for the diagnosis, characterization, prognosis and treatment of cancer, specifically targeting cancer stem cells are disclosed Provided is an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth, and a method of... Agent:

20110311556 - Anti-rhesus d monoclonal antibody: The invention relates to an anti-RhD monoclonal antibody, which is a tetrameric IgG1 immunoglobulin composed of two heavy chains and two light chains, the heavy chain comprising the amino acid sequence SEQ ID No. 2, harboring a phenylalanine residue at position 68, and the light chain comprising the amino acid... Agent: Lfb-biotechnologies

20110311555 - Tc11 as a transcriptional regulator: Methods and compositions for the diagnosis, prognosis and/or treatment of B cell chronic lymphocytic leukemia associated diseases are disclosed.... Agent: The Ohio State University

20110311557 - Reciprocal serum/plasma exchange for the treatment of cancer: Techniques for treating cancer are provided. The techniques include obtaining an amount of serum and/or plasma from at least a first patient with a given type of cancer and administering at least a portion of the serum and/or plasma obtained from the first patient to at least a second patient... Agent:

20110311558 - Recombinant bone marrow stromal antigen-2 in the treatment of autoimmune diseases: Methods, compositions and kits are disclosed for inhibiting interferon production and modulating immune responses, particularly an autoimmune response. In certain embodiments, the methods involve administering an effective amount of a BST2 protein or a nucleic acid encoding an BST2 protein to treat an autoimmune disease or disorder.... Agent: The Board Of Regents Of The University Of Texas System

20110311562 - Glycolipid mixture with anti-inflammatory activity obtained from oscillatoria planktothrix: It was observed that a highly purified preparation of polar glycolipids extracted from cells of the cyanobacterium Oscillatoria Planktothrix is characterized by the presence of at least one species of high molecular weight glycolipid comprising one or more units of rhamnose. In such mixture, having a level of nucleic acid... Agent:

20110311559 - Method of identifying cd4+ cd25+ t-cells activated to an antigen which express cd8: The invention relates to a method of identifying CD4+ CD25+ T cells activated to an antigen in a population of T cells, comprising identifying CD4+ CD25+ T cells which express CD8. The invention also relates to a method of isolating CD4+ CD25+ T cells activated to an antigen comprising isolating... Agent:

20110311560 - Methods and compositions relating to ccr5 antagonist, ifn-gamma and il-13 induced inflammation: The present invention includes compositions and methods for the treatment of Th1 and/or Th2 mediated inflammatory diseases, relating to inhibiting CCR5. This is because the present invention demonstrates, for the first time, that expression of IFN-γ, IL-13, and CCR5, mediates and/or is associated with Th1 and/or Th2 inflammatory diseases and... Agent:

20110311561 - Non-natural mic proteins: This invention describes soluble, monovalent, non-natural protein molecules that can activate NK cells and certain T-cells to attack specific cellular target cells by attaching the NKG2D-binding portions of monovalent MICA or MICB protein, i.e. their α1-α2 platform domain, to the intended target cell specifically. The α1-α2 domain is contiguous with... Agent: Avidbiotics Corp.

20110311567 - Immunogenically-enhanced polypeptides and related methods: Described herein are immunogenically-enhanced polypeptides, such as KSHV LANA1 polypeptides, related methods of eliciting an immune response to the polypeptides and related nucleotide sequences. Also described herein are novel polypeptides capable of inhibiting degradation and/or retarding synthesis of a protein when attached to or incorporated within that protein along with... Agent:

20110311564 - Method for producing intermediates for the production of novel macrocycles that are inhibitors of the proteasomic degradation of p27, such as argyrin and derivatives thereof, and uses of said macrocycles: The present invention relates to the use of particular macrocycles that are inhibitors of the proteasomic degradation of p27, in particular argyrin and derivatives thereof, for a treatment in a variety of conditions, such as the induction of immunotolerance, autoimmune diseases, bacterial infections, and proliferative diseases, such as cancers.... Agent:

20110311566 - Methods and materials for generating t cells: The document provides to methods and materials for generating T cells (e.g., antigen-specific CD4+ T cells). For example, methods and materials for using nested MHC class II epitopes as vaccines to generate activated CD4+ T cells in vivo or as reagents to generate activated CD4+ T cells ex vivo are... Agent:

20110311565 - Phage constructs, sequences and antigenic compositions for immunocontraception of animals: Disclosed are methods, compositions, zona pellucida binding peptides and polypeptides, and expression vectors for use in species-specific immunocontraception of animals, which include landscape bacteriophage. The disclosed compositions may include immunogenic compositions or vaccines.... Agent: Auburn University

20110311563 - Synthetic antigenic peptides and lipopeptides derived from mycobacterium avium subsp. paratubuerculosis: The current invention relates to the diagnosis and treatment of diseases resulting from infections by Mycobacterium avium subsp. paratuberculosis. In particular the invention relates to the use of an antigen selected among (a) a synthetic peptide 5P having the following formula: DPhe-NMeVal-Ile-Phe-Ala-OMe (SEQ ID NO: 1); (b) a lipopeptide L5P... Agent:

20110311568 - Vaccine: The present invention provides a foot and mouth disease (FMD) vaccine comprising or capable of expressing afoot and mouth disease virus (FMDV) VP1 polypeptide having a deletion of at least seven amino acids in the G-H loop such that the VP1 polypeptide lacks an RGD motif. The present invention also... Agent:

20110311569 - Hiv-1 peptides, nucleic acids, and compositions and uses thereof: This invention features polypeptides, variants thereof, and fragments thereof useful in eliciting an immune response (e.g., neutralizing antibodies) against abroad spectrum of HIV-I isolates. The polypeptides, variants, and fragments include a portion of the gp120 V2 domain of HIV-I. The polypeptides, variants, and fragments display an epitope that is recognized... Agent:

20110311570 - Proteins with repetitive bacterial-ig-like (big) domains present in leptospira species: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3... Agent: The Usa Gov. Represented By The Dep. Of Veterans Affairs,the Regents Of The University Of Californi

20110311571 - Methods and compositions for treating and preventing malaria using an invasion ligand directed to a protease-resistant receptor: This invention relates to an immunogenic molecule comprising a contiguous amino acid sequence of an invasion ligand of a strain of Plasmodium falciparum, the invasion ligand capable of binding to an erythrocyte receptor, the receptor function being resistant to trypsin and neuraminidase and chymotrypsin, wherein when administered to a subject... Agent:

20110311572 - Nucleotide and amino acid sequences encoding an exported protein 1 derived from plasmodium vivax and uses thereof: The present invention is directed to novel polynucleotides and polypeptides directed to EXP1 of Plasmodium vivax, and methods of using these polynucleotides and polypeptides in the detection of P. vivax antibodies or anti-P. vivax antibodies in a subject. The invention finds particular useful application in identifying recent exposure to P.... Agent: Abbott Laboratories

20110311573 - Method for preparing recombinant antigen complex using rotavirus nanoparticle: Disclosed are a construct for expressing a rotavirus antigen complex loaded with a heterologous virus epitope, a vaccine composition containing the rotavirus antigen complex, a virus-like particle of rotavirus containing the rotavirus antigen complex, and a vaccine composition containing the virus-like particle of rotavirus. According to the present disclosure, an... Agent: Chung-ang University Industry-academy Cooperation Foundation

20110311574 - Multiple vaccination including serogroup c meningococcus: Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular B. pertussis antigen; (b) co-administration with an inactivated poliovirus antigen; (c) supply in a kit together with a separate pneumococcal conjugate component, which may be in a liquid form; and (d) use in... Agent: Novartis Vaccines And Diagnostics Gmbh

20110311577 - Method of producing a vaccine: The present invention relates to a method for purifying bacterial cytolysins such as pneumococcal pneumolysin. A single chromatography step produces excellent purification of the cytolysin by binding soluble aggregated cytolysin to a hydrophobic interaction chromatography material in the presence of detergent and high salt.... Agent:

20110311575 - Mixing lyophilised meningococcal vaccines with d-t-pa vaccines: A liquid D-T-Pa component is used to reconstitute a lyophilised meningococcal component, thereby producing a combined vaccine.... Agent: Novartis Ag

20110311576 - Mixing lyophilised meningococcal vaccines with non-hib vaccines: An aqueous immunogen formulation is used to reconstitute a lyophilised component including conjugates of capsular saccharides from Neisseria meningitidis serogroups A, C, W135 and Y, thereby producing a combined vaccine. The aqueous formulation can include various immunogens but does not include a Hib conjugate.... Agent: Novartis Ag

20110311579 - Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof: This invention provides flavivirus vaccines that comprise live-attenuated flaviviruses and methods of making and using these vaccines. The flavivirus vaccines described herein possess higher potency due to in situ production of additional immunogens in a way that mimics viral infection and the vaccines have potential for higher potency, reducing costs... Agent:

20110311578 - Recombinant inactivated viral vector vaccine: A vaccine is described, comprising an inactivated viral vector having inserted an exogenous nucleotide sequence coding for a disease of concern; and, a pharmaceutically acceptable vehicle, adjuvant or excipient, which provides due protection against the disease of concern by using a viral vector titer similar to that required for an... Agent: Laboratorio Avi-mex, S.a. De C.v.

20110311580 - Settings for recombinant adenoviral-based vaccines: Described are new uses of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, also described are new assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy setting.... Agent: Crucell Holland B.v.

20110311582 - Novel lipids and compositions for the delivery of therapeutics: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention formula (I) provides lipids having the following structure XXXIII wherein: R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally... Agent:

20110311583 - Novel lipids and compositions for the delivery of therapeutics: (A1) Translate this text The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure (I) wherein R1 and R2 are each independently for each occurrence optionally substituted C10-C30... Agent: Alnylam Pharmaceuticals, Inc.

20110311581 - Reverse genetics of negative-strand rna viruses in yeast: The present invention relates to a methodology for the generation of infectious ribonucleoparticles (RNPs) of negative-strand RNA viruses, and in particular of non-segmented negative-strand RNA viruses in yeast, especially in budding yeast. Accordingly, the patent application relates to a recombinant yeast strain suitable for the rescue of infectious non-segmented negative-strand... Agent: Institut Pasteur

20110311584 - Use of flt3 ligand for enhancing immune responses in rna immunization: The invention relates to supplying vaccine RNA to cells. The invention relates in particular to a common use of vaccine RNA and Flt3 ligand for inducing, creating or enhancing an immune response when administered to animals (including humans).... Agent:

20110311585 - Therapeutic compositions and methods for treating hiv including identification and manipulation of particular domains associated with immunogenicity: Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity.... Agent: The Regents Of The University Of California

20110311586 - Materials and methods for respiratory disease control in canines: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions... Agent: Cornell Research Foundation, Inc.

20110311587 - Fusogenic virus-like particles and uses thereof: Provided herein are novel Paramyxovirus virus-like particles, wherein said virus-like particles are composed of surface glycoprotein G; surface glycoprotein F; and matrix protein M. Further provided is a vaccine comprising the virus-like particles described herein and a pharmaceutically acceptable carrier. Also provided is a method of vaccinating a subject against... Agent:

20110311588 - Agents and treatment for snoring and respiratory effort related arousals in sleep: A method for prophylaxis or treatment of respiratory effort related arousals during sleep of a subject is provided. The method comprises administering to the subject an effective amount of an agent for reducing or inhibiting infection or colonisation of the nasal cavity of the subject by Staphylococcus aureus. Typically, the... Agent:

20110311589 - Compositions and dosage regimes comprising a clostridial vaccine and levamisole: A composition and dosage regime including a vaccine and levamisole for the treatment of clostridial diseases and helminthiasis. New methods of administration relating to particular dosage regimes of such a composition are also claimed.... Agent: Bomac Research Limited

20110311590 - Compositions for treating an allergic or asthmatic condition: Compositions including human Tr1 cells directed to an allergen associated to an allergen or asthmatic provided the allergen is not a food allergen and use thereof for treating an allergic or asthmatic condition, excluding a food allergic condition.... Agent: Txcell

20110311591 - Antimicrobial coating: A substrate (100) comprising a sol-gel derived coating (101). The coating, is chemically bonded to the substrate (100) and is derived from a polysiloxane to form a network of silicon-carbon and silicon-oxygen bonds. An antimicrobial is releasably captured within the network and is capable of defusing from the coating in... Agent: Sheffield Hallam University

20110311594 - Controlled release compositions with reduced food effect: The present invention provides a controlled release pharmaceutical composition which exhibits reduced food effect.... Agent:

20110311595 - Dosage forms with improved bioavailability: A solid dispersion product comprising an effective amount of one or more active ingredients and an effective amount of one or more hydroxypropyl methylcellulose(s), which satisfies the Formula 0.35>ΔHtr (1) (wherein AHtr represents the endotherm (J/g) accompanying a transition at about 240° C.). The solid dispersion product is used for... Agent: Abbott Gmbh & Co. Kg

20110311592 - Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds: The subject invention relates to novel soluble forms of planar ring structured organic compounds including flavonoids, and their production. The invention also includes the use of these novel formulations of planar ring structured organic compounds in the preparation of formulations and products. The invention also relates to a wide variety... Agent: Api Genesis, LLC

20110311593 - N-hydroxylated amidine-, guanidine- and/or aminohydrazone-type prodrugs for application on the skin: The invention relates to N-hydroxylated amidines, guanidines and aminohydrazones for application on the skin. In particular, the invention relates to transdermal therapeutic systems containing N-hydroxylated amidines, guanidines and aminohydrazones as a prodrug, and to methods for producing and using such systems.... Agent:

20110311596 - Poly(amide) and poly(ester-amide) polymers and drug delivery particles and coatings containing same: The current invention relates to poly(amide) and poly(ester-amide) polymers, coatings including the polymers, and narrow polydispersity drug delivery particles including the polymers.... Agent: Abbott Cardiovascular Systems Inc.

20110311599 - Granulated powder containing vegetable proteins and fibers, process for producing same, and use thereof: The present invention concerns a granulated powder containing at least one vegetable protein and at least one vegetable fiber, characterized in that it has a laser volume mean diameter D4,3 of between 10 μm and 500 μm, preferably between 50 μm and 350 μm, and even more preferably between 70... Agent: Roquette Freres

20110311597 - Magnetically-oriented cosmetic fibers: There is provided a dissolvable film polymer matrix that includes a plurality of magnetically responsive kertin-like fibers for application to an individual's face or head. The dissolvable film polymer matrix product includes hairs that are magnetically oriented in a non-random plain to be applied on an individuals face or head... Agent: Avon Products, Inc.

20110311598 - Powdery emulsifying composition of alkyl polyglycosides, use thereof for preparing cosmetic emulsions, and method for preparing same: A powdery composition C1 contains for 100% of the mass: 5 to 70 mass % and more particularly 10 to 50 mass % of at least one compound of formula (I): R—O-(G)x-H, wherein R is a linear saturated aliphatic radical including 12 to 22 carbon atoms, G is the remainder... Agent: Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic

20110311600 - Anti-bacterial cleaning composition: The present invention is directed to a multi-surface cleaning composition having an anti-bacterial ingredient for cleaning furniture surfaces. The anti-bacterial cleaning component includes a quaternary ammonium chloride compound or combinations thereof. The composition further includes a pH adjuster to provide for a generally neutral pH in the range of about... Agent:

20110311601 - Antimicrobial medical devices: A medical device having a silane surface comprising an antimicrobial peptide exhibiting a complex tertiary structure, wherein the antimicrobial peptide is attached to the silane surface via reversible interaction.... Agent:

20110311602 - Transdermal venous access locking solutions: Microbial growth inhibiting solutions and methods of employing the microbial growth inhibiting solutions in flushing and coating medical devices are disclosed. In alternative embodiments, the microbial growth inhibiting solutions include combinations of a chelating agent with a C4-C9 carboxylate antimicrobial agent, for example, such as n-octanoic acid. Methods of using... Agent: Organic Medical Ventures, L.L.C.

20110311604 - Domestic appliance comprising an antimicrobial agent: The invention relates to a domestic appliance, such as an iron, provided with a surface layer. The surface layer comprises an antimicrobial agent associated with a carrier, the carrier being inorganic and selected such that the antimicrobial activity of the surface layer according to JIS Z2801:2000 has a value of... Agent: Koninklijke Philips Electronics N.v.

20110311603 - Materials, methods, and apparatuses for controlling pests: A bedding cover treated with a pesticide. The cover repels or kills pests such as bedbugs, dust mites, ticks, fleas, and other pests for use in bedrooms, hotels, motels, pet beds, and the like. The cover is preferably waterproof and disposable. Also a quilted material for controlling pests, and methods... Agent: Kiltronx Enviro Systems, LLC

20110311605 - Coating designs for the tailored release of dual drugs from polymeric coatings: Provided herein are coating designs for the tailored release of two therapeutic agents from polymer coatings and methods of making and using the same.... Agent: Abbott Cardiovascular Systems Inc.

20110311606 - Punctal plugs with continuous or pulsatile drug release mechanism: Disclosed are lacrimal inserts and their method of use for delivery of of medication to the eye. The plug includes a body portion sized to pass through a lacrimal punctum and be positioned within a lacrimal canaliculus of the eyelid. The plug may contain a core, or reservoir, at least... Agent:

20110311607 - Punctal plugs with continuous or pulsatile drug release mechanism: Disclosed are lacrimal inserts and their method of use for delivery of medication to the eye. The plug includes a body portion sized to pass through a lacrimal punctum and be positioned within a lacrimal canaliculus of the eyelid. The plug may contain a core, or reservoir, at least partially... Agent:

20110311608 - Stable chitosan hemostatic implant and methods of manufacture: Implantable hemostatic products with improved stability are prepared from crosslinked chitosan hemostatic compositions. The crosslinked chitosan hemostatic compositions have improved stability and can be prepared into a variety of implantable medical devices in various shapes and sizes so as to be usable for inhibiting blood flow and ooze from substantially... Agent: Abbott Vascular, Inc.

20110311609 - Wound healing device: The invention is directed to a wound healing device. Such wound healing device utilizes novel wound healing compositions embedded onto or into a natural plant-derived cloth-based matrix.... Agent:

20110311610 - Temperature reducing, healing wound dressing: The present invention relates to wound dressings having a wound contacting layer that contains a wound healing composition and which is adapted to maintain a temperature different from ambient, for example achieve and maintain a heat-absorbing effect on the underlying tissues. The specific physico-chemical structure of the devices of the... Agent: Laboratoire Medidom S.a.

20110311611 - Water dissolvable adherent article for topical application: An adherent article with a first substrate, soluble or dispersible in aqueous solutions, with a first and second side, and an aqueous-insoluble second substrate disposed on at least a portion of the second side of the first substrate, optionally, with an adhesive applied to at least a portion of the... Agent:

20110311612 - Humanized neuraminidase antibody and methods of use thereof: Antibodies against influenza neuraminidase, compositions containing the antibodies, and methods of using the antibodies are provided herein.... Agent: Fraunhofer Usa, Inc.

20110311615 - Novel gp41 antigens: The present invention deals with a modified polypeptide comprising three contiguous segments N, L and C represented by the formula N−L−C and comprising: a N-helix region of gp41 (N), a C-helix region of gp41 (C), and a connecting loop comprising a synthetic linker (L) between the N and C-helices, the... Agent: Mymetics Corporation

20110311614 - Splitting gp41: The present invention deals with a method for therapeutic or prophylactic treatment of HIV, in particular a prophylactic vaccinal method, comprising at least: administering to a patient a first antigen comprising the broadly neutralizing epitopes of the Membrane Proximal Ectodomain Region (MPER) of gp41, and administering to the same patient... Agent: Mymetics Corporation

20110311616 - Targeting tumor associated macrophages using bisphosphonate-loaded particles: Provided herein are compositions including particles that comprise a bisphosphonate compound and a tumor specific targeting peptide or peptidomimetic. Also provided herein are methods of reducing tumor associated macrophages and methods of treating cancer with said compositions.... Agent:

20110311613 - Topical formulations of flap inhibitors for the treatment of dermatological conditions: Described herein, are topical formulations for treating a dermatological disease, disorder, or condition. Topical formulations disclosed herein include a therapeutically-effective amount of a FLAP inhibitor formulated for dermal administration... Agent: Amira Pharmaceutical, Inc.

20110311618 - Inhalable particles comprising tiotropium: The present invention relates to inhalable particles comprising a stabilized amorphous form of tiotropium with a stabilizing agent. It also relates to inhalable particles comprising a stabilized amorphous form of tiotropium with a stabilizing agent mixed with one or more coarse excipients having a mean particle size of 15 to... Agent: Laboratorios Liconsa, S.a.

20110311617 - Oral vaccine: The present invention provides an oral vaccine against a bacterial infectious disease (e.g., typhoid fever, cholera, or dysentery). The oral vaccine of the present invention is a capsule formulation in which a transformed microorganism that expresses a flagellin antigen protein or that secretes a flagellin antigen protein out of the... Agent:

20110311619 - Pharmaceutical formulation of nanonised fenofibrate: The invention relates to a pharmaceutical formulation of nanonised fenofibrate, to a method for preparing same, and to the uses thereof.... Agent: Ethypharm

20110311620 - Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors: The present disclosure relates to novel dosage forms of xanthine oxidoreductase inhibitors.... Agent: Takeda Pharmaceuticals North America, Inc.

20110311622 - Method for adding sensory conditioning cues in a pharmacotherapeutic regimen: A method for administering pharmaceutical agents to a subject is provided. The method includes the steps of: a) providing a course of treatment for a subject, which course includes periodically administering an amount of medicine to the subject, which amount of medicine includes a dose of at least one active... Agent:

20110311621 - Pharmaceutical compositions and methods of delvery: The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent (such as CCK-8, octreotide), at least one salt of a medium chain fatty acid, a matrix forming polymer and a hydrophobic(lipophilic) medium. A surfactant may be... Agent:

20110311623 - Composition for manufacturing orally disintegrating dosage form to protect coating layer of active substance: The present invention relates to a composition for manufacturing an orally disintegrating dosage form that is used to prevent a coating layer of an active substance which is formed in a predetermined size in order to mask a bitter taste or an unpleasant taste. A predetermined ratio of an excipient... Agent:

20110311624 - Formulations of histone deacetylase inhibitor and uses thereof: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.... Agent: Pharmacyclics, Inc.

20110311625 - Solid dosage forms of fenofibrate: An improved solid dosage form of fenofibrate which exhibits improved dissolution properties leading to increased bioavailability of fenofibrate. A novel core-shell approach to the composition is provided as well as a process for the preparation of the improved solid dosage forms.... Agent:

20110311626 - Controlled release compositions comprising anti-cholinergic drugs: The present invention provides compositions comprising dicyclomine, or salts, and/or solvates and methods of making and using the compositions to treat intestinal hypermotility or Irritable Bowel Syndrome (IBS). The present invention also provides once-a-day orally disintegrating dosage forms comprising compositions of the present invention.... Agent:

20110311627 - Controlled release levetiracetam formulations and methods for producing the same: Pharmaceutical compositions in the form of tablets are disclosed including water-soluble active ingredients such as levetiracetam and a polymer component which primarily includes water-insoluble polymers comprising between 60% and 100% of the polymer component in the tablet core, preferably the entire polymer component in the tablet core. The pharmaceutical compositions... Agent:

20110311628 - Pulsatile release composition of therapeutic agent: A pulsatile release composition which releases the content rapidly after a predetermined lag time comprising a drug containing a core, coated with a pH sensitive graft copolymer. The coating suppresses the drug release at acidic pH prevalent in the stomach and releases it either immediately or after a lag time... Agent: Council Of Scientific And Industrial Research

20110311629 - Non-adhesive elastic gelatin matrices: The present invention is a substantially non-adhesive elastic gelatin matrix. The matrix is both non-adhesive to wounds, tissues and organs and is also elastic such that it is flexible. The matrix is a lyophilized mixture of protein(s), polymer(s), cross-linking agent(s) and optional plasticizer(s). The invention also provides methods for making... Agent: Covalon Technologies Inc.

20110311631 - Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients: The invention relates to a controlled release pharmaceutical composition, comprising a core, comprising a pharmaceutical active ingredient, whereby the core is coated by an ethanol resistance conferring coating layer which has the effect of conferring the release profile of the pharmaceutical active ingredient to be resistant against the influence of... Agent: Evonik R&#xd6 Hm Gmbh

20110311630 - Novel embedment particles for inhalation: The invention relates to the preparation of inhalable powders which exhibit a delayed release of active substance and processes for preparing them as well as medicaments that can be produced using these inhalable powders.... Agent: Boehringer Ingelheim International Gmbh

20110311632 - Stable chitosan hemostatic external patch and methods of manufacture: Hemostatic products with improved stability are prepared from crosslinked chitosan hemostatic compositions. The crosslinked chitosan hemostatic compositions have improved stability and can be prepared into a variety of medical devices in various shapes and sizes so as to be usable for inhibiting blood flow and ooze from substantially any type... Agent: Abbott Vascular, Inc.

20110311633 - Combination of a silicon containing component and a hormone: The invention relates to the use of a silicon-containing material to reduce the amount of hormone required in a method of hormone treatment to achieve a desired response, particularly in hormone replacement therapy (HRT) and especially in the maintenance of post-menopausal bone health and the management or treatment of osteoporosis,... Agent:

20110311634 - Formulations for animal feed comprising butyrate salt: The present invention relates to formulations for animal feed comprising coated granules comprising butyrate salt; the butyrate salt is preferably the salt of sodium or calcium salt. The coated granules have a particle size of 0.1 mm or more, preferably 0.2 mm or more and about 2 mm or less,... Agent: Sanluc International Nv

20110311635 - Hollow metal oxide spheres and nanoparticles encapsulated therein: A nanoparticle including a Group 3 atom-containing shell. In various embodiments, the nanoparticle includes a metal or metal catalyst-containing core, or a substantially metal-free core. In other embodiments, the nanoparticle shell is hollow. A method of preparing the nanoparticle and methods of using such particles are also provided.... Agent: The Regents Of The University Of California

20110311636 - Methods and medicaments for administration of ibuprofen: A method for administration of ibuprofen to a subject in need of ibuprofen treatment is provided, in which an oral dosage form comprising a therapeutically effective amount of ibuprofen and a therapeutically effective amount of famotidine is administered three times per day.... Agent:

20110311637 - Methods and medicaments for administration of ibuprofen: A method for administration of ibuprofen to a subject in need of ibuprofen treatment is provided, in which an oral dosage form comprising a therapeutically effective amount of ibuprofen and a therapeutically effective amount of famotidine is administered three times per day.... Agent:

20110311638 - Nanosilver porous material particles and fabricating method thereof: Nanosilver porous material particles and method for manufacturing the same are disclosed. The nanosilver porous material particles include nanosilver particles distributed on the surface thereof. First, a nanosilver precursor is dissolved in water and a proper quantity of a fixation agent is added to form a solution. Next, a proper... Agent: Apex Nanotek Corporation

20110311639 - Facile route to the synthesis of resorcinarene nanocapsules: Described is a direct method for the fabrication of resorcinarene nanocapsules by photopolymerization of compounds of formula (I), such as resorcinarene tetraalkene tetrathiol (RTATT), in the absence of any template or preorganization. Further, by varying the polymerization media, a variety of other polymeric architectures like lattices, fibrous networks, and nanoparticles... Agent: Old Dominion University Research Foundation

20110311641 - composition for making pathological tissues dehydration and/or contraction: The present invention provides a pharmaceutical composition for dehydrating and atrophying pathological tissues comprising ferric subsulfate, polyferric sulfate or a mixture thereof is disclosed. Ferric subsulfate and polyferric sulfate are traditionally used as water treatment agent. The inventor surprisingly discovered the medical value of these substances. The compositions are cost-effective,... Agent:

20110311640 - Cosmetic compositions comprising asteroidea body fluid and methods of use thereof: A skin care composition comprising an isolated Asteroidea body fluid or extract thereof is described. Uses and methods of use of the composition for the prevention and/or treatment of a skin disorder or condition, such as skin-aging signs, are also described.... Agent: Innovactiv Inc.

20110311642 - Composition and method for oral delivery of cobra venom: A composition of sterile cobra venom and a method for its oral administration to provide significant analgesic effects to a human and/or animal are disclosed. Such cobra venom compositions comprise a sterilized solution preserved by the addition of one or more suitable food-grade preservatives. The venom composition may be conveniently... Agent:

20110311644 - Plasma-adapted full electrolyte solution: The present invention describes a balanced aqueous electrolyte solution. In particular, a balanced aqueous electrolyte solution that is particularly suitable as a solution for intravenous and subcutaneous infusion because of its being plasma-adapted is described. In addition to the balanced electrolyte solution itself, an electrolyte mixture as well as a... Agent: B. Braun Melsungen Ag

20110311643 - Supplemented matrices for the repair of bone fractures: Supplemented matrices comprising a PTH releasably incorporated therein, optionally containing a granular material, which are used to heal bone fractures, particularly bone fractures with a risk of becoming delayed unions or non-unions, are described herein. The PTH is incorporated either through covalent linkage to the matrix or through non-covalent interaction... Agent: Kuros Biosurgery Ag

20110311645 - Microbiological control in oil and gas operations: A fracturing fluid may include water; at least one polymeric viscosifier; at least one proppant; and a solution of peracetic acid in an amount effective to inhibit bacterial growth. Other embodiments are directed to methods for inhibiting bacterial contamination in a fracturing fluid and/or ballast water.... Agent:

20110311646 - Peroxide contact lens care solution: A contact lens disinfecting solution that comprises 0.5 wt. % to 6 wt. % hydrogen peroxide, or a chemical precursor of hydrogen peroxide, and a P-metal modulating compound. The presence of the P-metal modulating compound in the disinfecting hydrogen peroxide solution slows the rate at which the hydrogen peroxide is... Agent:

20110311647 - Biofilm-removing antimicrobial compositions and uses thereof: The present invention provides novel compositions comprising: (a) protamine sulfate and (b) benzalkonium chloride or a silver containing particle; or (a) sodium metaperiodate and (b) 5-fluorouracil or chlorhexidine and uses thereof for the preparation of devices, and in particular medical devices, susceptible to colonization by biofilm forming bacteria.... Agent: Kane Biotech Inc.

20110311648 - Novel methods for the treatment of cancer: Compositions and methods for the treatment of malignancy and chronic viral infection are disclosed.... Agent:

20110311649 - Novel imidazole derivatives: The present invention relates to novel imidazole derivatives of formula (I) as active ingredients which have microbiocidal activity, in particular fungicidal activity: wherein R1 is halogen, C1-C4alkyl or C1-C4haloalkyl; R2 is an optionally substituted aryl or heteroaryl; R3 is halogen; R4 is hydrogen, halogen, C1-C4alkyl, C1-C4haloalkyl, hydroxyl, C1-C4alkoxy, OR6, C1-C4haloalkoxy... Agent: Syngenta Crop Protection, Inc.

20110311650 - Multiplexed biomarkers of insulin resistance: The invention, in some aspects, relates to methods for characterizing glucose-related metabolic disorders. In some aspects, the invention relates to methods and kits useful for diagnosing, classifying, profiling, and treating glucose-related metabolic disorders. In some aspects, the invention relates to methods useful for diagnosing, classifying, profiling, and treating diabetes.... Agent:

20110311651 - Cardenolides for the treatment of ocular cancer: The instant invention provides methods of using a class of compounds known as cardenolides in the treatment of proliferative diseases such as cancer. In particular, the instant invention provides methods of treating ocular cancer {e.g., retinoblastoma) using intraarterial infusion to administer cardenolides locally to the eye of a subject with... Agent: Sloan-kettering Institute For Cancer Research

20110311652 - Novel saponin compounds, methods of preparation thereof, use thereof and pharmaceutical compositions: This invention relates to novel saponin compounds of formula II wherein MBz denotes p-methoxybenzoyl, and R is selected from the group comprising C6-10 aryl, C6-10 aryl-C1-4 alkyl-, C1-18 alkanoyl, C3-18 alkenyl, C6-10 aryl-C(O)—, C6-10 aryl-C1-4 alkyl-C(O)—, wherein each of the groups can optionally be substituted. These compounds possess a selective... Agent:

20110311653 - Use of nitrite salts in chronic ischemia: Methods of treating a subject who has chronic tissue ischemia are disclosed. The methods can include administering to the subject a pharmaceutical composition comprising inorganic nitrite or a pharmaceutically acceptable salt thereof, for a time and in an amount sufficient to result in blood vessel growth in the ischemic tissue.... Agent: Louisiana State University

20110311654 - Methods and pharmaceutical compositions for treating the animal central nervous system for psychiatric disorders: The present invention comprises methods and pharmaceutical compositions for intranasal delivery of effective amounts of DFO directly to the CNS, in particular the brain treatments that inhibit GSK3b in patients with psychiatric disorders including, but not limited to, bipolar disorder, depression, ADHD and schizophrenia. In addition a treatment composition is... Agent: Healthpartners Research Foundation

20110311655 - Further preparations of silk proteins, seed oils, monosaccharide, natural botanicals and polysaccharide mixtures in compositions for hair care or hair repair, and skin care and topical treatments: The present invention intends to provide a composition for hair and skin treatment containing a combination consisting of silk amino acid and protein complexes, seed oils, polysaccharides, polyol, monosaccharide, and botanicals. The composition for hair and skin treatment containing the combination consisting of silk amino acid and protein complexes, seed... Agent:

20110311656 - Antimicrobial composition based on botanical extracts from oil palm vegetation liquor: The present invention provides an antimicrobial composition comprising compounds extracted from the vegetation liquor of the palm oil milling process has been suggested. This composition is rich in antioxidants and exhibits enhanced antimicrobial activity and bactericidal effect against a number of micro-organisms.... Agent: Malaysian Palm Oil Board

20110311657 - Use of a neuroprotective extract and pharmaceutical preparation thereof: The present invention discloses an extract having neuroprotective property prepared from a plant of the family Palmae, which is capable in preserving neurons against damage caused by oxidation, ageing and/or nitric oxide deficiency. Also disclosed is a pharmaceutical preparation and a comestible preparation comprising the extract as an active ingredient... Agent: Universiti Putra Malaysia

20110311658 - Topical composition: A topical composition comprising at least one active agent selected from a depilatory agent (s), an agent (s) for preventing or reducing the growth or re-growth of hair and an agent (s) for preventing or reducing in-growing hair, and a gas, wherein the at least one active agent and gas... Agent: Reckitt & Colman (overseas) Limited

20110311659 - Composition and method of treating lipid encapsulated virus infections: A method of treating a patient infected with a lipid encapsulated virus by administering to the patient about 1000 mg to about 5000 mg per day of a nutritional supplement having from about 40 to about 80 wt. % L-lysine, from about 20 to about 50 wt. % butylated hydroxytoluene... Agent:

20110311660 - Composition and methods for clotting blood: Disclosed herein are compositions and methods for use of such for clotting blood. In one example, a disclosed composition includes at least Stachys betonica, Achillea millefolium, Marrubium vulgare, and Urtica dioica. Methods of use of the disclosed compositions are also provided, including methods of preventing or inhibiting a nosebleed, bleeding... Agent:

20110311661 - Plant extracts and dermatological uses thereof: Plant extracts and dermatological formulations comprising one or more plant extracts that are capable of inhibiting one or more extracellular proteases selected from the group of: matrix metalloprotease-1 (MMP-1), matrix metalloprotease-2 (MMP-2), matrix metalloprotease-3 (MMP-3), matrix metalloprotease-9 (MMP-9) and human leukocyte elastase (HLE). A rapid method for screening plant extracts... Agent:

20110311662 - Cosmetic composition for skin moisturisation comprising pine-resin extract, pinus densiflora needle extract and pinus densiflora root extract: The present invention relates to a skin moisturizing cosmetic composition that includes a pine resin extract, a Pinus Densiflora needle extract, and a Pinus Densiflora root extract, as active ingredients. More specifically, the present invention includes a pine resin extract, a Pinus Densiflora needle extract, and a Pinus Densiflora root... Agent:

20110311663 - Feeds containing hop acids and uses thereof as supplements in animal feeds: Disclosed are methods for administering hop acids to alter the microbial population of the gastrointestinal tract of animals and to inhibit the growth of pathogenic organisms in the gastrointestinal tracts of animals. Also disclosed are methods of increasing weight gain, feed efficiency, milk production in mammals, and egg and meat... Agent:

20110305629 - Anti-alpha v beta 6 antibodies and uses thereof: The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize αvβ6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of... Agent: Biogen Idec Ma Inc.

20110305631 - Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases: Disclosed herein are compositions and methods of use comprising combinations of anti-CD22 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-CD22 antibody or may be separately administered, either before, simultaneously with or after the anti-CD22 antibody. In preferred embodiments, the therapeutic agent is an antibody... Agent: Immunomedics, Inc.

20110305630 - Misfolded proteins in cancer treatment and diagnosis: Cancer cells are identified and inhibited using agents that bind to epitopes unique to misfolded forms of surface proteins presented by the cancer cells. In one embodiment, cancer cells are identified and treated using antibodies that bind to a YYX epitope available on the misfolded form of the prion protein,... Agent:

20110305632 - Process for the preparation of asymmetrical bis(thiosemicarbazones): The present invention relates to a method of making asymmetrical bis(thiosemicarbazones), compounds useful as synthetic intermediates in the method, new bis(thiosemicarbazones) that can be readily accessed by use of the method and methods of treatment and imaging utilising some of the new bis(thiosemicarbazones).... Agent: The University Of Melbourne

20110305634 - Methods and systems for adenovirus interaction with desmoglein 2 (dsg2): The present invention provides compositions and methods for treating disorders associated with epithelial tissues.... Agent: University Of Washington Through Its Center For Commercialization

20110305633 - Methods for treatment, the prognostic assessment and the detection of breast cancer: The present invention relates to methods for the treatment, the prognostic assessment and the detection of breast cancer.... Agent: Inserm(institut National De La Sante Et De La Recherche Medicale)

20110305636 - Compounds, compositions, methods of synthesis, and methods of treatment: Briefly described, embodiments of this disclosure include compounds as described herein, labeled compounds as described herein, pharmaceutical composition including compounds described herein, methods of imaging, method of forming a compound as described herein, and the like. In particular, embodiments of the disclosure include a series of triamino-pyridine derivatives and labeled... Agent: Emory University

20110305635 - Myelin detection using benzofuran derivatives: The present invention relates to methods for the detection of myelin and a quantitative measurement of its local concentration in a sample using a benzofuran compound or its radioisotope derivatives. In one embodiment a method of myelin detection comprises identifying a subject at risk of or diagnosed with a myelin-associated... Agent: General Electric Company

20110305637 - Radiolabelled pde10 ligands: The present invention relates to novel, selective, radiolabeled PDE10 ligands which are useful for imaging and quantifying the PDE10A enzyme in tissues using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such... Agent: Janssen Pharmaceutica N.v.

20110305639 - Method and formulation for reducing aggregation of a macromolecule under physiological conditions: The invention provides a method for reducing aggregation and inhibiting flocculation of a macromolecule, such as a protein, under physiological conditions, by the addition of certain cyclodextrins (CDs). The invention also provides a method to minimize inflammation at the injection site during subcutaneous administration of a macromolecule and pharmaceutical formulations... Agent:

20110305640 - Method to treat psoriasis and other hyperproliferative skin disorders: Soluble adenylyl cyclase (sAC) is implicated in proliferation of keratinocytes. Inhibitors of sAC are useful for the treatment and/or prevention of psoriasis and other hyperproliferative skin disorders. Assays to identify such compounds are also described.... Agent: Cornell University

20110305638 - Modulation of macrophage activation: The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that modulate macrophage activation. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to... Agent: Abt Holding Company

20110305641 - Compositions and methods for treatment of angiogenesis-associated ocular disorders: The invention provides methods and compositions for identifying and quantifying pathological changes on the retina.... Agent:

20110305642 - Micronutrient supplement: A micronutrient supplement the supplement being characterized by having at least two types of distinct dosage units wherein said distinct dosage units which physically separate nutritional, vitamin or mineral supplements which are known or proven to be negatively interacting when co-mingled or co-administered, the distinct dosage units being designed to... Agent: Duchesnay Inc.

20110305644 - wool care composition: The present invention relates to a wool care composition comprising pyrethroid insecticide, a copolymer and a solvent wherein the said copolymer binds with the solvent and pyrethroid insecticide. This composition can be an improved aerosol spray formulation for treating of pure or blended woollen clothing and textile, fur and feather... Agent:

20110305645 - Crystal form of glycopyrronium chloride: A new crystal form of threo glycopyrronium chloride is useful in pharmaceutical applications.... Agent: Chiesi Farmaceutici S.p.a.

20110305646 - Fatty acid monoglyceride compositions: The present invention relates to a method of treating a fungal condition caused by T. rubrum, by administering a composition comprising a fatty acid monoester of glycerol. According to an embodiment, the fatty acid monoester of glycerol is 1-monocaprin. According to another embodiment, the fungal condition is onychomycosis.... Agent:

20110305643 - High oil-content emollient aerosol foam compositions: Described herein are high oil-content emulsions and compositions for the treatment of inflammatory skin disorders. The emulsions may be formulated as aerosol compositions. The aerosol propellant may be a hydrofluoroalkane propellant. The emulsions or compositions may comprise active agents, such as corticosteroids. Also described are methods of treating inflammatory skin... Agent: Precision Dermatology, Inc.

20110305647 - Use of a polysaccharide which is excreted by the vibrio diabolicus species for the regeneration and protection of the periodontium: The invention relates to the use of a polysaccharide which is excreted by the Vibrio diabolicus species for the regeneration and protection of the non-mineralised connective tissue of the periodontium.... Agent: Institut Francais De Recherche Pour L'exploitation De La Mer (ifremer)

20110305648 - Methods of preparing personal care compositions: Disclosed herein are embodiments of a method of predicting and adjusting the viscosity of consumer product compositions prior to their final formulation. The prediction aides the determination of the amount of a viscosity modifier to introduce in the manufacture of the final formulation to ensure the compositions have viscosities that... Agent:

20110305652 - Anionic surfactant stable cocoamide monoethanolamine (cmea) composition: Disclosed herein is a composition containing liquid high activity micellar or lamellar phase liquid crystals of cocamide monoethanolamine (CMEA) and a detersive surfactant. The composition of the invention can be added to any personal care composition to form a personal care product and enable CMEA blending at room temperature. Also... Agent:

20110305649 - High humectant high internal phase emulsion: A high humectant high internal phase emulsion is described. The emulsion has a high content of humectant and less than about 70% by weight water in the internal phase. The emulsion yields excellent moisturizing results when applied and is not sticky during or after application.... Agent: Conopco, Inc., D/b/a Unilever

20110305653 - Personal care compositions with ethylene acrylic acid copolymer aqueous dispersions: Described are personal care compositions, comprising an aqueous dispersion comprising an ethylene acrylic acid copolymer and a least one cosmetically acceptable surfactant, emollient, or cosmetic active.... Agent:

20110305650 - Stabilization of cosmetic compositions: Disclosed is the Use of UV absorbers selected from (a1) diphenylacrylates; and (a2) specific hydroxyphenyl triazines for stabilizing cosmetic compositions comprising an organic UV absorber selected from (b1) a specific benzophenone derivative, (b2) a specific benzotriazole derivative and (b3) a specific triazine derivative and UV filters selected from (c1) cinnamic... Agent: Basf Se

20110305651 - Sunless tanning compositions with nucleophile functionalized sulfonic acids: Sunless tanning compositions with nucleophile functionalized sulfonic acids are described. The compositions are stable and result in excellent tanning results when sunless tanning agents like 1,3-dihydroxy-2-propanone are used.... Agent: Conopco, Inc. D/b/a Unilever

20110305654 - Anhydrous petroleum jelly/elastomer-free depigmenting compositions comprising a solubilized phenolic compound: Novel dermatological depigmenting compositions, especially for topical application, contain as pharmaceutical active agents a dissolved phenolic compound, formulated as anhydrous compositions free of petroleum jelly and free of elastomer.... Agent: Galderma Research & Development

20110305655 - Moisturizing and shine-imparting emulsion lip compositions: The present invention is directed to an emulsion lip composition, in solid or stick form, containing: (a) at least one polyamine; (b) an oil-soluble polar modified polymer; (c) water; (d) at least one non-volatile solvent capable of solubilizing the oil-soluble polar modified polymer; and (e) at least one colorant.... Agent: L'oreal S.a.

20110305656 - Aqueous fragrancing composition comprising at least one volatile linear alkane; fragrancing process: The present invention also relates to a process for fragrancing human keratin materials or clothing, which consists in applying to the said keratin materials or the said clothing an aqueous fragrancing composition as defined previously.... Agent: L'oreal

20110305657 - Cooling mixtures with an enhanced cooling effect of 5-methyl-2-(propane-2-yl)cyclohexyl-n-ethyloxamate: The invention relates to a cooling mixture comprising or consisting of 5-methyl-2-(propane-2-yl)cyclohexyl-N-ethyloxamate and one, two, three or more certain polyols. It further relates to a cosmetic composition comprising such a cooling mixture or to a sanitary article comprising such a cooling mixture. The invention also relates to the use of... Agent: Symrise Ag

20110305658 - Lengthening mascara composition: The present invention is directed to a lengthening and smudge proof mascara composition for making up eye lashes having: (a) at least one alkyl ethoxylated polymer wax; (b) at least one oil soluble polar modified polymer; (c) at least one oil soluble high carbon polar modified polymer; (d) water; (e)... Agent: L'oreal S.a.

20110305659 - Freshening compositions comprising malodor binding polymers and malodor control components: Freshening compositions comprising a malodor binding polymer, malodor control components, and an aqueous carrier; and methods thereof are provided. In some embodiments, the freshening composition comprises a homopolymeric polyethylenimine having a molecular weight of about 1,000 to about 2,000,000 and a mixture of volatile aldehydes. Such freshening compositions may be... Agent:

20110305660 - Omega-functionalized polymers, junction-functionalized block copolymers, polymer bioconjugates, and radical chain extension polymerization: Polymeric compounds having spatially controlled bioconjugation sites are described. Functionalization is achieved by selective co-terminal chain extension of polymer chains by radical polymerization, such as reversible addition-fragmentation chain transfer (RAFT) polymerization.... Agent: University Of Washington

20110305661 - Carbazole compounds and therapeutic uses of the compounds: Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases.... Agent:

20110305662 - Methods of treating immunodeficiency virus infection: The present disclosure provides methods and compositions for reducing the reservoir of latent immunodeficiency virus in an individual, and for treating an immunodeficiency virus infection in an individual.... Agent:

20110305664 - Novel vaccines against multiple subtypes of influenza virus: An aspect of the present invention is directed towards DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of influenza virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient. The DNA plasmid is capable of expressing a consensus influenza antigen in a... Agent:

20110305665 - Pegylated interleukin-10: Interleukin-10 (IL-10) conjugated via a linker to one or more polyethylene glycol (PEG) molecules at a single amino acid residue of the IL-10, and a method for preparing the same, are provided. The method produces a stable mono-pegylated IL-10, which retains IL-10 activity, where pegylation is selective for the N-terminus... Agent: Schering Corporation

20110305663 - Serum albumin binding molecules: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.... Agent: Bristol-myers Squibb Company

20110305666 - Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases: Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infections.... Agent:

20110305668 - Methods for using interferon gamma to absorb fluid from the subretinal space: Particular aspects of the invention provide methods for decreasing the amount of fluid present in the subretinal space of the eye by administering interferon gamma to the basolateral side of the retinal pigment epithelium. Adverse ocular conditions associated with the accumulation of fluid in the subretinal space can be treated... Agent: The United States Of America, As Represented By The Secretary, Dept.of Health And Human Services

20110305667 - Use of a dead-box rna helicase for inducing cytokine production: The invention relates to the use of a DEAD-box RNA helicase from a yeast, a mammal, Leishmania infantum, or fragments thereof for inducing the production of cytokines by a peripheral blood mononuclear cell (PBMC) of a mammal, and to the applications thereof.... Agent: Institut Pasteur

20110305669 - Process for the preparation of glycosylated interferon beta: The present invention relates to a process for the production of interferon beta, and to an interferon beta composition having a unique glycosylation pattern.... Agent: Ares Trading S.a.

20110305670 - Nucleic acid encoding fusion polypeptides that prevent or inhibit hiv infection: The present invention is directed to an isolated nucleic acid molecule encoding a fusion polypeptide the expression of which in cells is capable of blocking the entry of HIV-1 into host cells and methods of using the nucleic acid molecule.... Agent: President And Fellows Of Harvard College

20110305671 - Cell compositions and methods for hair follicle generation: The application describes a method of generating a hair follicle, comprising administering a composition comprising epidermal matrix cells, dermal papilla cells, dermal sheath cells and outer root sheath cells to the scalp of a mammal. The composition may optionally be administered with a hair growth agent and/or a carrier. The... Agent: Alvi Armani Genomics Inc.

20110305679 - Blood-cholesterol-lowering strain of lactobacillus delbrueckii: The invention relates to a novel strain of Lactobacillus delbrueckii having blood-cholesterol-lowering properties, and to the use thereof for the manufacture of blood-cholesterol-lowering fermented products, in particular of milk products.... Agent: Compagnie Gervais Danone

20110305673 - Compositions and methods for tissue repair: The invention features compositions comprising mesenchymal stem cells or multipotent stromal cells, agents secreted by such cells in culture, and methods featuring such cells for the repair or regeneration of a damaged tissue or organ. The present invention is based, at least in part, on the discovery that agents secreted... Agent: The University Of Vermont And State Agriculture College

20110305672 - Compositions for mesoderm derived isl1+ multipotent cells (imps), epicardial progenitor cells (epcs) and multipotent cd56c cells (c56cs) and methods of producing and using same: The present invention relates to inter alia, methods for the generation and maintenance of Mesoderm-derived ISL1+ Multipotent Progenitors (IMPs), the production of a number of pluripotent cells including and epicardial pluripotent cells (EPCs) and using these cells to produce endothelial cells, cardiomyocytes, smooth muscle cells, vascular cells and other cells... Agent: University Of Georgia Research Foundation, Inc.

20110305677 - Human embryonic stem cell cultures, and compositions and methods for growing same: Human pluripotential embryonic stem cell cultures are provided, as are human feeder cells useful for growing the human embryonic stem cells, conditioned medium obtained from cultures of the human feeder cells, and factors derived from the conditioned medium. Also provided are methods of growing human embryonic stem cells in the... Agent:

20110305676 - Methods for enhancing hematopoietic stem/progenitor cell engraftment: Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to an... Agent: Children's Medical Center Corporation

20110305675 - Methods for expansion of hematopoietic stem and progenitor cells: Described herein are methods and compositions for expanding hematopoietic stem and progenitor cells (HSPC) ex vivo and in vivo, and methods and compositions for transplanting HSPCs and treatment of anemia in a human subject. HSPCs are expanded in the presence of an inhibitor of serine threonine kinase 38 (STK38), wherein... Agent: The General Hospital Corporation

20110305674 - Pathways to generate hair cells: This disclosure relates to methods and compositions for modulating (e.g., increasing) Atoh1 activity (e.g., biological activity) and/or expression (e.g., transcription and/or translation) in vivo and/or in vitro, e.g., in a biological cell and/or in a subject. The methods and compositions described herein can be used in the treatment of diseases... Agent: Massachusetts Eye & Ear Infirmary

20110305678 - Use of mesenchymal stem cells for treating genetic diseases and disorders: A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal.... Agent:

20110305680 - Composition containing osteopontin for differentiating natural killer cell as an active ingredient and a method of differentiation using thereof: The present invention relates to a composition for differentiating natural killer cells comprising osteopontin (OPN) as an active ingredient and a method for differentiation using the same. More precisely, osteopontin of the present invention accelerates differentiation of natural killer cells from hematopoietic stem cells and increases cytotoxic activity of natural... Agent: Korea Research Institute Of Bioscience And Biotechnology

20110305681 - Topical hair care formulation and method of making: A topical hair care formulation and method of making includes combining herbal powders to form a herbal powder mixture. The herbal powder mixture is steeped in an amount of carrier oil for a period of time to form an infused oil. A portion of an amount of olive oil is... Agent:

20110305682 - Compositions and methods for treating s. pneumonia infection: The present invention relates to novel compounds that are useful for inhibition and prevention of pathogen cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of pathogen cell adhesion and cell adhesion-mediated pathologies. The... Agent: Ben Gurion University Of The Negev Research And Development Authority

20110305683 - Stabilization of perhydrolases: Disclosed herein is a method for stabilization of the perhydrolase activity of the CE-7 esterase in a formulation with a carboxylic acid ester that employs the addition of a buffering agent, substantially undissolved, to the mixture of the CE-7 esterase and the carboxylic acid ester. Further, disinfectant and laundry care... Agent:

20110305684 - Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunostimulatory oligonucleotides of the invention preferably comprise novel... Agent: Idera Pharmaceuticals, Inc.

20110305685 - Supramolecular approach for preparation of size controllable nanoparticles: A supramolecular approach has been developed for preparation of size-controllable nanoparticles, from three different molecular building blocks.... Agent: The Regents Of The University Of California

20110305693 - Anitigen-binding constructs: The invention relates to combinations of RANKL antagonists with TNF-alpha antagonists and provides antigen-binding constructs which bind to RANKL comprising a protein scaffold which are linked to one or more epitope-binding domains wherein the antigen-binding construct has at least two antigen binding sites at least one of which is from... Agent: Glaxo Group Limited

20110305687 - Anti-fgfr2 antibodies: Monoclonal antibodies that bind and inhibit biological activities of human FGFR2 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation or overexpression of FGFR2.... Agent:

20110305692 - Antigen-binding contructs: The invention relates to combinations of RANKL antagonists with TNF-alpha antagonists and provides antigen-binding constructs which bind to RANKL comprising a protein scaffold which are linked to one or more epitope-binding domains wherein the antigen-binding construct has at least two antigen binding sites at least one of which is from... Agent: Glaxo Group Limited

20110305690 - Antitumor combinations containing antibodies recognizing specifically cd38 and cyclophosphamide: Pharmaceutical composition comprising an antibody specifically recognizing CD38 and cyclophosphamide.... Agent: Sanofi-aventis

20110305691 - Modified polypeptides stabilized in a desired conformation and methods for producing same: a

20110305694 - Multivalent and/or multispecific rankl-binding constructs: The invention relates to a combination of RANKL antagonists with OSM antagonists, and provides antigen-binding constructs which bind to RANKL comprising a protein scaffold which are linked to one or more epitope-binding domains wherein the antigen-binding construct has at least two antigen binding sites at least one of which is... Agent:

20110305688 - New virulence factors of streptococcus pneumoniae: The present invention provides proteins/genes, which are essential for survival, and consequently, for virulence of Streptococcus pneumoniae in vivo, and thus are ideal vaccine candidates for a vaccine preparation against pneumococcal infection. Further, also antibodies against said protein(s) are included in the invention.... Agent: Stichting Katholieke Universiteit, More Particularly The Radboud Univeristy Nijmegen Medic

20110305686 - Therapies for chronic renal failure using one or more integrin antagonists: The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain integrin antagonists.... Agent:

20110305689 - Treatment of chronic inflammatory respiratory disorders: This invention relates, e.g., to a method for treating a subject having a chronic inflammatory respiratory disorder, comprising administering to the subject an effective amount of an inhibitor of the expression of and/or the activity of VEGF-A and/or VEGFR1 and/or VEGFR2 and/or NP1, or a combination thereof. Also described are... Agent: The Johns Hopkins University

20110305696 - anti-serum albumin binding variants: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.... Agent: Glaxo Group Limited, A Corporation

20110305697 - Fc fusion proteins: The invention relates to fusion proteins comprising at least a first domain and a second domain selected from a constant Fc immunoglobulin domain; wherein there is at least one amino acid overlap between the first domain and the second domain in the fusion region. In a preferred embodiment of the... Agent:

20110305695 - Wnt antagonists and methods of treatment and screening: The present invention relates to compositions comprising Wnt antagonists and methods of treating Wnt-associated diseases and disorders, such as cancer, inducing differentiation, and reducing the frequency of cancer stem cells, as well as novel methods of screening for such Wnt antagonists. In particular, the invention discloses soluble FZD, SFRP and... Agent: Oncomed Pharmaceuticals, Inc.

20110305700 - Anti-lipid antibodies: The present invention relates, in general, to anti-lipid antibodies and, in particular, to methods of inhibiting HIV-1 infection using anti-lipid (e.g. antiphospholipid) antibodies.... Agent: Duke University

20110305701 - Methods and compositions to treat and detect misfolded-sod1 mediated diseases: The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1)... Agent:

20110305698 - Treating breast cancer and inhibiting cancer-associated bone loss with anti-il-20 antibody: Use of an anti-IL-20 antibody, either alone or in combination with an anti-RANKL antibody, for treating breast cancer and inhibiting cancer-associated bone loss.... Agent: National Cheng Kung University

20110305699 - Treating oral cancer with anti-il-20 antibody: Treating oral cancer with an anti-IL-20 antibody.... Agent: National Cheng Kung University

20110305705 - Antibodies to thymic stromal lymphopoietin receptor molecules and uses thereof: The present invention provides Thymic Stromal Lymphopoietin Receptor (TSLPR) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TSLPR polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases,... Agent: Amgen Inc.

20110305704 - Antibody to cytolethal distending toxin of campylobacter jejuni: Methods for preventing IBS, reducing the likelihood of developing IBS and/or treating IBS by administering COT inhibitors and/or COT neutralizers to a subject in need thereof are described. Methods of eliciting a specific immune response and methods of vaccinating a subject to prevent IBS or to reduce the likelihood of... Agent: Cedars-sinai Medical Center

20110305702 - Epitopes: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.... Agent: Ucb Pharma S.a.

20110305703 - Isolated vegf-c and vegf-d peptides and uses thereof: The invention relates to an isolated peptide, comprising residues 147 to 151 of SEQ ID NO: 1, or a modification thereof, and antibodies thereto and uses thereof, wherein the peptide comprises 100 or fewer amino acids.... Agent: Vegenics Pty Limited

20110305706 - Compositions and methods for treating a disease mediated by soluble oligomeric amyloid beta: The present invention relates to methods for restoring fast axonal transport in a cell affected by oligomeric amyloid beta and for treating an oligomeric amyloid beta-mediated disease such as Alzheimer's disease using a Casein Kinase 2 inhibitor and, in some embodiments, a Glycogen Synthase Kinase 3 inhibitor.... Agent:

20110305707 - Compositions and methods for treating cancer: The present invention provides methods for treating cancer in a subject, as well as related compositions and kits that employ a therapeutic agent, or a nucleic acid sequence encoding a therapeutic agent, selected from apolipoprotein A-1 (ApoA1) or biologically active fragment, an ApoA1 mimetic, an agent that increases expression of... Agent: The Cleveland Clinic Foundation

20110305708 - Compositions and methods for the therapy and diagnosis of cytomegalovirus: The present invention provides novel anti-cytomegalovirus antibodies and related compositions and methods. These antibodies may be used in the diagnosis, prevention, and treatment of cytomegalovirus infection.... Agent: Theraclone Sciences, Inc.

20110305709 - Calcium sensor stim1 and the platelet soc channel orai1 (cracm1) are essential for pathological thrombus formation: The present invention relates to a pharmaceutical composition comprising an inhibitor of stromal interaction molecule 1 (STIM1) or an inhibitor of STIM1-regulated plasma membrane calcium channel activity, in particular an inhibitor of Orai1 (also designated as CRACM1), and optionally a pharmaceutically active carrier, excipient or diluent. The invention further relates... Agent:

20110305711 - Cgrp antibodies: The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.... Agent: Eli Lilly And Company

20110305710 - Novel compounds for the treatment of glaucoma or ocular hypertension: This invention relates to compositions and methods for the treatment or prophylaxis of glaucoma and ocular hypertension, and for lowering of intraocular pressure. The invention provide VEGFR-1 agonists and combinations of vascular endothelial growth factor B (VEGF-B) with placenta growth factor (PLGF), ‘ Secreted protein acidic cysteine-rich’ (SPARC) antagonists, insulin,... Agent:

20110305712 - Ctla4 proteins and their uses: The present disclosure relates to CTLA4 proteins and uses of such proteins, for example to treat diseases associated with the dysregulation of immune responses.... Agent:

20110305714 - Identification and engineering of antibodies with variant fc regions and methods of using same: The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to... Agent: Macrogenics, Inc.

20110305713 - Methods and compositions to enhance vaccine efficacy by reprogramming regulatory t cells: The immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) is expressed by a subset of murine plasmacytoid DCs (pDCs) in tumor-draining LNs, where it can potently activate Foxp3 regulatory T cells (Tregs). We now show that IDO functions as a molecular switch in tumor-draining LNs, maintaining Tregs in their normal suppressive phenotype when... Agent: Medical College Of Georgia Research Institute, Inc

20110305715 - Antibodies to 3-hydroxycotinine and methods of use thereof: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to 3-hydroxycotinine (3HC). The invention also provides compositions containing these antibodies and fragments thereof, and to their use in diagnostic and therapeutic applications for diseases involving nicotine activity (e.g., smoking and/or smokeless tobacco use).... Agent:

20110305716 - Targeted cytokine for treatment of diseases: Provided are proteins and polynucleotides, complexes and compositions containing the proteins, and methods for their use in administration to subjects and for disease treatment. Among the provided proteins and complexes are complexes containing a TGF-beta associated with immunoglobulins (such as IgGs) or functional portions thereof including Fc portions, such as... Agent:

20110305717 - Cultured myeloid dendritic cells isolated from peyer's patches and uses thereof: Cultured lysozyme-secreting myeloid dendritic cells isolated from the subepithelial dome of Peyer's patches in the small intestine are provided. The myeloid dendritic cells are used in screening methods to identify agents which interact with myeloid dendritic cells, for example, antigens, allergens, antimicrobial agents, or agents that modulate the activity of... Agent:

20110305719 - Inhibition of pro-inflammatory cytokine induced response: Method and compositions for reducing the inflammation after cytokine exposure of an islet cell transplant without affecting the viability and potency are disclosed herein. The present invention describes a composition comprising Withaferin A (WA), a steroidal lactone derived from Withania somnifera to effectively block NF-kB activation in beta cells, minimize... Agent: Baylor Research Institute

20110305718 - Recombinant protein body-inducing polypeptides: Polypeptide sequences for inducing recombinant protein bodies are described. The sequences comprise a polyproline II (PPII) structure and/or a proline-rich sequence between two cysteine residues on either end. Recombinant protein bodies are useful for protein production because they allow for simple and efficient purification of high quantities of recombinant protein.... Agent: Era Biotech S.a.

20110305720 - Peptide adjuvants: Adjuvant compositions comprising specific 5 mer polypeptides in combination with antigen delivery systems and/or immunostimulatory molecules, such as immunostimulatory nucleic acid sequences, for enhancing the immune response of a coadministered antigen, are described.... Agent:

20110305721 - Compounds and methods for immunotherapy and diagnosis of tuberculosis: Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more M. tuberculosis proteins and DNA molecules encoding such polypeptides. Such compounds may be formulated into vaccines and/or pharmaceutical compositions for immunization against M.... Agent: Corixa Corporation

20110305722 - Mage-c2 antigenic peptides and uses thereof: This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA... Agent:

20110305723 - Molecular antigen array: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The... Agent: Cytos Biotechnology Ag

20110305724 - Immunotherapeutic, anti-tumorigenic compositions and methods of use thereof: This invention relates to immunotherapeutic vaccine composition comprising an ISG15 tumor antigen and to methods of preventing and treating a tumor growth by using said immunotherapeutic composition.... Agent:

20110305725 - Methods and compositions for immunizing pigs against porcine circovirus: The present invention relates to the isolation and identification of two new strains of type 2B porcine circovirus. These two new strains of porcine circovirus may be used for the preparation of vaccine or immunogenic compositions for immunizing pigs against postweaning multisystemic wasting syndrome (PMWS). Accordingly, the invention provides methods... Agent: Wyeth LLC

20110305726 - Infectious bronchitis vaccines derived from ib-qx-like vaccine strains: The present invention relates to infectious bronchitis (IB) viruses derived from a recently identified genotype of IB virus known as IB-QX, or from viruses that are genetically related to IB-QX, herein referred to as IB-QX-like viruses. The IB viruses of the invention may be live and attenuated or inactivated. Live,... Agent: Wyeth LLC

20110305727 - Rsv f protein compositions and methods for making same: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain... Agent: Novartis Ag

20110305728 - Drug for treating infections: The invention relates to the use of glycoproteins extracted from the Klebsiella Pneumoniae bacterium for the production of a drug for the remedial treatment of acute or chronic infections. Said glycoproteins work by causing a quick lysis of all types of pathogens by means of very intense stimulation of all... Agent:

20110305730 - Mono-and disaccharide derivatives: The present invention relates to a novel family of monosaccharide derivatives and disaccharide derivatives and to a method of preparation thereof. A mono- and disaccharide derivatives according to the invention comprises at least one fatty acid ester and may further comprise one or more anionic groups and are useful for,... Agent:

20110305729 - Scriptaid isosteres and their use in therapy: Compounds of the invention are of the formula (I); wherein: is a double bond and X is C; or is a single bond and X is N, CH or CQR1; and wherein: n is 1 to 10; R is H or QR1; each R′ is independently selected from... Agent:

20110305732 - Methods and uses for inhibiting platelet coagulation: The present disclosure provides methods and uses of Slit proteins and nucleic acids for inhibiting platelet coagulation and related disorders. Further provided is a vascular device coated with Slit protein or a cell expressing a Slit protein.... Agent:

20110305731 - Pharmaceutical formulation between jasmonates and it derivatives and nanocarries or microcarries: The present invention refers to pharmaceutical compositions comprising a jasmonic acid derivative and a carrier, preferably cyclodextrin or a polyamidoamine. The compositions may be used for treating cancer.... Agent:

20110305733 - Pharmaceutical formulations comprising metformin and a fibrate, and processes for obtaining them: The present invention relates to granulates comprising particles of metformin and particles of a fibrate. The invention further relates to pharmaceutical compositions containing such granulates. The invention also relates to processes for preparing said granulates and said pharmaceutical compositions.... Agent: Fournier Laboratories Ireland Limited

20110305740 - Granulated powder containing vegetable proteins and maltodextrins, process for producing same, and uses thereof: The present invention also concerns process for manufacturing this granulated powder its use in various industrial field, and more particularly in the food-processing field, where it is used as a functional agent such as an emulsifying, overrun, stabilizing, thickening and/or gelling agent, in particular for totally or partially replacing certain... Agent: Roquette Freres

20110305739 - Method for preparing a non-ionic surfactant stable personal care dispersion: Disclosed herein are methods for preparing dispersions containing small diameter, liquid crystals of a high charge density cationic polymer and a detersive surfactant. Also disclosed herein are uses of these dispersions to prepare personal care products and liquid cleansing products.... Agent:

20110305737 - Multi-active microtargeted anti-aging skin cream polymer technology: A comprehensive, single agent cosmetic cream or lotion containing a high number of ingredients that target anti-aging in a defined manner. The cream or lotion contains a high number and variety of active substances that demonstrate excellent safety and efficacy in all of the various defined categories of skin aging,... Agent: Ny Derm LLC

20110305734 - Nucleic acid nanoparticles and uses therefor: The present invention provides nanoparticle compositions including one or more nucleic acids. The present invention achieves delivery (particularly transdermal delivery) of such nucleic acids without the need for nucleic acid modification, or for use of chemical or mechanical abrasion or disruption of skin.... Agent: Anterios, Inc.

20110305738 - Oxygenating oral compositions: Oral compositions, which are preferably chewable compositions, containing a peroxide source and a peroxide decomposition catalyst in a contactless manner liberate molecular oxygen in the oral cavity upon use by catalyzed decomposition of the peroxide source. The oral composition promotes oral health by providing a more aerobic environment for oral... Agent:

20110305735 - Skin antiaging treatment: A method for skin antiaging treatment comprising administering Botulinum toxin to an area of facial and/or neck skin, combined with the administration of a cosmetic or pharmaceutical composition comprising a cosmetically or pharmaceutically effective amount of at least one peptide derived from the SNAP-25 protein and/or at least one enkephalin-derived... Agent: Lipotec, S.a.

20110305736 - Stratiform perforated biomatrices: The present invention relates to stratiform biomatrices that are formed from regularly shaped, uniformly arranged portions which are connected to one another by continuous, straight-through perforations, and also to the use thereof as cosmetic or pharmaceutical agents, such as, in particular, as agents for wound treatment. The present invention further... Agent: Dr. Suwelack Skin & Health Care Ag

20110305741 - Composition and method for delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis: A composition comprising a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor and an osteoconductive material where the synthetic growth factor analogue is attached to and can be released from the osteoconductive material and... Agent: Biosurface Engineering Technologies, Inc.

20110305742 - Pharmaceutical compositions: having an ethylene carbonate content of 70 to 100 Mol %, an intrinsic viscosity of 0.4 to 4.0 dl/g measured in chloroform at 20° C. at a concentration of 1 g/dl and a glass transition temperature of from 5 to 50° C., degradable by surface erosion which is governed by... Agent:

20110305743 - Ocular implant made by a double extrusion process: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.... Agent: Allergan, Inc.

20110305744 - Preparation for vaginal and rectal use and relative production method: A preparation for vaginal and rectal use comprising hyaluronic acid, with an average particle size comprised between about 50 micrometers and about 200 micrometers and a molecular weight comprised between about 1,000,000 Da and about 1,800,000 Da.... Agent: Farma-derma Srl

20110305745 - Pollulan regenerative matrix: Compositions and methods are provided for the manufacture and use of a pullulan-based collagen hydrogel film with controlled porosity. The hydrogel is fabricated with salt-induced phase inversion and cross-linking to form a reticular scaffold. This soft collagen scaffold displays excellent handling characteristics, durability, and a porous dermal-like ultrastructure that is... Agent:

20110305746 - Patch for treating constipation using crude drugs: The present invention relates to a patch for treating constipation, which contains rhubarb ingredients selected from among crude drugs (medical herbs). More particularly, the present invention relates to a patch for treating constipation in which powder obtained by boiling, filtering, and free-drying rhubarb selected from among pure crude drugs is... Agent:

20110305747 - Combination of dapsone with other anti-acne agents: A composition suitable for topical application that contains at least two active ingredients, one of these being dapsone and one selected from the group consisting of adapalene, tazarotene and treinion for the effective treatment of acne and other dermatological conditions.... Agent: Allergan, Inc.

20110305751 - Glutathione-based drug delivery system: The invention relates to methods of targeted drug delivery of compounds, including, chemical agents, (poly)peptides and nucleic acid based drugs (like DNA vaccines, antisense oligonucleotides, ribozymes, catalytic DNA (DNAzymes) or RNA molecules, siRNAs or plasmids encoding thereof). Furthermore, the invention relates to targeted drug delivery of compounds to extravascular and... Agent: To-bbb Holding B.v.

20110305749 - Hiv-1 envelope polypeptides for hiv vaccine: Immunogenic HIV-1 envelope polypeptides are provided, wherein specific amino acid residues are mutated to repress immunosuppression in GP41, thereby boosting the immune response against HIV-1. Specifically, mutation of those specific residues does not affect the fusogenic properties of the viral particle and/or the overall protein structure of the viral envelope... Agent:

20110305752 - Liposome-encapsulated glutathione for oral administration: The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related... Agent:

20110305750 - Membrane type-1 matrix metalloprotein inhibitors and uses thereof: Based on the discovery that a soluble polypeptide including a nonphosphorylatable form of the cytoplasmic domain is capable of inhibiting in a dominant negative manner, the present invention provides compositions including MT1-MMP inhibitors such as peptide inhibitors, and methods for treating diseases associated with MT1-MMP activity. Such diseases include cancer,... Agent: Angiochem Inc.

20110305748 - Vaccines for pandemic influenza: Pharmaceutical and vaccine compositions comprise recombinant hemagglutinin from a pre-pandemic or pandemic influenza virus and an adjuvant comprising GLA. A particularly relevant pre-pandemic influenza virus is H5N1. Kits and methods of using the compositions are also provided.... Agent: Immune Design, Corp.

20110305753 - Treatment of celiac disease with iga: A process is provided for inhibiting symptoms of food allergy or food intolerance in a subject that includes the oral adminstration to the subject suffering from food allergy or food intolerance an IgA or an IgM. When administered in a therapeutic quantity based on the subject characteristics and the type... Agent:

20110305754 - Controlled release micro-capsule for osteogenic action: The present invention relates to a microcapsule for controlled release of flavanoid compound and a process for preparation thereof. The microcapsule comprising a core particle consisting of a calcium salt, Pluronic F68 [poly (ethylene oxide-co-polypropylene co-polypropylene oxide), block poly oxyethylene-polypropylene block copolymer], loaded with a flavanoid compound, the resulting core... Agent:

20110305755 - Method of adding botanical agents/dietary supplements to pharmaceutical agents in a pharmacotherapeutic regimen: A method for administering an active pharmaceutical agent (APA) is provided that includes the steps of: a) providing a medicine having a dose of at least one APA and at least one active botanical agent (ABA) or dietary supplement; and b) dosing the APA within the medicine such that within... Agent:

20110305756 - Coated solid preparation: A coated solid preparation includes an active ingredient including valproic acid or a pharmacologically acceptable salt thereof, and a coating layer containing polyvinyl alcohol and swelling clay coating the active ingredient wherein mass ratio of the polyvinyl alcohol to the swelling clay is 8:2 to 3:7 and the swelling clay... Agent: Toray Industries, Inc.

20110305757 - New pharmaceutical combinations: A pharmaceutical composition including a compound of Formula I (Compound I) or pharmaceutically acceptable salts thereof and one or more diuretics as effective components, wherein said one or more diuretics are selected from thiazide derivatives. Methods for preparing the pharmaceutical compound including Compound I and thiazide derivatives and its use... Agent: Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi

20110305758 - Orally disintegrating tablet having inner core: The present invention provides an orally disintegrating tablet with improved photostability of a medicament unstable to light. The orally disintegrating tablet has an inner core and an outer layer that covers the surface of the inner core, wherein the inner core contains the medicament unstable to light and the outer... Agent:

20110305759 - composition comprising calcium carbonate as a white pigment: A white colouring composition comprising calcium carbonate as a white pigment. It may be used in the manufacture of food and pharmaceutical products.... Agent: Chr-hansen A/s

20110305760 - Tissue regeneration system: A system for growing tissue based upon layers of an inorganic extracellular matrix, wherein each layer of the inorganic matrix is designed to dissolve at a separate rate and result in sequential growth factor delivery upon its dissolution.... Agent: Wisconsin Alumni Research Foundation

20110305763 - Lantibiotics and uses thereof: The present invention provides isolated lantibiotics that inhibit. Gram negative and Gram positive microbes. The antibiotic includes an amino acid sequence, wherein the amino acid sequence of the compound and the amino acid sequence of SEQ ID NO:21 or SEQ ID NO:22 have at least 80% identity. The lantibiotics have... Agent: Regents Of The University Of Minnesota

20110305762 - Pharmaceutical composition comprising n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4- quinazolinamine: The present invention relates to a pharmaceutical composition comprising N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine as active pharmaceutical ingredient and a process of preparing such composition.... Agent: Ratiopharm Gmbh

20110305761 - Polymersomes, colloidosomes, liposomes, and other species associated with fluidic droplets: The present invention relates generally to vesicles such as liposomes, colloidosomes, and polymersomes, as well as techniques for making and using such vesicles. In some cases, the vesicles may be at least partially biocompatible and/or biodegradable. The vesicles may be formed, according to one aspect, by forming a multiple emulsion... Agent: President And Fellows Of Harvard College

20110305764 - Use of a mare's milk concentrate dried on a highly-dispersed, biologically inert matrix: The invention relates to the use of a mare's milk concentrate dried on a highly-dispersed, biologically inert matrix, for producing a preparation for the treatment of skin diseases, especially dry skin diseases.... Agent: Nutropia Ernahrungsmedizinische Forschungs Gmbh

20110305765 - Preparation and methodology of silk fibroin nanoparticles: Disclosed are nanoparticles for delivery of drugs and/or nutraceuticals that include a fibroin polypeptide and a drug or nutraceutical, wherein the nanoparticle has a diameter of about 1 nm to about 500 nm, and compositions of the nanoparticles. The nanoparticles may further include a chitosan, or a proteoglycan such as... Agent: Board Of Regents, The University Of Texas System

20110305766 - Method for controlled release of parathyroid hormone from encapsulated poly(lactic-glycolic)acid microspheres: The present invention provides a method for producing a controlled release microsphere with mean average size greater than 50 μm, comprising preparing a water-in-oil (w/o) emulsion comprising an inner aqueous layer containing a pharmaceutically effective amount of a biologically active polypeptide with activity similar to parathyroid hormone, and an oil... Agent: Kaohsiung Medical University

20110305767 - Polymer particles prepared from polymerisable alkylene glycol (meth) acrylate monomers: The invention provides polymer particles that are obtainable by a method selected from emulsion methods, diffusion methods and evaporation methods carried out in the presence of surface-engineering surfactant which is one or more polymer that displays a lower critical solution temperature, in aqueous media, that is between 10 to 90°... Agent:

20110305769 - Branched cationic lipids for nucleic acids delivery system: The present invention is directed to cationic lipid for the delivery of oligonucleotides and methods of modulating an expression of a targeted gene using the nanoparticle compositions. In particular, the invention relates to cholesterol and its derivatives having multiple positively charged moieties via branching spacers, and nanoparticle compositions of oligonucleotides... Agent: Enzon Pharmaceuticals, Inc.

20110305768 - Quick-dissolving oral thin film for targeted delivery of therapeutic agents: This invention describes a quick-dissolving thin film strips comprising bioactive components encapsulated within pH-sensitive polymeric microparticles. The microparticles are embedded within the thin film and provide protection to components encapsulated within. The invention further describes methods to incorporate bioactive components encapsulated within pH-sensitive polymeric microparticles into a quick-dissolving thin film... Agent: The Johns Hopkins University

20110305770 - Releasable polymeric lipids for nucleic acids delivery system: The present invention relates to polymer conjugated releasable lipids and nanoparticle compositions containing the same for the delivery of nucleic acids and methods of modulating gene expression using the same. In particular, this invention relates to releasable polymeric lipids containing an acid-labile linker based on a ketal or acetal-containing linker,... Agent: Enzon Pharmaceuticals, Inc.

20110305771 - Krill extracts for treatment of cardiovascular diseases: The present invention relates to a method of treatment and/or prevention of cardiovascular disease, rheumatoid arthritis, skin cancer, premenstrual syndrome, diabetes and transdermal transport enhancement. The method comprises the administration of a therapeutically effective amount of krill and/or marine oil to a patient. The present invention also relates to a... Agent: Neptune Technologies & Bioressources Inc.

20110305772 - Compositions and methods for ex vivo hepatic nucleic acid delivery: The invention provides compositions and methods for delivery of nucleic acids to the liver ex vivo. The method includes slow, low pressure infusion of the nucleic acid into the liver to efficiently transduce cells with minimal cell damage.... Agent: The Johns Hopkins University

20110305773 - Approach to the treatment of compartment syndrome: The present invention relates to the use of an antisecretory protein or a derivative, homologue, and/or fragment thereof, having antisecretory activity, and/or a pharmaceutically active salt thereof, for the manufacture of a pharmaceutical composition and/or a medical food for the treatment and/or prevention of compartment syndrome. A compartment syndrome may... Agent:

20110305774 - Treatment of retroviral reservoirs exploiting oxidative stress: Activation of HIV-1 replication causes oxidative stress, which in turn potentiates HIV-1 replication. The common basis for the compounds of the present invention is: A) the capacity of reactivating HIV-1 from latency, and B) the ability to counteract the cellular machinery which activates in order to limit the effects of... Agent: Istituto Superiore Di Sanita

20110305775 - Micronutrient supplement dispensing package: Provided herein is a prenatal and postpartum multivitamin and mineral supplement package provided in the form of a plurality of solid oral dosage units individually contained in blister packs wherein a portion of the dosage forms are iron-containing while at least half of the dosage units are essentially iron-free and... Agent: Duchesnay Inc.

20110305776 - Thiochromene derivatives as hif hydroxylase inhibitors: The present invention relates to novel compounds, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).... Agent: Fibrogen, Inc.

20110305777 - Dimeric iap antagonists: Smac mimetics that inhibit IAPs.... Agent: Tetralogic Pharmaceuticals Corporation

20110305778 - Chemically stabilized anti-dandruff compositions for use in personal care compositions: The present invention is directed to a stabilized anti-dandruff composition comprising about 10 wt. % to about 40 wt. % of an insoluble anti-dandruff agent, about 6 wt. % to about 12 wt. % of a stabilizer, less than about 1 wt. % of a preservative, and about 0.5 wt.... Agent:

20110305779 - Phytochemical combinations that regulate pathological immunity: Disclosed are dietary supplements comprising a combination of a spice, a partially purified phytochemical, and a fully purified phytochemical that synergistically downregulates inflammation and promotes wellness, good health, and fitness in a mammal. Methods of identifying and making such supplements are likewise provided. The method of identifying comprises contacting mammalian... Agent:

20110305780 - Marrubiin and composition for reducing snoring, package and method: The invention comprises a composition for the reduction of snoring, a packaging therefor and a method for the manufacture thereof. The composition can be applied in the pharynx in different variants, in particular as spray, as gel or as foam formulation. Application of the composition at least temporarily reduces the... Agent: Puranox Medical B.v.

20110305781 - Use of eclipta prostrata and other ppar-gamma inhibitors in cosmetics and compositions thereof: The present invention describes compositions and methods for improving the appearance of skin, particularly, treating, ameliorating, preventing, delaying, and/or improving one or more signs of excess accumulation and/or production of subcutaneous fat, such as cellulite, and conditions related thereto, by topically applying compositions comprising Eclipta prostrata extracts or other anti-lipid... Agent: Avon Products, Inc.

20110305782 - Methods of cholesterol reduction using isoflavones: This invention relates to natural products containing phyto-oestrogens, or phyto-oestrogen analogues, which have various beneficial physiological effects in man, and which have a variety of uses, such as to promote good health and as a dietary additive, for example. The invention describes a method of improving the health of a... Agent: Novogen Research Pty Ltd.

20110305783 - Method and pharmaceutical composition for treating psoriasis, squamous cell carcinoma and/or parakeratosis by inhibiting expression of squamous cell carcinoma-related antigen: In a first aspect thereof, the present invention provides a method for treatment and/or prevention of a disease selected from the group consisting of psoriasis and squamous cell carcinoma by inhibiting the expression of squamous cell carcinoma antigen (SCCA) by cells. In another aspect thereof, the present invention provides a... Agent: Shiseido Company, Ltd.

20110305784 - Fractionated products obtained from gamboge resin, and medical uses of the same: Disclosed herein are seventeen new compounds and five fractionated products obtained from an acetone-extracted product of gamboge resin. The seventeen new compounds and the five fractionated products have activities in inhibiting the growth of tumor/cancer cells. In addition, the acetone-extracted product of gamboge resin and the five fractionated products obtained... Agent: Taiwan Sunpan Biotechnology Development Co, Ltd.

20110305785 - Bulbine frutescens extract: A method of producing a Bulbine frutescens extract in a stable form by treating juice expressed from the leaves of the Bulbine frutescens plant with hydrogen peroxide, removing the remaining hydrogen peroxide and stabilizing the extract using a suitable stabilizer. The Bulbine frutescens extract is used in the therapeutic or... Agent: Cremer Oleo Gmbh & Co. Kg

20110300066 - Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases: Disclosed herein are compositions and methods of use comprising combinations of anti-CD74 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-CD74 antibody or may be separately administered, either before, simultaneously with or after the anti-CD74 antibody. In preferred embodiments, the therapeutic agent is an antibody... Agent: Immunomedics, Inc.

20110300069 - methods of using labeled ligands having human cd4 specificity: s

20110300068 - Agent for prophylaxis or treatment of cancer: The present invention provides an agent for the prophylaxis or treatment of kidney cancer or urinary bladder cancer, and a diagnostic reagent for these cancers which comprise an antibody against nerve growth factor 2/neurotrophin-3 or a partial peptide thereof or a salt thereof, which antibody neutralizes nerve growth factor 2/neurotrophin-3... Agent: Takeda Pharmaceutical Company Limited

20110300067 - Methods for increasing efficacy of radioimmunotherapy of melanoma: Methods are disclosed for using agents and treatments that cause the release of melanin from melanin-containing melanomas to increase the efficacy of therapy and imaging of the melanomas with radiolabeled anti-melanin antibodies and peptides.... Agent:

20110300070 - Biomolecule complexes as contrast agents in positron emission tomography (pet) based methods for the assessment of organ function: The present invention relates to complexes comprising one or more markers and one or more biomolecules for use as a contrast agent in positron emission tomography based imaging. The complexes according to the present invention preferably accumulate in a target compartment, such as the kidney. The present invention further relates... Agent:

20110300071 - Targeting npr-c in angiogenesis and atherosclerosis with a c-type atrial natriuretic factor (canf)-comb nanocomplex: Tracers are disclosed comprising an amphiphilic comb-like nanostructure conjugated with an oligopeptide such as a fragment of a natriuretic peptide, and a signaling moiety such as a positron-emitting radionuclide. A fragment of a natriuretic peptide comprises Arg-Ile-Asp-Arg-Ile (SEQ ID NO:1). Further disclosed are methods of imaging distribution of C-type atrial... Agent: Washington University

20110300073 - 18f-labelled three-and four-carbon acids for pet imaging: Compositions containing three and four-carbon acids labeled with 18F at the 2-position and to their use for emission tomography are disclosed.... Agent: Sloan-kettering Institute For Cancer Research

20110300072 - Benzimidazole-derived compounds use as markers in the case of neurodegenerative diseases: Use of benzimidazole-derived compounds of formula (I) according to the following structure, wherein x is a heteroatom selected from N, S, O, P, SO, SO2 and SO3, preferably from N, S and SO3 and most preferably from N and SO3; n may be 0 or 1, R1 is a group... Agent: Servicios Cientificos Neuroinnovation Ltda.

20110300074 - 3,6-disubstituted xanthylium salts: This invention pertains generally to processes, uses, methods and materials utilising particular xanthylium compounds, including compounds of formula (I) and (II), as further defined herein. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer's disease.... Agent:

20110300075 - Method of risk management for patients undergoing natalizumab treatment: Progressive multifocal leukoencephalopathy (PML) has been identified in patients taking natalizumab (NMAB) for the treatment of multiple sclerosis (MS). This patent application provides a novel method of patient screening and monitoring intended to decrease the risk of PML and other opportunistic central nervous system (CNS) diseases in patients undergoing MS... Agent: Seedlings Life Science Ventures, LLC

20110300077 - Human anti-alpha-synuclein antibodies: Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for α-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in... Agent: Panima Pharmaceuticals Ag

20110300078 - Isolation of microbubbles of selected size range from polydisperse microbubbles: In one aspect of the disclosed subject matter, a method for isolating target microbubbles having a predetermined size range from polydisperse microbubbles is disclosed. The method includes applying a first centrifugal field having a first field strength to a suspension comprising the polydisperse microbubbles for a first duration of time,... Agent: The Trustees Of Clumbia University In The City Of New York

20110300076 - Methods for preparation of znte nanocrystals: Nanocrystals having a ZnTe core and methods for making and using them to construct core-shell nanocrystals are described. These core-shell nanocrystals are highly stable and provide quantum yields and stability suitable for applications such as flow cytometry, cellular imaging, and protein blotting, medical imaging, and other applications where cadmium toxicity... Agent: Life Technologies Corporation

20110300079 - Compositions for use with a system for improved cooling of subcutaneous lipid-rich tissue: A composition or cryoprotectant for use with a system for improved cooling of subcutaneous lipid-rich tissue of a subject having skin is provided. The cryoprotectant is a non-freezing liquid, gel, or paste for allowing pre-cooling of a treatment device below about 0° C. while preventing the formation of ice thereon.... Agent: Zeltiq Aesthetics, Inc.

20110300080 - Acidified chlorite disinfectant compositions with olefin stabilizers: A two-part disinfecting systems, as well as disinfecting compositions and methods for making and using the same. The two-part disinfecting system contains a first part and a second part adapted to be mixed to yield an aqueous disinfecting composition, wherein the first part comprises a chlorite and the second part... Agent: Ecolab Usa Inc.

20110300081 - Orosoluble and/or effervescent compositions containing at least a salt of s-adenosyl methionine (same): The present invention refers to pharmaceutical, dietary and/or nutraceutical orosoluble and/or effervescent compositions for oral use containing at least a salt of S-adenosyl methionine (SAMe), combined with physiologically acceptable excipients and optionally additional active ingredients. In particular the invention refers to compositions with high palatability formulated in tablet, capsule or... Agent: Graal Srl

20110300084 - Detoxification method for obtaining a zinc containing pigment compound with no ecotoxicity: A detoxification method for obtaining a pigment compound free from acute and chronic aquatic ecotoxicity by mixing at least one zinc-based component with good anti-corrosive properties but high toxicity-with a phosphate or hydrogen phosphate of a magnesium, sodium, potassium, calcium, strontium, aluminum, ammonium, or organic type or any other compound... Agent: Societe Nouvelle Des Couleurs Zinciques

20110300082 - Partial esters of a polyglycerol with at least one carboxylic acid and one polyfunctional carboxylic acid, their preparation and use: The present disclosure relates to specific (poly-)glycerol partial esters with at least one carboxylic acid and one polyfunctional carboxylic acid, and to the use thereof as emulsifier and to formulations comprising partial esters of the present disclosure.... Agent: Evonik Goldschmidt Gmbh

20110300083 - Personal care formulations containing alkyl ketal esters and methods of manufacture: e

20110300085 - Home and personal care compositions: The present invention relates to home and personal care compositions comprising a silicone oil-in-water emulsion stabilized by a protein or peptide and at least one home and/or personal care ingredient. Such compositions tend to provide desirable characteristics for the care and conditioning of hair, skin and fabric.... Agent:

20110300086 - Film-forming solutions comprising vitamin d or derivative thereof and a corticosteroid and dermatological applications thereof: Topically applicable film-forming solutions, e.g., nail varnishes, useful for such dermatological applications as the prevention or treatment of nail psoriasis, contain, as active agents solubilized therein, vitamin D or derivative thereof and a corticosteroid, formulated into a topically applicable, physiologically acceptable medium therefor.... Agent: Galderma S.a.

20110300087 - Transfer-resistant and long wear foundation in emulsion form containing oil absorbing powders: The present invention is directed to a transfer resistant and long wear cosmetic composition having a unique gel-like texture with good pickup, payoff, and spreadability properties, as well as a silky smooth feel containing: (a) at least one polyamine; (b) at least one oil-soluble polar modified polymer; (c) water; (d)... Agent: L'oreal S.a.

20110300089 - Hydrating and moisturizing aqueous lip gloss composition: The present invention is directed to an aqueous lip gloss composition imparting high gloss, non-sticky, hydration and moisturization onto lips having: (a) at least one alkyl ethoxylated polymer wax; (b) at least one oil soluble high carbon polar modified polymer; (c) water; (d) at least one non-volatile oil capable of... Agent: L'oreal S.a.

20110300090 - Non-sticky, hydrating and moisturizing aqueous lip gloss composition: The present invention is directed to a non-sticky, hydrating and moisturizing aqueous lip gloss having: (a) at least one alkyl ethoxylated polymer wax; (b) at least one oil soluble polar modified polymer; (c) water; (d) at least one non volatile oil capable of solubilizing the polar modified polymer; and (e)... Agent: L'oreal S.a.

20110300088 - Water-insoluble reaction product of a polyamine and an oil-soluble polar modified polymer: The invention relates to a water-insoluble reaction product of an oil-soluble polar modified polymer and a polyamine.... Agent: L'oreal S.a.

20110300091 - Translucent deodorant sticks containing solubilized 3,4,4'-trichlorocarbanilide: The present invention is a solid translucent deodorant stick that exhibits remarkable efficacy against gram positive bacteria. Maintenance of translucency in spite of a high level of antimicrobial is possible through use of solubilized 3,4,4′-trichlorocarbanilide. The solubilized TCC is formed as a premix which is then added to the some... Agent: The Dial Corporation

20110300094 - Silicone oil-in-water emulsions: A silicone oil-in-water emulsion comprising 3 to 90% by volume of a silicone oil phase, characterized in that the emulsion is stabilized by a protein and/or peptide present at 0.25 to 20% by weight of the emulsion. The emulsion contains less than 25% by weight and preferably zero % by... Agent:

20110300093 - Cosmetic composition containing an amphiphilic zwitterionic copolymer: The present invention relates to a cosmetic composition that includes an amphiphilic zwitterionic copolymer. The amphiphilic zwitterionic copolymer can particularly be used for imparting rheological properties, in particular a beneficial texture, to said composition and/or to the foam resulting from said composition.... Agent: Rhodia Operations

20110300092 - Mascaras obtained via multi-phase product: Disclosed is a multi-phase mascara product, including a first container having disposed therein a first phase comprising a wax, a second container having disposed therein a second phase comprising a film forming polymer, and a third container into which relative amounts of said first and second phases may be introduced,... Agent: L'oreal

20110300095 - Malodor neutralizing compositions comprising undecylenic acid or citric acid: Compositions comprising undecylenic acid or citric acid and certain esters are effective for reducing malodors. The esters are in the molecular weight range of between 150-200 when the acid is undecylenic acid and in the range of between 130-230 when the acid is citric acid. These compositions can be used... Agent:

20110300096 - Polymers with structure-defined functions: An alternating copolymer comprising a backbone of residues of a maleic anhydride derivative and those of a compound containing vinylic unsaturation, which also comprises residues of an active compound containing a nucleophilic group, bound to the backbone by a residue of the nucleophilic group, including such a copolymer comprising residues... Agent:

20110300102 - Composition for skin regeneration, containing a secretion in the culture of an embryonic stem cell-derived endothelial progenitor cell or fractions thereof, and use thereof: The present invention relates to a composition for skin regeneration, using a culture medium or a secretion in the culture of an embryonic stem cell-derived endothelial progenitor cell, and to the use thereof. As the present invention uses the secretion in the culture as a medicine and not the embryonic... Agent: Cha Bio & Diostech Co., Ltd.

20110300103 - Heterocyclic antiviral compounds: Method for treating an HCV infection and inhibiting HCV replication with a compound of formula I wherein R1, R2, R3, R4, X1, X2, X3 and X4 and as defined herein... Agent: Roche Palo Alto LLC

20110300100 - Il-11 muteins: The present invention relates generally to the treatment of an interleukin-11 (IL-11)-mediated condition. More particularly, the present invention provides the use of modified forms of IL-11 which modulate IL-11 signaling in the treatment of IL-11-mediated conditions.... Agent: Csl Limited

20110300097 - Method and composition for the treatment of moderate to severe keratoconjunctivitis sicca: The present invention relates to topical ophthalmic compositions for treating or preventing epithelial lesions or ophthalmic disorders, including dry eye or keratoconjunctivitis sicca.... Agent:

20110300101 - Methods for treating viral infection using il-28 and il-29 cysteine mutants: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof... Agent: Zymogenetics Inc

20110300098 - Methods of treating cancer using il-21 and monoclonal antibody therapy: Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with... Agent: Zymogenetics, Inc.

20110300099 - Multi-level specific targeting of cancer cells: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13Rα2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one... Agent:

20110300104 - Hepatitis c virus inhibitors: which inhibit RNA-containing virus, particularly the Hepatitis C Virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the Hepatitis C Virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a... Agent:

20110300105 - Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo: The present invention concerns methods and compositions for forming PEGylated complexes of defined stoichiometry and structure. In preferred embodiments, the PEGylated complex is formed using dock-and-lock technology, by attaching a therapeutic agent to a DDD sequence and attaching a PEG moiety to an AD sequence and allowing the DDD sequence... Agent: Ibc Pharmaceuticals, Inc.

20110300106 - Therapeutic amoeba and uses thereof: The present invention relates to amoebae (slime molds) and uses thereof. In particular, the present invention relates to the use of amoebae or their environmentally stable spores to treat microbial infections and other uses.... Agent: Amebagone, LLC

20110300107 - Compositions and methods to treat cardiac pacing conditions: The method may include administering to a subject in need thereof an effective amount of an HCN polynucleotide. The HCN polynucleotide includes a nucleotide sequence encoding an HCN polypeptide having channel activity. The amino acid sequence of the HCN polypeptide and the amino acid sequence of a reference polypeptide have... Agent: Medtronic, Inc.

20110300113 - Death receptor cd95 controls neurogenesis of adult neural stem cells in vivo and in vitro: The present invention relates to the activation of the CD95L/CD95 system for inducing neuronal differentiation in vitro and in vivo and the use of CD95L compositions to effect differentiation.... Agent: Deutsches Krebsforschungszentrum

20110300116 - Method for generating a recombinant clonal cell line and novel reagents for use in the method: A method for generating a recombinant clonal cell line expressing a target cell surface receptor at a specific level of expression from a cell population comprising cells transfected with a plasmid encoding the cDNA sequence of the target receptor and expressing the target cell surface receptor, the method comprising (c)... Agent: Cellaura Technologies Ltd

20110300114 - Method of cell culture and method of treatment comprising a vepo protein variant: In one aspect the present invention is concerned with a method of cell culture, comprising the steps of (i) obtaining a stem or progenitor cell sample, (ii) culturing the stem or progenitor cell sample in media and under closed conditions appropriate to cause proliferation or differentiation of the stem or... Agent: Vossius & Partner

20110300115 - Use of inductor agents gse24.2 for producing pharmaceutical compositions for treating illnesses relating to cellular senescence: This invention describes the use of an inductor or activator compound GSE24.2 for producing a medicament or pharmaceutical composition for treating a preferably human illness or pathological situation caused by a senescence process. Said pharmaceutical composition can be useful for a treatment of tissue regeneration, for example of epithelial tissues... Agent:

20110300108 - Herbal compositions for the control of hematophagous parasites: There is described an herbal hematophagous parasite control composition which comprises Picraena excelsa (Quassia), Foeniculum vulgare (fennel) and Azadirachta indica folium (Neem) provided that the composition is substantially free Juglans nigra folia (black walnut) and/or Allium sativim (garlic). There are also described a method of controlling hematophagous parasites.... Agent: Parakill Limited, C/o Intechnology PLC

20110300109 - Compositions and methods for treating cancer: The present invention is based, in part, on our discovery of compositions and methods that can be used to systemically deplete arginine and thereby treat arginine-dependent cancers. Our studies indicate that administering a composition that depletes arginine directly to the patient's small intestine will provide effective treatment for arginine-dependent cancers.... Agent: Kyon Biotech Ag

20110300110 - Enaminocarbonyl compound/beneficial organism combinations: e

20110300117 - Novel lactobacillus strain, composition and use thereof for improving the syndrome of diabetes and complication thereof: The invention relates to a composition for improving the syndrome of diabetes and complication thereof. The composition comprises an effective amount of Lactobacillus strain which is at least one selected from the group consisting of: Lactobacillus reuteri GMNL-89 strain, Lactobacillus gasseri GMNL-205 strain, Lactobacillus reuteri GMNL-263 strain and a pharmaceutical... Agent: Genmont Biotech Inc.

20110300118 - Agents for promoting iga production: The present invention provides Lactobacillus bacteria which enhance the functional of Peyer's patch and promote IgA production and which have a characteristics of localizing on human intestine as well as an agent for promoting IgA production. The present invention is directed to an agent for promoting IgA production containing Lactobacillus... Agent:

20110300111 - Generation of induced pluripotent stem cells without the use of viral vectors: Presented herein, generally, are methods for generating reprogrammed mammalian cells, e.g., induced pluripotent stem cells, from differentiated mammalian cells without the use of viral or plasmid vectors. In one aspect, the methods involve contacting a differentiated cell with transducible polypeptides comprising a reprogramming factor polypeptide linked to a cell penetration... Agent: Cedars-sinai Medical Center

20110300112 - Methods for enhancing yield of stem cell cultures and enhancing stem cell therapy: The present application relates to methods and compositions for the generation of therapeutic cells having reduced incidence of karyotypic abnormalities. In several embodiments cardiac stem cells are cultured in an antioxidant-supplemented media that reduces levels of reactive oxygen species, but does not down regulate DNA repair mechanisms. In several embodiments,... Agent: Cedars-sinai Medical Center

20110300119 - Methods of enriching and using regulatory t cells: Disclosed are methods of isolating and using a population of FOXP3+ regulatory T cells in a variety of preventative and therapeutic approaches to autoimmune diseases, graft-versus-host disease and transplant rejection.... Agent: The United States Of America, As Represented By The Secretary, Department Of Health

20110300120 - Oligosaccharide-protein conjugates: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.... Agent:

20110300121 - Stabilization of perhydrolases: Disclosed herein is a method for stabilization of the perhydrolase activity of the CE-7 esterase in a formulation with a carboxylic acid ester that employs the addition of a buffering agent, substantially undissolved, to the mixture of the CE-7 esterase and the carboxylic acid ester. Further, disinfectant and laundry care... Agent:

20110300122 - Method for treating a patient: Intra-arterial administering at least one blood coagulation to a bleeding patient is provided, together with a pharmaceutical composition therefor.... Agent:

20110300123 - Pharmacological vitreolysis: A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to,... Agent: Thrombogenics Nv

20110300125 - Compositions and methods for combined therapy of disease: A desired physiological state can be induced by altering the amount of gene products in target cells of a subject. The target cells are treated with at least one compound designed to reduce expression of at least one first gene by RNAi, and with at least one compound designed to... Agent:

20110300124 - Soaking agent for the treatment of hemorrhoids and method of use: A natural gel/ointment for the treatment of hemorrhoids. Bromelain is one primary active ingredient in the gel/ointment. A second active ingredient in the form of Witch Hazel may be combined with the Bromelain. Supplemental ingredients include alcohol, de-ionized water, Butylene Glycol, PEG-40 Hydrogenated Castor Oil, Hydroxyethylcellulose, Eucalyptus Globulus Oil, Aloe... Agent:

20110300126 - Dispersion and debundling of carbon nanotubes using gemini surfactant compounds: The current application relates to a method for solubilizing (dispersing and debundling) of carbon nanotubes using a gemini surfactant, which has head groups and a spacer linking the head groups. The dispersion of nanotubes produced by said method can be used as a delivery system for biologically active agents to... Agent:

20110300127 - Drug-containing composition: It is an object of the present invention to provide a drug-containing composition capable of stably retaining a water-soluble compound without the loss of drug efficacy of a pharmaceutically active ingredient and thus preventing the compound from diffusing in the body, which is unlikely to cause disassociation at a non-target... Agent: Fujifilm Corporation

20110300128 - Use of foxp2 as a marker for abnormal lymphocytes and as a target for therapy of disorders associated with abnormal lymphocytes: The present invention is directed to a method for detecting abnormal lymphocytes said method comprising detecting an amount or expression of the FOXP2 gene in lymphocytes in a sample, wherein an increased amount or expression of the FOXP2 gene in said lymphocytes indicates the presence of abnormal lymphocytes. Additionally, the... Agent: Isis Innovation Limited

20110300129 - Systems and methods for enhancing vaccine efficacy: Pharmaceutical compositions of the invention include an antigen or a nucleic acid molecule encoding the antigen; one or both of a PPAR ligand and an RxR ligand; and a pharmaceutically suitable carrier. The pharmaceutical composition can optionally include a mitogen or other additives. Also disclosed are methods of inducing B... Agent: University Of Rochester

20110300132 - 4-aminoquinazoline prodrugs: This invention relates to prodrugs of 4-aminoquinazoline compounds, and to pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of the EGFR and HER2.... Agent: Concert Pharmaceuticals, Inc.

20110300140 - Antigen binding polypeptides: The invention relates to a platform technology for production of antigen binding polypeptides having specificity for a desired target antigen which is based on the conventional antibody repertoire of species in the family Camelidae, and to antigen binding polypeptides obtained using this technology platform. In particular, the invention provides an... Agent: Argen-x B.v.

20110300133 - Chimeric and humanized antibodies to alpha5beta1 integrin that modulate angiogenesis: The present invention provides chimeric and humanized antibodies that specifically recognize α5β1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.... Agent: Abbott Biotherapeutics Corp.

20110300131 - Detection and treatment of pancreatic, ovarian and other cancers: The application provides methods of diagnosis, prognosis, prophylaxis and treatment of ovarian, pancreatic and other cancers using antibodies that specifically bind to denatured CD70.... Agent: Seattle Genetics, Inc.

20110300139 - Generation, expression and characterization of the humanized k33n monoclonal antibody: The present invention provides humanized antibodies that immunospecifically recognize human 9 integrin. Some of these antibodies inhibit the biological functions of the 9 integrin, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with 9 integrin, including cancer, e.g., the growth and metastasis of a cancer cell,... Agent:

20110300138 - Human anti tshr antibodies: According to one aspect there is provided an isolated human antibody molecule which binds to the TSHR and which reduces ligand-induced stimulation of the TSHR but has no effect on TSHR constitutive activity, wherein the isolated human antibody molecule has the characteristic of patient serum TSHR autoantibodies of inhibiting TSH... Agent:

20110300130 - Impaired wound healing compositions and treatments: Methods, compounds, compositions, kits and articles of manufacture comprising one or more gap junction modulating agents for treatment of wounds that do not heal at expected rates, including chronic wounds, delayed healing wounds, incompletely healing wounds, and dehiscent wounds in a subject in need thereof.... Agent:

20110300135 - Method and formulation for reducing aggregation of a macromolecule under physiological conditions: The invention provides a method for reducing aggregation and inhibiting flocculation of a macromolecule, such as a protein, under physiological conditions, by the addition of 5% to 20% polyvinylpyrrolidone (PVP) with a molecular weight range of 2000 to 54,000 daltons. The invention further provides a method to minimize inflammation at... Agent:

20110300134 - Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof: The present invention relates to novel “reverse amide” compounds comprising a zinc chelator group, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6.... Agent: Acetylon Pharmaceuticals

20110300136 - Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor: The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNFα-inhibitor.... Agent: Genentech, Inc.

20110300137 - Use of lumefantrine and related compounds in the treatment of cancer: The present application discloses the use of the anti-malarial drug lumefantrine and related compounds in the treatment of cancer.... Agent:

20110300144 - Methods and compositions for diagnosis and treatment of cancer: The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues such as ovarian tumor and lung tumor tissues and which represent targets for therapy or diagnosis of tumor diseases in a subject.... Agent:

20110300141 - Novel alphabeta-binding protein and its peptide derivatives and uses thereof: A protein kinase C inhibitor that binds B-amyloid and its peptide derivatives with the same function are disclosed. These may be useful in the treatment of Alzheimer's disease, for example as pseudo vaccines comprising antibodies, or as part of fusion proteins which are able to pass through cell membranes or... Agent:

20110300143 - Prenatal enzyme replacement therapy: The invention also contemplates a method for treating a metabolic disorder, such as HPP, in a fetus or embryo were a protein is administered to a pregnant mother. The fusion protein comprises a Fc fragment of an IgG1 antibody peptide-bonded to TNSALP. The protein crosses the placenta of the mother... Agent: Saint Louis University

20110300142 - Use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants: The invention relates to the use of 1-(β-D-Ribofuranosyl)-1,2-dihydropyrimidin-2-one derivative or mimetic or an analogue, derivatives, metabolites, variants or salts thereof for the manufacturing of a medicament to increase the amount of Indoleamine 2,3-dioxygenase (IDO) production in order to induce immunological tolerance as well as a method of treating a mammal... Agent:

20110300145 - Interferon alpha antibodies and their uses: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules... Agent: Medarex, Inc

20110300146 - Anti-cmet antagonists: The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.... Agent: Genentech, Inc.

20110300148 - Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases: The present invention relates to small peptides derived from a cytokine, interleukin-4 (IL-4), capable of binding to the IL-4 receptors and inhibiting macrophage activation, and thereby preventing the onset of inflammatory response. The invention further relates to use of said peptides for the production of a medicament for the treatment... Agent:

20110300147 - Inhibiting tumor cell invasion, metastasis and angiogenesis: The present invention relates to new compositions and methods useful for preventing, treating and diagnosing metastatic and/or invasive cancer and undesirable angiogenesis. For example, the invention relates to inhibitors of proteases that are specifically expressed in tumors, prodrugs activated in the tumor microenvironment and methods for using those inhibitors and... Agent: The Scripps Research Institute

20110300149 - Ljungan virus: The present invention relates to a new group of Ljungan viruses, proteins expressed by the viruses, antibodies to the viruses and proteins, vaccines against the viruses, diagnostic kits for detecting the viruses, uses of the viruses, proteins, antibodies and vaccines in therapy, uses of the viruses, proteins, antibodies and vaccines... Agent: Apodemus Ab

20110300150 - Compositions and methods for treatment of autoimmune and other disease: Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.... Agent:

20110300151 - Uses and compositions for treatment of hidradenitis suppurativa (hs): The invention provides methods, uses and compositions for the treatment of hidradenitis suppurativa. The invention describes methods and uses for treating hidradenitis suppurativa, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to treat hidradenitis suppurativa in a subject. Also described are methods... Agent:

20110300152 - Compositions and methods for modulating cell-cell fusion via intermediate-conductance calcium-activated potassium channels: Compositions and methods are provided for modulating cell-cell fusion by using agents that modulate expression, activity, or function of intermediate-conductance calcium-activated potassium (SK4) channel. In some embodiments, the compositions and methods of the invention provide for inhibition of multi-nucleated osteoclastogenesis and cell-cell fusion, especially cell fusion involving macrophages. In such... Agent: Boehringer Ingelheim International Gmbh

20110300153 - Antibody produced using ostrich and method for production thereof: Disclosed is an antibody produced using an ostrich. Also disclosed is a method for producing the antibody. By using an ostrich, it becomes possible to produce antibodies (particularly antibodies for medical use), which have been hardly produced by using the mammals such as the mouse and the rat, homogeneously in... Agent: Japan Science And Technology Agency

20110300158 - Anti-serum albumin binding variants: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-14, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.... Agent:

20110300156 - Human antibodies against tissue factor: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.... Agent: Genmab A/s

20110300157 - Metalloproteinase 9 and metalloproteinase 2 binding proteins: Proteins that bind to matrix metalloproteinase 9 and to matrix metalloproteinase 2 and methods of using such proteins are described.... Agent: Dyax Corp.

20110300155 - Modulating xrn2: The present invention relates to a method for modulating miRNA, said method being characterized in that a modulator of XRN2 is used. Also provided are uses of said method for therapeutical purposes, reagents therefore, as well as screening methods.... Agent: Novartis Forschungsstiftung, Zweigniederlassung, F Riedrich Miescher Institute For Biomwdical Resear

20110300154 - Treatment of airway hyperreactivity: The invention provides strategies for treating and preventing airway hyperreactivity and non-allergic asthma comprising antagonizing IL-17 activity and/or production by iNKT cells. Provided herein is a method of diagnosing non-allergic asthma and airway hyperreactivity comprising neutrophils quantification in sputum.... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20110300161 - Methods for the treatment and the prognostic assessment of malignant pleural mesothelioma: The present invention relates to methods for the treatment and the prognostic assessment of malignant pleural mesothelioma.... Agent: Inserm (institut National De La Sante Et De Reche Medicale)

20110300160 - Sulfation of wnt pathway proteins: Provided is a protein comprising an antibody binding site that binds to a sulfated epitope of a Wnt pathway protein that is not Wnt5A, Wnt11, or Wnt3a. Also provided is a composition comprising an isolated and purified Wnt pathway protein, where the protein is sulfated but not glycosylated. Additionally provided... Agent:

20110300159 - Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor: Provided are antibodies that bind to: a sulfonated epitope of the protein Sclerostin, to Sclerostin portions comprising a sulfonated amino acid and to dimerized forms of Sclerostin. Further provided are compositions and peptides comprising a sulfonated epitope of sclerostin. Also provided by this invention are methods for production of such... Agent:

20110300162 - Drug conjugate composition: The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human either of the compositions such that... Agent: Immunogen, Inc.

20110300163 - Ige ch3 peptide vaccine: The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier, compositions comprising the immunogens, and methods for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and... Agent: Pfizer Vaccines LLC

20110300164 - Immunostimulatory dna:rna oligonucleotides: Immunostimulatory sequence-specific RNA oligonucleotides corresponding to 3′ terminal sequences of single-stranded minus-sense RNA genomic RNAs are provided. Also provided are compositions and methods relating to an immunostimulatory 4-mer RNA motif provided as 5′-C/U-U-G/U-U-3′. Incorporation of this short RNA motif is sufficient to confer new and altered immunostimulatory properties in new... Agent: Coley Pharmaceutical Group, Inc.

20110300165 - Substituted isoxazole compounds: Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.... Agent: The Board Of Trustees Of The University Of Illinoi University Of Illinios

20110300166 - Vaccine compositions for inducing immune responses against components of drusen: Disclosed are compositions and methods for treating or preventing the formation of drusen in a patient in need thereof. The compositions include an effective amount of at least one polypeptide present in drusen, or an immunogenic fragment or variant thereof that induces an immune response against the polypeptide, together with... Agent: Northwestern University

20110300167 - Cxcr5 receptor compounds: The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor CXCR5. The CXCR5 receptor compounds are derived from the intracellular loops and domains of the CXCR5 receptor. The invention also relates to the... Agent:

20110300168 - Compositions and methods for inducing an immune response against influenza antigens: This disclosure provides compositions and methods for inducing an immune response against influenza antigens, for example in elderly populations, as well as a sensitive artificial antigen presenting cell (aAPC) stimulation assay that can be used for expansion and analysis of multiple antigen specific T cell populations simultaneously.... Agent: The Johns Hopkins University

20110300170 - Hcv vaccines: Disclosed are methods and compositions for inducing immune responses against Hepatatis C virus (HCV). The compositions comprise one or more epitope from a hotspot epitope. In certain embodiments, an HCV vaccine comprising at least two epitopes, each from a different hotspot epitope, is provided.... Agent:

20110300169 - Pharmaceutical composition comprising an antigen: The invention relates to immunogenic compositions. In certain embodiments, the invention provides pharmaceutical compositions comprising an antigen, an immunostimulating substance selected form neuroactive compounds, hormones, compounds having a growth hormone activity, and mixtures thereof, and a polycationic polymer.... Agent: Intercell Ag

20110300171 - Factor h binding protein immunogens: The invention relates to immunization against pathogenic bacterial strains which express or can express multiple factor H binding proteins. Certain aspects of the invention include vaccine compositions comprising at least two factor H binding proteins derived from a pathogenic bacterial strain which expresses multiple facto H binding proteins.... Agent: Novartis Vaccines And Diagnostics S.r.l.

20110300172 - Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis: A fusion protein comprising an antigenic fragment of apoB-100 and a suitable carrier and related compositions methods and systems.... Agent:

20110300173 - Capsule composition for use as immunogen against campylobacter jejuni: Immunogenic compositions, and method of using the compositions to elicit an immune response against Campylobacter jejuni. The compositions are isolated polysaccharide polymers derived from Campylobacter jejuni capsule.... Agent:

20110300174 - Conjugates for the prevention or treatment of nicotine addiction: m

20110300175 - Composition for promoting control of total and ldl cholesterol, and/or weight loss and/or thermogenesis: A composition for promoting control of total and LDL cholesterol and/or weight loss and/or thermogenesis in individuals, the composition including green tea extract in a quantity of about 200 mg to about 300 mg; guarana extract in a quantity of about 160 mg to about 260 mg; yerba mate extract... Agent: Sigma Alimentos, S.a. De C.v.

20110300176 - Microorganisms for therapy: Therapeutic methods and microorganisms therefor are provided. The microorganisms are designed to accumulate in immunoprivileged tissues and cells, such as in tumors and other proliferating tissue and in inflamed tissues, compared to other tissues, cells and organs, so that they exhibit relatively low toxicity to host organisms. The microorganisms also... Agent:

20110300178 - Hpv types and variants associated with cervical cancer and the uses thereof: The invention relates to identification of novel sequences associated with cervical cancer, probes and kits for the identification of said sequences, and vaccines suitable for vaccination against new cancer causing HPV types.... Agent: Ddl Diagnostics Laboratory B.v.

20110300177 - Triterpene saponins, methods of synthesis, and uses thereof: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the... Agent:

20110300179 - Novel compositions and uses thereof: The present invention provides a cellular vaccine for therapeutic or prophylactic treatment of a pathological condition, the vaccine comprising or consisting of a population of CD 4+ T cells modified such that they contain an antigenic component, and/or a nucleic acid molecule encoding an antigenic component thereof, wherein the T... Agent:

20110300180 - plant-derived vaccines against respiratory syncytial virus: A plant-derived vaccine against respiratory syncytial virus (RSV) is disclosed. The vaccine includes an immunogenic complex that includes plant cells transformed with a chimeric gene containing a nucleotide sequence adapted for protein expression in plants and an RSV coding sequence that encodes an antigenic protein of RSV. Also disclosed are... Agent:

20110300181 - Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines: The present invention relates to methods for purification of Vaccinia viruses (W) and/or Vaccinia virus (W) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus preparation in a sterilized way with high efficiency and desirable yield in... Agent:

20110300182 - Nucleic acid drug for treatment of allergic disease: This invention provides double-stranded (ds) RNA capable of suppressing the expression of STAT6 related to allergic diseases mediated by Th2-type cytokines via RNA interference and a pharmaceutical composition for prevention or treatment of allergic diseases comprising such dsRNA. Such dsRNA is a double-stranded RNA (dsRNA) molecule targeting mRNA of the... Agent:

20110300183 - Method of preparing adenosine-resistant anti-tumor t lymphocytes for adoptive immunotherapy: In the past, adoptive immunotherapy often failed because the transferred immune cells were inactive in vivo. This disclosure provides a method of producing immune cells that are highly active in vivo. The immune cells may be expanded in vitro in the presence of an adenosine receptor agonist or an antisense... Agent: Northeastern University

20110300193 - Ambient stored blood plasma expanders: A liquid plasma expander or resuscitation fluid composition for use in a subject in need thereof, comprising, consisting of, or consisting essentially of: (a) a keratin derivative (preferably alpha keratose, gamma keratose, or combinations thereof, and with basic alpha keratose preferred over acidic alpha keratose); and (b) an electrolyte solution,... Agent:

20110300189 - Antimicrobial colloidal silver products and method of making same: Gelatinous materials combined with the Colloidal Silver additive to formulate an antimicrobial product having cushioning properties. Embodiments of the present invention can include gelatinous materials selected from a group consisting of thermosetting polymer, Styrene-Ethylene-Butadiene-Styrene polymer (SEBS), Thermoplastic Elastomer (TPE), and Polyurethane (PU) gelatin with and without a raised geometry on... Agent:

20110300187 - Antioxidant camptothecin derivatives and antioxidant antineoplastic nanospheres thereof: The present invention is directed to antioxidant derivatives of camptothecin and antioxidant derivatives of camptothecin analogs and the preparation of nanometer-sized camptothecin prodrugs. Methods of synthesizing the antioxidant derivatives of camptothecin and antioxidant derivatives of camptothecin analogs, spontaneous emulsification or nanoprecipitation thereof to produce antioxidant camptothecin nanosphere prodrugs and their... Agent: Cedar- Sinai Medical Center

20110300190 - Compound, composition and uses thereof: The disclosure herein provides a compound of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof. The steps of synthesis of compound of formula I is described. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration,... Agent: Krisani Biosciences (p) Ltd

20110300194 - Flexible bone composite: The present invention relates in general to implantable flexible bone composites, and method for preparing the same. The flexible bone composite includes at least one polymeric layer and at least one calcium-containing layer. The polymeric layer can be a polymeric layer including a synthetic polymer. The calcium-containing layer can include... Agent: Synthes Usa, LLC

20110300186 - Functionalized nano- and micro-materials for medical therapies: Compositions containing an optionally surface-functionalized mesoporous support and a biologically active agent, and pharmaceutical compositions of the same, are provided herein. Such compositions can be useful in the treatment of tumors, for example, by injection of the composition at a location near the site of the tumor.... Agent: University Of Washington Through Its Center For Commercialization

20110300188 - Glassy calcium phosphate particulates, coatings and related bone graft materials: Calcium phosphate and related coating powder particles comprising a surface component comprising a silicate content, plasma sprayed coatings thereof on implantable medical/dental devices, and bone grafting materials of such coated particles. Optionally, biologically active agents such as bone morphogenetic proteins, growth factors, analgesics, and antibiotics can be incorporated therein.... Agent:

20110300185 - Immunogenic escherichia coli heat stable enterotoxin: The present invention relates to methods and compositions for the treatment and prevention of diarrhea and diarrheal related diseases and disorders in both animals and humans. In some embodiments, the invention relates to the treatment of said diarrhea and diarrheal related diseases and disorders with a vaccine. In still further... Agent:

20110300192 - Magnesium oxide granules: e

20110300191 - Multiple-layer immune barrier for donor cells: A system is provided, including a plurality of donor cells and a first alginate structure that encapsulates the plurality of donor cells. The first alginate structure has a guluronic acid concentration of between 64% and 74%. The system additionally includes a second alginate structure that surrounds the first alginate structure,... Agent: Beta-o2 Technologies Ltd.

20110300195 - Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors: The embodiments disclosed herein relate to ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors, and more particularly to methods for treating an ocular disease and/or condition using the disclosed compositions. According to aspects illustrated herein, there is provided a pharmaceutical composition that includes a calcineurin inhibitor or an mTOR inhibitor;... Agent: Lux Biosciences, Inc.

20110300184 - Pharmaceutical compositions for treating or preventing bone conditions: Provided herein is a pharmaceutical composition for treating, preventing or ameliorating a bone or cartilage condition and methods of making and using the same.... Agent: The Regents Of The University Of California

20110300200 - Effect pigment and the use thereof in cosmetics and in the foods and pharmaceuticals sector: The present invention relates to intensely coloured and light-stable effect pigments based on transparent, undoped SiO2 flakes, which are distinguished by the fact that they are covered with an iron-oxide layer having a thickness of 30-150 nm, and all SiO2 flakes have an identical thickness, and the thickness of the... Agent:

20110300197 - Food product: The present invention relates to a food product comprising an outer portion and an inner portion, wherein the inner portion comprises myrtle and has a moisture content of from about 10% to about 25% by weight, the food product for use in oral health applications, and the use of the... Agent: Mars, Incorporation

20110300198 - Hydrocolloid - essential oil patches: The present invention relates to dermal patches comprising natural polysaccharides without the need for any pressure sensitive synthetic polymers. Particularly, the present invention relates to patches comprising a bioadhesive composition comprising a polysaccharide exudate and an essential oil useful for transdermal delivery of therapeutic or cosmetic agents.... Agent:

20110300196 - Method and system for automatic or manual evaluation to provide targeted and individualized delivery of cosmetic actives in a mask or patch form: A system and method are provided for targeted and individualized delivery of multiple skin benefit agents to the skin of a user. The image of a predetermined treatment area of the user's skin is first captured by an imaging device. Selective data input from analysis tools and the end user... Agent:

20110300199 - Peptides used in the treatment and/or care of the skin, mucous membranes and/or scalp and their use in cosmetic or pharmaceutical compositions: Peptides of general formula (I): R1-Wp-Xn-AA1-AA2-AA3-AA4-Ym-R2 their stereoisomers, mixtures thereof, and/or their cosmetically or pharmaceutically acceptable salts, a method of preparation, cosmetic or pharmaceutical compositions containing them and their use for the treatment, prevention and/or care of conditions, disorders and/or diseases of the skin, mucous membranes and/or scalp.... Agent: Lipotec, S.a.

20110300201 - Delivery system for co-formulated enzyme and substrate: The invention provides methods, compositions, systems, and kits that include an enzyme/substrate co-delivery system. The liquid delivery system includes at least one enzyme encapsulated in a water-soluble polymeric matrix and a substrate for the enzyme in a carrier liquid in which the polymeric matrix is insoluble. When water is added,... Agent: Danisco US Inc.

20110300203 - Cartilage regeneration without cell transplantation: Provided is a method of causing a cell to migrate to a scaffold. Also provided is a method of treating a mammal that has a cartilage defect. Further provided is a tissue scaffold comprising stromal cell-derived factor-1 (SDF-1) and transforming growth factor-β (TGF-β). Additionally, a method of making a tissue... Agent: Trustees Of Columbia University In The City Of New York

20110300202 - Medical item for long term durg release: Polymeric articles capable of releasing drugs at therapeutic levels over extended periods of time, and methods for producing the extended release articles.... Agent:

20110300204 - Nutritional compositions with large lipid globule size: The present invention relates to a nutritional composition for infants and/or toddlers comprising a lipid component which has a large lipid globule size, having a volume weighted mode diameter above 1.0 μm and/or with a diameter of 2 to 12 μm in a amount of at least 45 volume %... Agent: N.v. Nutricia

20110300205 - Self replicating rna molecules and uses thereof: This application discloses self-replicating RNA molecules that contain modified nucleotides, compositions that contain the self-replicating RNA molecules, and methods for using the self-replicating RNA molecules, for example, to raise an immune response.... Agent: Novartis Ag

20110300206 - Vaccines against chlamydial infection: The present invention relates to compositions comprising proteins or polynucleotides of Chlamydia sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis of Chlamydia infection.... Agent: Corixa Corporation

20110300207 - Method of treating post-surgical acute pain: A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than... Agent: Aaipharma Inc.

20110300208 - Segmented pharmaceutical dosage forms: A pharmaceutical tablet adapted for accurate division of a dose of a drug into two or more smaller doses, which tablet has two or more segments.... Agent:

20110300209 - Modified release solid pharmaceutical compositions of trimetazidine and process thereof: There is provided a modified release solid pharmaceutical composition comprising Trimetazidine and polyethylene oxide, wherein the composition does not include any lubricant.... Agent: Micro Labs Limited

20110300210 - Controlled release nanoparticulate clozapine compositions: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.... Agent: Elan Pharma International Limited

20110300211 - Soft-gelatin capsule formulation: The present invention provides a soft gelatin capsule formulation of a 15-keto-prostaglandin compound, which includes: a soft gelatin capsule shell including gelatin and sugar alcohol as a plasticizer, and a mixture including a 15-keto-prostaglandin compound and a pharmaceutically acceptable vehicle which is filled in the shell. By encapsulating the 15-keto-prostaglandin... Agent: R-tech Ueno, Ltd.

20110300212 - Pharmaceutical formulation: The present invention is directed to pharmaceutically acceptable polymeric compositions suitable for injection molding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being... Agent: Pfizer Inc.

20110300213 - Oral formulations of bipolar trans carotenoids: The subject invention relates to a variety of formulations of bipolar trans carotenoids including pharmaceutical compositions for oral delivery of a bipolar trans carotenoid comprising i) a bipolar trans carotenoid, ii) a cyclodextrin, and iii) a coating. The invention also relates to preparation of such formulations and their uses.... Agent:

20110300214 - Pharmaceutical compositions comprising 5-chloro-n-(-methyl)-2-thiophencarboxamid: The invention relates to pharmaceutical compositions comprising 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid and processes of preparing such compositions. In a second aspect, the present invention relates to a preferred pellet-layering process for preparing such compositions.... Agent: Ratiopharm Gmbh

20110300215 - Tablet formulation of ezatiostat: Disclosed herein are tablets comprising ezatiostat hydrochloride wherein the ezatiostat hydrochloride comprises from about 75 to about 82 percent by weight of the tablet.... Agent: Telik, Inc.

20110300216 - Chewable, swallowable and effervescent solid dosage form for oral delivery of pharmaceutical actives: A tablet comprising: (a) an active ingredient; and (b) at least one member of an effervescent couple, wherein said tablet dissolves in water in not more than three minutes and in the mouth in not more than thirty seconds, and wherein said tablet is capable of acting as an effervescent... Agent:

20110300217 - Hydromorphone therapy: A hydromorphone composition, a hydromorphone dosage form and a method for administering hydromorphone are disclosed, indicated for the management of pain.... Agent:

20110300219 - Nanostructures for drug delivery: The present invention provides compositions, preparations, formulations, kits, and methods useful for treating subjects having cancer or at risk of developing cancer. Some embodiments of the invention may comprise a composition comprising a plurality of particles comprising a platinum(IV) therapeutically active precursor.... Agent: Massachusetts Institute Of Technology

20110300218 - Novel solid state forms of ranolazine salts: Provided herein are solid state forms of ranolazine salts. Also provided is a stable amorphous form of ranolazine hydrochloride having a water content of less than about 0.5% by weight. Further provided are amorphous co-precipitates of ranolazine or a pharmaceutically acceptable salt thereof with povidone. Processes for the preparation of... Agent: Actavis Group Ptc Ehf

20110300220 - Solid calcium lactate in substantially spherical form: Solid calcium lactate in the form of substantially spherical particles, characterised in that the spherical particles have a particle size distribution such that most of the particles are between 280 and 550 microns in size and the calcium lactate can be rapidly dissolved in water.... Agent: Galactic Sa

20110300221 - Therapeutic inhibitor of vascular smooth muscle cells: Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle... Agent:

20110300223 - Immunogenic composition: An immunogenic composition includes as an effective ingredient an antigen-adjuvant microparticle complex containing an antigen encapsulated in an adjuvant microparticle composed of an amphiphilic polymer(s) whose hydrophobic segment is a poly(hydroxy acid), or a particle composed of the antigen-adjuvant microparticle complex associated together, can induce a high immune response against... Agent: Toray Industries, Inc.

20110300222 - Luminescent porous silicon nanoparticles, methods of making and using same: The disclosure relates to imaging agents and drug delivery systems.... Agent: The Regents Of The University Of California

20110300224 - Taste masked dosage form of pharmaceutically acceptable salt of escitalopram: A taste masked dosage form of pharmaceutical acceptable salt of escitalopram comprising (a) resin complex of pharmaceutical acceptable salt of escitalopram and cationic exchange resin or adsorbing or coating non-pareil seeds or inert particles with a mixture of pharmaceutically acceptable salt of escitalopram, cationic polymer and optionally other polymer(s) or... Agent: Genepharm A.e.

20110300225 - Nutritional compositions with coated lipid globules: The present invention relates to a nutritional composition for infants and/or toddlers comprising a lipid component which has a lipid globules coated with phospholipids. The composition is used for increasing bone mineral content, bone mineral density, preventing osteoporosis, and/or preventing ostopenia.... Agent: N.v. Nutricia

20110300226 - Peptide particle formulation: A composition as disclosed is comprised of a plurality of groups of particles. The particles are comprised of a biocompatible polymer which maybe a co-polymer such as PLGA combined with a peptide of a sequence of interest, e.g. a sequence which corresponds to a sequence presented on a surface of... Agent:

20110300228 - Composition, with/without at least one easily oxidised component, comprising an edible processed oil or fat mixture, for promoting growth in an animal, preventing oxidative stress, avoiding that fish develop enlarged liver and feed composition: The present invention relates to a composition for reducing the tendency of an animal to enter sexual maturation, reducing or preventing oxidative damage in an animal, for reducing or preventing oxidative stress in an animal, promoting growth of an animal and for avoiding enlarged liver size in fish. The present... Agent: Pronova Biopharma Norge As

20110300227 - Malignant neoplasm treatment protocol: Methods, compositions, and strategies for the treatment of malignant neoplasms are presented herein. The treatment modalities are directed towards exploiting characteristics of cancer cells as well as correcting defective biochemical pathways and systems in the body.... Agent: North Texas Medical Associates

20110300229 - Treating or preventing rotavirus infection: Use of one or more of conjugated linoleic acid (CLA), high CLA milk fat, or one or more bovine milk lipid compositions to treat or prevent rotavirus infection.... Agent: Fonterra Co-operative Group Limited

20110300230 - Fluid purification system: Disclosed are systems and methods of preparing dialysate for use in a home dialysis system that is compact and light-weight relative to existing systems and consumes relatively low amounts of energy. The method includes coupling a household water stream to a dialysis system; filtering the water stream; heating the water... Agent: State University

20110300231 - Fluid purification system: Certain disclosed embodiments concern systems and methods of preparing dialysate for use in a home dialysis system that is compact and light-weight relative to existing systems and consumes relatively low amounts of energy. The method includes coupling a household water stream to a dialysis system; filtering the water stream; heating... Agent: State Of Oregon Acting By And Through The State Board Of Higher Eduction On Behalf Of Oregon

20110300232 - Effects of nitric oxide (no) and inos on expression and signal transduction in cancer and its use in drug discovery and cancer therapy design: Nitric Oxide (NO) acts as double-edged sword, which induces and prevents cell death, depending on various factors. The mechanism for the NO regulation of cells is not fully understood. The present invention provides experiment design methods and therapy design methods leveraging viable hypothesis supported by current research findings. This invention... Agent:

20110300233 - Conditioning composition: The present invention is directed to a composition for the conditioning of a dental mineralized surface and/or a dental implant and/or for increasing the hydrophilicity of a dental implant having a metal containing surface. The composition comprises EDTA in a concentration of about 21-55% by weight and hydrogen peroxide at... Agent: Straumann Holding Ag

20110300234 - Methods of treating tumor cells using rhcc protein, fragment or variant: Methods of treating tumor cells in an individual comprise administering to the individual a drug having anti-tumor effect, wherein the drug is delivered into the tumor cells via Right-Handed Coiled-Coil (RHCC) protein or a fragment or variant thereof. The drug may, for example, be a metal-containing compound, a protein or... Agent:

20110300235 - Gallium-containing sealant for medical use: Chronic rhinosinusitis and other bacterial sinus conditions may be treated by applying a solvating system containing a surfactant to a bacterial biofilm in a nasal or sinus cavity, disrupting the biofilm, and applying a protective layer of a polymeric film-forming medical sealant.... Agent: Medtronic, Inc.

20110300237 - Protective solutions for organs: Described is a protective solution for avoiding ischemic, storage or ischemia/reperfusion to organs, or to isolated cell systems, or to tissue components after perfusion, surgery, transplantation, or cryopreservation and subsequent reperfusion, which contains alkali ions, and if need be also alkaline earth ions as the electrolyte, a buffer e.g. on... Agent:

20110300236 - Method of treating impaired mitochondrial function: Disclosed in certain embodiments is a pharmaceutical composition comprising a sugar; a Krebs cycle intermediate, precursor of a Krebs cycle intermediate, salt thereof, or combination thereof; and a component selected from the group consisting of an unsaturated lipid, phenylethylamine, a soluble calcium compound, or a combination thereof.... Agent:

20110300238 - Mixture of inorganic compounds, preparations containing the mixture and use of the mixture: A mineral mixture including at least' MgO and its equilibrium of Mg(OH)2, and MgCl2, in which MgO—Mg(OH)2 constitutes between 85 and 99.99% by weight; and MgCl2 constitutes between 0.01 and 15% by weight of the magnesium compounds in the mineral mixture. Preparations containing the salt mixture and the use of... Agent:

20110300239 - Blood flow improving agent: An object of the present invention to obtain a blood flow improving agent composed of natural components, which increase activity or circulation of blood flow and accelerate decomposition, detoxication and elimination of toxic substances and supplement each other, and the production method thereof. The blood flow improving agent of the... Agent:

20110300240 - Cajanus extracts and glucosamine for inflammatory disorders: The present invention relates to novel compositions comprising Cajanus and glucosamine as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders.... Agent:

20110300241 - Oral care compositions for treating xerostomia: Disclosed herein are oral care compositions for promoting salivary flow. Thus, also disclosed are methods of treating and preventing xerostomia. The oral care compositions can contain all-natural ingredients, including, for example, green tea polyphenols and jaborandi extract.... Agent: Medical College Of Georgia Research Institute, Inc

20110300242 - Novel botanical formulation for treating sickle cell disease: An improved plant medicament composition, comprising a mixture of extractions of Piper guineense, Eugenia caryophyllum and Sorghum bicolor plant material, without the use of Pterocarpus osun stem, for treating sickle cell disease is disclosed. A method for the preparation of said composition is also provided.... Agent:

20110300243 - Disinfectant making air fresh and preparation and method and use thereof: The air-refreshing disinfectants currently sold in the market mostly contain artificially synthesized chemical disinfectants. Frequent exposure to the air containing such chemicals may be somewhat harmful to the human body. Therefore the present invention provides an air-refreshing disinfectant, and in particular an air-refreshing disinfectant which is not chemically synthesized and... Agent: Everite Consultants Ltd.

20110300244 - Water-soluble extracts of artemisia dracunculus (tarragon) for improvement of glucose metabolism: An extract obtainable by a method comprising the steps extracting Russian Tarragon with water or a mixture of water with up to 20% by volume of a C1 to C3 alcohol.... Agent:

20110300245 - Topical, palatable, anti-inflammatory and analgesic for specific application to intraoral, gingival and extraoral areas correlated with, and related to, the trigeminal nerve and its nerve branches and plexus. to mitigate, attenuate or prevent migraine-typ: The invention is a new unique, palatable, topical, anti-inflammatory and analgesic designed around a specific set of painful conditions, with specifically designated applications, using a different methodology and formulation, with no NSAIDS, steroids or salicylites, than the prior art for this specific set of painful conditions. Thus creating an improved... Agent:

20110300246 - Herbal extracts for treatment of diabetic complications and oxidative stress: Compositions, functional foods, methods of preparation, and their uses for the treatment of diabetic complications and oxidative stress are provided. The compositions, functional foods, and methods relate to herbal extracts from the rhizome of Curcuma L., Puerariae radix, the root of herb Pueraria lobat, Fructus corni, the fruit of herb... Agent:

20110300247 - Flaxseed lignan complex and its use thereof: The invention relates compositions and methods for treating pathological lung conditions using whole-grain flaxseed or flaxseed lignans. Specifically, the invention relates to the dietary use of flaxseed lignans.... Agent:

20110293511 - Specific binding proteins and uses thereof: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies... Agent:

20110293512 - Compositions and methods for inhibiting growth of smad-4 deficient cancers: The present invention is in the fields of cell biology, immunology and oncology. The invention relates to the discovery that there is a relationship between the expression levels of the tumor suppressor gene smad4 (also known as dpc4) and integrin αvβ6, and the responsiveness of patient populations to αvβ6-active compounds... Agent: Biogen Idec Ma Inc.

20110293513 - Immunoconjugates with an intracellularly-cleavable linkage: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.... Agent: Immunomedics, Inc.

20110293514 - Methods of using il-31 monoclonal antibodies to reduce inflammation: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by... Agent: Zymogenetics, Inc.

20110293515 - Heterofunctional segment-poly (ethylene glycol) polymers as delivery vehicles: Heterofunctional segment-poly(ethylene glycol) polymers, conjugates of these molecules with therapeutic and/or imaging agents, and methods for their use are disclosed. The heterofunctional segment-poly(ethylene glycol) polymers are useful as drug delivery conjugates, i.e., the heterofunctional segment-poly(ethylene glycol) polymers can be covalently attached to therapeutic agents (e.g., pharmaceutically active agents) and serve... Agent: The Uab Research Foundation

20110293516 - Compositions and methods of use of targeting peptides against placenta and adipose tissues: The present invention concerns compositions comprising and methods of identification and use of targeting peptides for placenta or adipose tissue. In certain embodiments, the targeting peptides comprise part or all of SEQ ID NO:5-11, SEQ ID NO:13-22 or SEQ ID NO:144. The peptides may be attached to various therapeutic agents... Agent:

20110293517 - Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic... Agent: The University Of Melbourne

20110293518 - Diagnosis of whiplash associated disorders (wad) by using pet with d-[methyl-11c]-deprenyl (dde): Positron Emission Tomography (PET) tracers such as D-[methyl-11C]-Deprenyl (DDE) and [11C]-GR205171 (GLD), methods for and methods of preparing biological mechanisms that identify treatment targets in connection with Whiplash-Associated Disorder (WAD) are provided. Associated kits for the evaluation of the biological mechanisms are also provided.... Agent: Ge Healthcare Limited

20110293519 - Molecular imaging agents: Provided is radiolabeled ammonium salts and uses thereof as myocardial perfusion agents in molecular imaging.... Agent: Hadasit Medical Research Services & Development Limited

20110293520 - New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases: The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions... Agent: Ludwig-maximilians-universitat Munchen

20110293521 - Anti-viral compositions and methods for administration: Certain embodiments disclosed relate to compositions, including therapeutic compositions, methods, articles of manufacture, systems, and devices. Certain embodiments relate to anti-viral compositions, methods, articles of manufacture, systems and devices.... Agent: Searete LLC, A Limited Liability Corporation Of The State Of Delaware

20110293523 - Diagnostic agent: A method of conducting an endoscopic observation of an inner wall of a gastrointestine by applying a diagnostic agent to the inner wall of the gastrointestine, the diagnostic agent being an acidic aqueous solution of pH 1 to 5 containing a colorant, and conducting the endoscopic observation of the inner... Agent: National University Corporation Okayama University

20110293522 - Surface modification of polymers via surface active and reactive end groups: Polymer surface modification method comprising the steps of first forming a surface of primary reactive end groups tethered to the polymer chain ends during fabrication of an article, and then modifying the reactive surface with bio-active molecules, hydrophilic and hydrophobic monomers, oligomers, or polymers to attain specific surface properties. Alternatively,... Agent: DsmIPAssets B.v.

20110293526 - Compositions and methods to modulate hair growth: The invention provides compositions and methods to modulate hair growth in a tissue comprising administering to the tissue an effective amount of an agent that inhibits or augments Bone Morphogenic Protein (BMP) signaling in the tissue, thereby facilitating or inhibiting hair growth.... Agent: University Of Southern California

20110293524 - Methods and compositions for the regulation of lectin complement pathway (lcp)-associated complement activation in hyperglycemic myocardial damage: The present invention relates to methods and compositions for regulating lectin complement pathway (LCP)-associated complement activation. In particular, the invention relates to methods and compositions for inhibiting LCP-associated complement activation in order to inhibit hyperglycemic myocardial damage. The invention also relates to the treatment of cardiomyopathy and/or hypertrophy, such as... Agent: The Brigham And Women"s Hosptial Inc.

20110293525 - Tumor stem cells: Tumor stem cells can be obtained by culturing a tumor cell population, and exposing the cultured tumor cell population to free radicals. In certain embodiments, the free radical agent can be a nitric oxide (NO) donor. In one embodiment, the free radical agent can be Diethylenetriamine NONOate (DETA NONOate) or... Agent: Board Of Trustees Of The University Of Illinois

20110293528 - Enema preparations and their use: This invention relates to improved methods of photodynamic treatment and diagnosis of cancer and non-cancerous conditions, and in particular to improved enema preparations for use in such methods, said enema preparations comprising a photosensitiser which is 5-aminolevulinic acid (5-ALA) or a precursor or derivative thereof, e.g. a 5-ALA ester. Such... Agent: Photocure Asa

20110293527 - Modified vaccinia virus strains for use in diagnostic and therapeutic methods: Modified viruses and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including cancer, and as anti-tumor and/or antiangiogenic agents. The viruses also can be used in... Agent:

20110293531 - Porphyrazine optical and dual optical/mr contrast and therapeutic agents: Porphyrazines capable of localizing in a tumor of a mammal are disclosed. The porphyrazines are used in methods of imaging a tumor and in methods of treating tumors, either alone or in combination with a chemotherapeutic agent and/or radiation.... Agent: Hoffman/barrett, L.L.C.

20110293530 - Methods and compositions for using bleomycin-derivatized microbubbles: Methods and compositions for using tumor targeting compounds bound to microbubbles to facilitate drug delivery and diagnostic imaging at tumor sites.... Agent: Arizonia Board Of Regents

20110293529 - Fluorescent nirf activatable probes for disease detection: Fluorescent activatable probes for imaging biological processes and disease detection in vitro and in vivo. There is also described a method for detecting the presence of an enzyme. A sample is contacted with a nanoparticle including a monomer, at least one cleavable spacer comprising at least one fluorescence activation site,... Agent:

20110293532 - Antiperspirant compositions: An antiperspirant composition may include an aqueous carrier; and at least 4 to 7 weight percent of an aluminum and/or aluminum-zirconium antiperspirant active containing at least a Peak 4 specie. An antiperspirant composition may also include an aqueous carrier; and an aluminum and/or aluminum-zirconium antiperspirant active containing at least a... Agent: Coty Inc.

20110293533 - Synergistic mixtures of anthranilamide invertebrate pest control agents:

20110293534 - Aerosol can spray incorporating a nutritional cell scaffold for use as first aid treatment for wounds/burns and for use in cell therapy/tissue repair: A First Aid aerosol can spray using a propellant authorized for human use. Spray will be in the form of a ‘light emulsion’ for use on burns and wounds at incident sites. If propellant is not used, two of the spray constituents, namely sterile cornstarch granules, a nutritional cell scaffold... Agent:

20110293536 - Buccal, polar and non-polar spray containing zolipidem: Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide zolpidem for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, zolpidem, and optional flavoring agent; formulation II:... Agent:

20110293535 - Composition for buccal absorption of nicotine for the purpose of smoking cessation: Composition intended for buccal absorption of nicotine into the system circulation and distribution to the central nervous system for the purpose of smoking cessation or nicotine substitution in conditions adverse for smoking according to the invention contains nicotine solution in form of a base and/or its salt with organic acid... Agent: Heglund, A.s.

20110293537 - formulations with anti-neoplastic activity: Pharmaceutical formulation comprising at least one aryl hydrocarbon receptor ligand and at least one cyclodextrin for the prevention and/or treatment of carcinomas, preferably squamous cell carcinomas, more preferably oral squamous cell carcinomas.... Agent:

20110293540 - Branched polymers, compositions, and uses thereof: Provided herein are branched polymers synthesized from: at least one (A1) reactive monomer having a vinyl functional group, or (A2) a hybrid reactive monomer having (a) at least one vinyl functional group and (b) at least one reactive non-vinyl functional group; and at least one: (B1) branching agent having at... Agent: Isp Investments Inc.

20110293539 - Film containing compositions: An oral care, personal care or cleansing composition with a carrier comprising a functional material and at least two polymers. One polymer has a greater solubility in water than the other polymer; one of the polymers may be water-soluble and the other polymer water-insoluble. The polymers are selected and apportioned... Agent: Colgate-palmolive Company

20110293538 - Use of rubusoside for reducing or suppressing certain unpleasant taste impressions: The invention relates to the use of rubusoside and certain mixtures containing rubusoside, preferably the use of certain rubusoside-containing mixtures, in particular Rubus suavissimus extracts, for masking, reducing or suppressing a bitter, sour and/or astringent taste impression. The invention further relates to orally consumable preparations, comprising at least one bitter,... Agent: Symrise Ag

20110293541 - Oral care compositions and methods of making oral care compositions comprising silica from plant materials: Embodiments of a method of making an oral care composition comprise providing plant material comprising silica, burning the plant material to remove organic impurities from the plant source material, removing inorganic impurities from the burnt plant material by hydrolyzing with an aqueous acid solution, separating the silica from the burnt... Agent:

20110293542 - Antibacterial agent composition and antiviral agent composition comprising silicon-containing compound; antibacterializing method, cleaning/mouth rinsing method; method for fixing antibacterial agent and antiviral agent: Disclosed is an antibacterial agent composition which is highly safe and has excellent antibacterial abilities, by using a silicon-containing compound that is obtained by a specific manufacturing method. The antibacterial agent composition has a more stable antibacterial component, and is capable of imparting antibacterial abilities to teeth, while being also... Agent:

20110293543 - Anhydrous composition comprising a dibenzoylmethane compound and a color pigment: The invention relates to an anhydrous color cosmetic composition including a cosmetically-acceptable hydrophobic vehicle that includes a wax component, an oil component, and an organic UV filter component that includes a dibenzoylmethane compound. The composition also includes a powder component that includes a color pigment and an oil-absorbing powder.... Agent:

20110293545 - Dolichos biflorus extract for use in cosmetic skin treatment: The present invention pertains to a Dolichos biflorus extract enhancing collagen production and cosmetic compositions comprising said extract. Furthermore, it pertains to a method of using the extract or compositions for cosmetic purposes, especially to their use in enhancing collagen production. Finally, a method for preparing the extract for cosmetic... Agent: CognisIPManagement Gmbh

20110293544 - High unsaponifiables and methods of using the same: Materials with high levels of unsaponifiable matter, such as extracts from plants, produce hydrolysates with unique properties. Properties that are sought in traditional saponification of natural oils are a result of low levels of unsaponifiables. These properties include high levels of aqueous surfactant activity, water-solubility or ready water-dispersability, activity as... Agent: International Flora Technologies, Ltd.

20110293546 - Antibacterial artificial nail composition: Disclosed is an antibacterial artificial nail composition comprising (A) a compound having at least one radical polymerizable unsaturated double bond and an antibacterial group in the molecule and/or (B) an antibacterial filler, (C) a compound having at least one radical polymerizable unsaturated double bond in the molecule, and (D) a... Agent:

20110293547 - Pvd metal effect pigment having gradient on nanoscale metal particles, method for the production thereof and use thereof: A platelet-shaped PVD metallic effect pigment having first and second outer faces, the platelet-shaped PVD metallic effect pigment having at least one PVD layer, the at least one PVD layer including elemental metal with clusters of elemental metal and metal oxide. The amounts of elemental metal in the first outer... Agent:

20110293548 - Solid, compact powder cosmetic product and process for obtaining the same: The present invention provides a solid cosmetic product consisting of a substantially anhydrous, compact cosmetic powder comprising, as essential ingredients, one or more thermoreversible polysaccharides, one or more humectants, one or more emollients and a powder phase, and also optionally conventional cosmetic ingredients. The present invention further provides a process... Agent: Color Cosmetics S.r.l.

20110293549 - Composition, method and kit for enhancing hair: e

20110293552 - Hair care composition comprising a dendritic macromolecule: Hair care composition comprising an emulsified hydrophobically functionalised dendritic macromolecule.... Agent:

20110293550 - Long-wear, waterproof and washable mascara composition: The present invention is directed to long wear, washable and waterproof eye makeup composition having a unique texture and feel containing: (a) at least one polyamine; (b) at least one oil-soluble polar modified polymer; (c) at least one oil-soluble high carbon polar modified polymer; (d) water; (e) optionally, at least... Agent: L'oreal S.a.

20110293551 - Water-in-oil emulsion composition for hair: Present invention is related to conditioning composition for hair especially suited for leave-in application in water-in-oil (W/O) emulsion form. The object of the present invention is water in oil emulsion composition for hair comprising at least one oil, at least one silicone surfactant. at least one alkoxylated and hydroxylated amino... Agent:

20110293553 - Identification of insect attractant, arresting, and/or aggregation compounds and methods thereof: Compounds, compositions, kits, devices, and methods of attracting, detecting, eradicating, controlling, or killing an insect, such as a bed bug, by utilizing insect attractant, arresting, and/or aggregation compounds and compositions is provided. Insect attractant, arresting, and/or aggregation compounds identified from insect fecal extract by an analytical technique, such as gas... Agent:

20110293554 - Recombinant human g-csf dimer and use thereof for the treatment of neurological diseases: This invention relates to a recombinant human G-CSF (rhG-CSF) dimer and its use in the treatment of neurological disorder. In particular, upon ischemic neural injury in animal, this invention can be used to protect neurons with the use of rhG-CSF dimer such that function of injured nerves can be restored.... Agent: Generon (shanghai) Corporation Ltd.

20110293556 - Treatment of insulin resistance/metabolic syndrome to alleviate the risks of dementia: This invention relates to Applicant's discovery that Metabolic Syndrome , a cluster of disorders stemming from a resistance to insulin, contributes directly to dementia, particularly Alzheimer's disease. Applicant's invention includes a screening method to determine susceptibility and diagnosis of dementia based on the risk factors for Metabolic Syndrome. Applicant's invention... Agent: Sanford-burnham Medical Research Institute

20110293555 - Tumor necrosis factor-alpha mutants: The present invention has an object to provide a tumor necrosis factor mutant protein, particularly, a tumor necrosis factor mutant protein specific to TNF-R1 or TNF-R2; tumor necrosis factor inhibitor; or tumor necrosis factor preparation containing it as an effective ingredient, and the object is solved by providing a tumor... Agent: Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo

20110293561 - Anti-kir combination treatments and methods: Compositions comprising anti-KIR antibodies and one or more secondary anti-cancer agents or anti-viral agents and methods of using such combinations (as combination compositions or in separate administration protocols) in the treatment of cancers (e.g., lung cancer) or viral infection (e.g., HIV or HCV infection) are provided.... Agent: Novo Nordisk A/s

20110293559 - Catabolic agents: This invention relates to the use of agents which are capable of the catabolism of components of cartilage extracellular matrix to promote cartilage regeneration within cartilage pathologies and to promote cartilage integration within focal defects.... Agent:

20110293557 - Conjugates for the administration of biologically active compounds: The invention relates to a conjugate that comprises an Apo A molecule or a functionally equivalent variant thereof and a compound of therapeutic interest wherein both components are covalently coupled as well as to the use of said conjugates in therapy for the specific targeting of said compounds to those... Agent: Proyecto De Biomedicina Cima, S.l.

20110293558 - Material properties of t cells and related methods and compositions: The invention in some aspects relates to methods, devices and compositions for evaluating material properties, such as mechanical and rheological properties of substances, particularly biological substances, such as cells, tissues, and biological fluids. In some aspects, the invention relates to methods, devices and compositions for evaluating material properties of deformable... Agent: Massachusetts Institute Of Technology

20110293560 - Method for determining immune system activity and medicament for influencing same: A method for the determination of the state of the immune system, e.g. the state of activity and activation, respectively, of the immune system, using the determination of presence of a blood or peripheral mononuclear cell or plasma marker. The marker can be determined directly, e.g. by determination of its... Agent: Medizinische Hochschule Hannover

20110293562 - Use of cardiotrophin-1 for the treatment of metabolic diseases: The invention is related to the use of cardiotrophin-1 (CT-1) for the treatment of obesity and associated disorders: hyperglycaemias, insulin resistance, development of type 2 diabetes and dyslipemias and given its anorexigenic role, fat oxidation stimulant, hypoglycaemic, sensitizing agent of the action of insulin on a skeletal muscle level and... Agent: Proyecto De Biomedicina Cima, S.l.

20110293563 - 1'substituted carba-nucleoside analogs for antiviral treatment: Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.... Agent: Gilead Sciences, Inc.

20110293564 - 2-morpholino-pyrido[3,2-d]pyrimidines: This invention relates to compounds of Formula (I) as Pi3k inhibitors for treating autoimmune diseases, inflammatory disorders, multiple sclerosis and other deseases like cancers.... Agent: Merck Serono S.a.

20110293565 - Novel synthetic agonists of tlr9: The invention relates to synthetic chemical compositions that are useful for modulation of Toll-Like Receptor (TLR)-mediated immune responses. In particular, the invention relates to agonists of Toll-Like Receptor 9 (TLR9) that generate unique cytokine and chemokine profiles.... Agent: Idera Pharmaceuticals, Inc.

20110293566 - Diffocin and methods of use thereof: This disclosure relates to the discovery and isolation of the entire cluster of genes encoding R-type high molecular weight bacteriocins that specifically kill Clostridium difficile bacteria, dangerous human pathogens. Also disclosed are methods of producing the R-type bacteriocins in innocuous producer cells that, unlike C. difficile, do not die in... Agent: Avidbiotics Corp.

20110293567 - Use of bacteria for the sensing and killing of cancer cells: The present invention relates to the field of cancer therapy. Specifically, a chemotaxis fusion-receptor that directs bacteria towards tumors is disclosed. Further encompassed by the present invention is a bacterial cell that comprises at least one chemotaxis fusion-receptor and, preferably, a killing module for the destruction of tumor cells.... Agent: Dkfz Deutches Krebsforschungszentrum Stiftung Des &#xd6 Ffentlichen Rechts

20110293585 - Compositions and methods for treatment of lysosomal storage disorders: Compositions and methods for treating lysosomal storage diseases are disclosed. Lysosomal dysfunction is usually the result of deficiency of a single enzyme necessary for the metabolism of lipids, glycoproteins (sugar containing proteins) or mucopolysaccharides which are fated for breakdown or recycling. The compositions contain triplex-forming molecules which can be used... Agent: Helix Therapeutics, Inc.

20110293586 - Glucagon analogues: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metablic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the... Agent: Zealand Pharma A/s

20110293587 - Glucagon analogues: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the... Agent: Zealand Pharma A/s

20110293568 - Lactobacillus helveticus cncm i-4095 and weight control: The present invention generally relates to the field of obesity. In particular the present invention relates to the use of probiotics to support weight management and to treat or prevent obesity. One embodiment of the present invention relates to the use of Lactobacillus helveticus CNCM I-4095 for the preparation of... Agent: Nestec S.a.

20110293569 - Lactobacillus rhamnosus cncm i-4096 and weight control: The present invention generally relates to the field of obesity. In particular the present invention relates to the use of probiotics to support weight management and to treat or prevent obesity. One embodiment of the present invention relates to the use of Lactobacillus rhamnosus CNCM I-4096 for the preparation of... Agent: Nestec S.a.

20110293570 - Isolation of novel bacteria contributing to soilborne disease suppression: Embodiments relate to plant disease suppressive microorganisms and compositions including the same, methods for isolating disease suppressive microorganisms, and methods for controlling plant diseases using disclosed compositions and microorganisms.... Agent: The Ohio State University Research Foundation

20110293571 - Method for vector delivery: Provided is a lentiviral vector for delivery to the brain for use in treating a neurological condition, wherein the lentiviral vector is delivered directly to the brain by delivering the lentiviral vector via six or fewer tracts per hemisphere, at a single deposit point per tract.... Agent: Oxford Biomedica (uk) Ltd.

20110293579 - Bi-specific fusion proteins: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and... Agent: Merrimack Pharmaceuticals, Inc.

20110293581 - Bone-regenerating composition containing angiogenin: The present invention relates to a bone-regenerating composition containing angiogenin and to a bone-generating scaffold comprising the composition. Angiogenin has a superior ability to induce initial angiogenesis and bone regeneration as compared to the platelet rich plasma (PRP) which is used as a conventional element for stimulating bone regeneration, thus... Agent:

20110293580 - Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues: Methods for obtaining pluripotent (embryonic stem) cells from parthenogenetic embryos, especially primates, are provided. These cells are useful for producing differentiated cells, tissues and organs, especially human and non-human primate cells, tissues and organs.... Agent: Advanced Cell Technology, Inc.

20110293574 - Hematopoietic stem cell growth factor: The present invention relates, in general, to stem cells and, in particular, to a hematopoietic stem cell (HSC) growth factor and to methods of using same.... Agent:

20110293572 - Increasing the plasticity of stem cells: The invention relates to methods of culturing non-embryonic cells to increase their plasticity and their potential to differentiate into multi-lineage cell types.... Agent:

20110293576 - Mesenchymal stromal cell populations and methods of isolating and using same: The invention relates to mesenchymal stromal cells produced by culturing the cells in platelet lysate supplemented media and methods of using these cells to treat neurological and kidney associated disorders.... Agent: Allocure Inc.

20110293573 - Method and apparatus for culturing tissue: A method for culturing microtissue is provided. The method includes steps of: (a) forming a pattern microarray on a hydrophobic film; (b) adhering the hydrophobic film to a carrier; (c) disposing a plurality of cells on the hydrophobic film for culturing depending on the pattern microarray, and forming a plurality... Agent: National Taiwan University

20110293583 - Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy: Methods for treating a subject suffering from a compromised endogenous hematopoietic system are described that comprise administering to the subject a therapeutically effective amount of adherent stromal cells. Methods of preparing adherent stromal cells and pharmaceutical compositions comprising the cells are also described.... Agent: Pluristem Ltd.

20110293582 - Methods for enhancing hematopoietic stem/progenitor cell engraftment: Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using farnesyl compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to... Agent: Children's Medical Center Corporation

20110293575 - Photochemical internalisation of kinase inhibitors: The present invention relates to a method for enhancing the activity of kinase inhibitors in target cells, and more specifically for enhancing the activity of tyrosine kinase inhibitors (TKIs), said method comprising contacting a cell with a kinase inhibitor and a photosensitizing agent and irradiating said cell with light of... Agent: PCi Biotech As

20110293577 - Therapeutic methods using adipose tissue-derived cell suspensions comprising adipocytes: Provided herein is a use of an adipose tissue-derived cell suspension which comprises adipocytes for the preparation of a pharmaceutical composition for use in the treatment of an inflammatory disorder, a cartilage or bone disorder and/or the alleviation of pain associated with an inflammatory disorder in a mammalian subject. Also... Agent: Regeneus Pty Ltd.

20110293584 - Tissue regeneration: The present invention relates to a method of treating a tissue defect in a human or animal body comprising the steps of implanting into said body an unseeded scaffold; allowing or effecting a wound healing response at the site of said defect; allowing said scaffold to be vascularized until a... Agent: Progentix B.v.

20110293578 - Use of stem cells to prevent neuronal dieback: The invention is generally directed to treatment of neuronal injury. In particular, the invention is directed to reducing axonal retraction (“dieback”) that occurs as a result of the interaction of activated macrophages with dystrophic axons that are produced during nervous system acute or chronic injury. The invention is also directed... Agent: Abt Holding Company

20110293588 - Metabolic uncoupling therapy: A combination of chemical agents reduces reductive stress by limiting the accumulation of high-energy electrons potentially available to the electron transport chain. A method of metabolic uncoupling therapy comprises: analyzing a specific physiologic process involving reductive stress; identifying a plurality of MUT agents that modulate metabolic pathways by influencing electron... Agent:

20110293589 - Method of treating vitamin b12 deficiency: A novel method and composition for treating vitamin B12 deficiency mammals that fail to respond to oral vitamin B12 therapy.... Agent: Emisphere Technologies, Inc.

20110293591 - Composition: The present invention provides a composition, and a process for preparing and method for using such a composition. The composition comprises (i) a surface coating material; and (ii) (ii) a cross-linked enzyme crystal or cross-linked enzyme aggregate wherein the enzyme is cross-linked with a multifunctional cross-linking agent and wherein the... Agent:

20110293590 - Pharmaceutical preparation: The pharmaceutical preparation for the treatment of pancreatic insufficiency comprises a liquid administering form of enzymes.... Agent:

20110293592 - Method of treating coronary arteries with perivascular delivery of therapeutic agents: A method of treating the intraluminal disease in a coronary artery by injecting therapeutic agents perivascularly into the myocardium near the site of disease.... Agent: Biocardia, Inc.

20110293593 - Siva 2 stabilization: The present invention relates to modulation of SIVA2 stability by N-acetylglucosamine, phosphorylation of ubiquitination in treatment or prevention of diseases, disorders or conditions.... Agent: Yeda Research And Development Co., Ltd.

20110293596 - Disease control with tick phospholipase a2: The present invention relates to reagents and methods for the modulation of viability of bacteria. A process is provided wherein a protein sequence from A. americanum saliva effective in reducing the viability of gram positive, gram negative, or acid-fast bacteria and spirochetes including B. burgdurferi is administered. The inventive protein... Agent: The Government Of The United States Of America As Represented By The Secretary Of The Department

20110293595 - Prophylactic and therapeutic treatment of alzheimer's disease, neuro-degenerative diseases, protein aggregation diseases, parkinson's disease and amyloid diseases, using phytic acid and phytate: A composition and method for the treatment of Alzheimer's Disease, and/or related protein aggregation diseases and/or amyloidoses and/or a neuro-degenerative disease, and/or Parkinson's Disease and/or Parkinsonism including an effective amount of a compound selected from the group consisting of phytic acid (inositol hexakisphosphate), a phytate salt, an isomer or hydrolysate... Agent:

20110293594 - Removal of serine proteases by treatment with finely divided silicon dioxide: The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized... Agent: Baxter International Inc.

20110293597 - Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders: The present invention relates to chimeric derivatives of serine protease zymogen containing the activation peptide of factor X or a fragment thereof for improving the half-life of said derivatives. Preferably, said chimeric derivatives are protein C and factor X derivatives. The invention also relates to said derivatives for the prevention... Agent:

20110293600 - Anticancer composition comprising antitumor agent and substance having inhibitory effects on l1cam activity and expression: The present invention relates to an anticancer composition comprising an antitumor agent as well as a substance having inhibitory effects on the activity or expression of L1CAM; more particularly, to an anticancer composition, which comprises an anti-L1CAM antibody specific to L1CAM, serving as a substance for inhibiting the activity of... Agent: Korea Research Institute Of Bioscience And Biotechnology

20110293599 - Method for modulating muscle differentiation or regeneration: Present invention relates to method for promoting or inhibiting muscle differentiation or regeneration using an enhancer or an inhibitor capable of modulating the binding of TAZ polypeptide with MyoD polypeptide; method for screening a substance capable of up- or down-regulating muscle differentiation or regeneration by use of interaction between TAZ... Agent: Ewha University - Industry Collaboration Foundation

20110293598 - Method to produce an immunoglobulin preparation with improved yield: The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In... Agent: Baxter International Inc.

20110293603 - Amino acid sequences directed against multitarget scavenger receptors and polypeptides: The present invention relates to amino acid sequences that are directed against (as defined herein) multitarget scavenger receptors such as e.g. Lox-1, RAGE, CD36, SR-A1, SR-B1, galectin-1, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such... Agent: Ablynx N.v.

20110293608 - Annexin a2 as immunological target: AnnexinA2 (ANXA2), a member of the Annexin family of calcium-dependent, phospholipid binding proteins, is one of a panel of identified antigens recognized by the post-vaccination sera of patients who demonstrated prolonged disease-free survival following multiple vaccinations. AnnexinA2 is abundantly expressed in pancreatic adenocarcinomas and cell surface/membrane AnnexinA2 increases with the... Agent: The Johns Hopkins Univeristy

20110293610 - Antibodies that immunospecifically bind to b lymphocyte stimulator protein: The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or... Agent: Human Genome Sciences, Inc.

20110293605 - Antibody formulation: Herein described are liquid formulations of antibodies and biologically active fragments thereof that specifically bind to a human ICOS polypeptide, exhibit increased in vivo ADCC activity and undergo reversible self-association in solution.... Agent:

20110293609 - Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.... Agent: Roche Glycart Ag

20110293607 - Antibody variants having modifications in the constant region: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.... Agent:

20110293606 - Antitumor combinations containing antibodies recognizing specifically cd38 and vincristine: Pharmaceutical composition comprising an antibody specifically recognizing CD38 and vincristine.... Agent: Sanofi-aventis

20110293601 - Composition and method for treatment of reperfusion injury and tissue damage: The present invention provides compounds and methods for the treatment and prophylaxis of ischemia reperfusion injury. In particular the invention provides compounds which function to suppress Toll-like Receptor 2 biological function or expression.... Agent: Opsona Therapeutics Ltd

20110293604 - Polynucleotides and polypeptide sequences involved in the process of bone remodeling: This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling; variants and derivatives of the polynucleotides and corresponding polypeptides; uses of the polynucleotides, polypeptides, variants and derivatives; and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders.... Agent: Alethia Biotherapeutics Inc.

20110293602 - Vegf-like factor antibodies and methods of use thereof: A novel human gene having a significant homology with a VEGF-C gene, a member of the VEGF family, has been isolated by the PCR method using primers designed based on the sequence of EST that is assumed to be homologous with the C-terminal region of the VEGF-C gene. Mouse and... Agent: Chugai Seiyaku Kabushiki Kaisha

20110293612 - Method for the treatment of neurodegenerative diseases: Disclosed are methods for treating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Alzheimer's Disease, Parkinson's Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Kennedy's Disease, and Spinocerebellar Ataxia, by administration of a compound that blocks the interaction of CD40 and CD40L.... Agent: Als Therapy Development Institute

20110293611 - Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade: Compositions and methods are provided for transplantation of pluripotent stem cells and differentiated cells derived therefrom.... Agent:

20110293613 - Bispecific antibodies: The present invention relates to bispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.... Agent:

20110293614 - Isoform specific anti-her4 antibodies: Compositions and methods useful for detecting and treating cancers which express the HER4 JM-a isoform are disclosed.... Agent:

20110293615 - Use of combination of anti-angiogenic substance and c-kit kinase inhibitor: The object of the present invention is to find a pharmaceutical composition and a method for treating cancer that show an excellent antitumor effect. Combinational use of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and analogues thereof can result in an excellent antitumor effect when combined with a substance having a c-kit kinase-inhibiting activity.... Agent: Eisai R&d Management Co., Ltd.

20110293618 - Anti-human clcp1 antibody and use thereof: The present invention provides novel antibodies that recognize the extracellular domain of a human CLCP1 antigen; nucleic acids encoding the antibodies; vectors carrying the nucleic acids in an expressible manner; transformed cells containing the vectors; methods for producing the antibodies; diagnostic methods for cancer or prognosis of cancer, immunohistological or... Agent: Oncomics Co., Ltd.

20110293617 - Anti-p-selectin antibodies and methods of their use and identification: Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which... Agent:

20110293623 - Antibodies as t cell receptor mimics, methods of production and uses thereof: The present invention relates to a methodology of producing antibodies that recognize peptides associated with a tumorigenic or disease state, wherein the peptides are displayed in the context of HLA molecules. These antibodies will mimic the specificity of a T cell receptor (TCR) but will have higher binding affinity such... Agent:

20110293622 - Antibodies to il-6 and use thereof: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding... Agent:

20110293616 - Antigen-presenting complex-binding compositions and uses thereof: A composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen is disclosed.... Agent: Technion Research & Development Foundation Ltd.

20110293619 - Cross-species-specific psmaxcd3 bispecific single chain antibody: The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2,... Agent: Micromet Ag

20110293624 - Genes of an otitis media isolate of nontypeable haemophilus influenzae: The invention relates to the polynucleotide sequence of a nontypeable stain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and/or the nasopharynx.... Agent: Nationwide Children's Hospital, Inc.

20110293621 - Immunogenic polypeptides comprising a scaffold polypeptide and a l2 polypeptide or a fragment thereof: The present invention relates to an immunogenic polypeptide comprising a) a scaffold polypeptide, and b) a L2 polypeptide or a fragment of said L2 polypeptide, wherein said scaffold polypeptide constrains the structure of said L2 polypeptide, or of a fragment of said L2 polypeptide. Moreover, the present invention relates to... Agent: Dkfz Deutsches Krebsforschungszentrum

20110293620 - Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease: The specification describes the sequences for antibodies that recognize the HLA-A2-restricted peptide PR-I in the context of HLA presentation on the surface of cancer cells. Use of these antibodies in the diagnosis and treatment of cancer and immune-related diseases are also provided.... Agent:

20110293625 - Inhibition of vegf-a secretion, angiogenesis and/or neoangiogenesis by sina mediated knockdown of vegf-c and rhoa: The invention relates to the use of short interfering nucleic acid molecules (siNAs, such as siRNAs) that modulate the expression of VEGF-C and/or RhoA involved in neovascular angiogenesis. In the present invention, inhibition of VEGF-C and/or RhoA gene expression lead to decreased expression of VEGF-A, which is required for initiation... Agent:

20110293627 - Combination therapy to enhance nk cell mediated cytotoxicity: The function of natural killer (NK) cells is regulated by inhibitory and activating signals delivered by cell surface receptors, 1-7F9 is a fully human monoclonal antibody (mAb) directed against KIR2DL1 and KIR2DL2/3 receptors that block its interaction with its HLA-C ligands breaking NK cell tolerance to autologous tumor cells. Lenalidomide... Agent: Novo Nordisk

20110293626 - Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof: The present invention provides compositions and methods based on genetic polymorphisms that are associated with autoimmune disease, particularly rheumatoid arthritis. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and... Agent: Celera Corporation

20110293630 - Antibodies to human gdf8: The present invention provides isolated human or humanized antibodies or antigen-binding fragments thereof which specifically bind to Growth and Differentiation Factor-8 (GDF8) and block GDF8 activity. The antibodies and antibody fragments of the present invention may be used in therapeutic methods for treating conditions or disorders which are ameliorated or... Agent: Regeneron Pharmaceuticals, Inc.

20110293631 - Mast cell markers and prevention, diagnosis, and therapy for chronic pelvic pain syndrome: The present invention provides compositions and methods for detection, diagnosis, treatment and/or prevention of chronic pelvic pain syndrome. In particular, the present invention provides biomarkers of chronic pelvic pain syndrome (e.g., mast cell markers (e.g., tryptase)), and/or inhibition of mast cell function (e g inhibition of MCP-1 and/or MIP-1α) to... Agent: Northwestern University

20110293629 - Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists: The invention relates generally to methods of treating and/or preventing proliferative diseases, such as cancers, using antagonists of IL-17. The invention also relates to methods and kits for identifying subjects who are likely to respond to treatment and/or prevention of proliferative diseases with antagonists of IL-17.... Agent:

20110293628 - Pain treatment using erk2 inhibitors: This application describes methods and compositions for reducing, inhibiting and/or treating pain that involve use of ERK2 inhibitors.... Agent: Cornell University

20110293634 - Antibodies binding to adrenomedullin receptors and uses thereof as drugs: The invention relates to antibodies binding to the proteins forming adrenomedullin receptors, and to the uses thereof as a drug.... Agent: Universite De La Mediterranee (aix-marseille Ii)

20110293635 - Composition and methods for modulating toll-like receptor activity: The present invention relates to compositions and methods for use in the treatment of conditions such as septicaemia and septic shock. The invention further provides compositions and methods for the suppression of Toll-like Receptor 14 interaction with CD14 during Toll-like Receptor mediated signalling. The invention further provides screening assays to... Agent:

20110293636 - Method for prongf assay for in vitro diagnosis of cancer in particular breast, thyroid or lung cancer and therapeutic use of prongf: A ProNGF inhibitor for preparing a drug, said drug being in particular useful for blocking remote dissemination and cell invasion in patients suffering from cancer, in particular breast, thyroid or lung cancer.... Agent: Biomerieux

20110293632 - Polypeptide variants with altered effector function: The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.... Agent: Genentech, Inc.

20110293633 - Preparation useful for, and method for treatment of neonatal alloimmune thrombocytopenic purpura (nait): A preparation useful for, and a method for the prophylactic treatment of women post-childbirth in order to avoid immunization and antibody production, which could induce NAIT and fetal/neonatal bleeding in subsequent pregnancies comprising administering a preparation containing antibodies to HPA 1a within 72 hours after delivery in the first non-compatible... Agent: Tto Nord As

20110293637 - Compositions and methods of identifying tumor specific neoantigens: The present invention related to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. Specifically, the invention provides a method of identifying tumor specific neoantigens that alone or in combination with other tumor-associated peptides serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor responses.... Agent: Dana-farber Cancer Institute, Inc.

20110293638 - Method to produce an immunoglobulin preparation with improved yield: The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In... Agent: Baxter International Inc.

20110293639 - Ideotypically modulated pharmacoeffectors for selective cell treatment: In a method embodiment, a method includes introducing a plurality of Ideotypically Modulated Pharmacoeffectors (IMP) into a population of cells. Each IMP may include a detection domain and an activation domain. One or more epitopes is bound by the detection domain. The activation domain is activated in response to the... Agent:

20110293641 - A vaccinia virus protein a46 peptide and use thereof: A peptide for inhibiting Toll-like receptor 4 (TLR4) signalling comprising the amino acid sequence of SEQ ID NO. 4, SEQ ID NO 55, SEQ ID NO 68, SEQ ID NO. 69, SEQ ID NO 70, SEQ ID NO 71, SEQ ID NO 72, SEQ ID NO 79, SEQ ID NO... Agent:

20110293640 - Cholinesterase inhibitors for treating inflammation: A method of treating a subject with a cytokine-mediated inflammatory disorder comprising administering to the subject an effective amount of a pharmaceutically acceptable cholinesterase inhibitor, provided that the inhibitor is not galantamine.... Agent: The Feinstein Institute For Medical Research

20110293643 - Compounds and methods for inhibiting mmp2 and mmp9: The present invention relates to specific inhibitors of MMP2 and MMP9 and their use in immunosuppression.... Agent:

20110293642 - Modulation of splenocytes in cell therapy: The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that have one or more of the following effects in an injured subject: interact with splenocytes, preserve splenic mass, increase proliferation of CD4+ and CD8+... Agent: Abt Holding Company

20110293644 - Compositions and methods for treatment of celiac disease: The invention provides agents and vaccines for treating and diagnosing celiac disease. In particular, the present invention provides a combination of three peptides that are useful for treating and diagnosing celiac disease in a large proportion of patients.... Agent: Immusant, Inc.

20110293647 - Immunogenic lhrh compositions and methods relating thereto: The present invention relates generally to an immunogenic LHRH composition and more particularly to an immunogenic LHRH composition comprising a LHRH C-terminal fragment of at least five amino acids. The present invention is useful, inter alia, as a prophylactic and/or therapeutic agent for the modification of fertility and behaviour patterns... Agent: Pfizer Inc.

20110293646 - Pan-dr binding polypeptides and uses thereof: The present invention provides novel artificial oligopeptides capable of binding HLA Class II molecules encoded by several alleles. The oligopeptides include the sequence AX1FVAAX2TLX3AX4A (SEQ ID NO:1), wherein X1 is selected from the group consisting of W, F, Y, H, D, E, N, Q, I and K; X2 is selected... Agent: Epimmune Inc.

20110293648 - Ssx-2 peptides presented by hla class ii molecules: The invention describes HLA class II binding peptides encoded by the SSX-2 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating to the peptides. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating... Agent: Ludwig Institute For Cancer Research Ltd.

20110293645 - Wdrpuh epitope peptides and vaccines containing the same: The present invention provides peptides containing the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino... Agent: Oncotherapy Science, Inc.

20110293651 - Hpv e6 protein t cell epitopes and uses thereof: The present invention is directed to the examination of the pattern of immunodominant T cell epitopes in the E6 protein of Human Papilloma virus and its further characterization in terms of its amino acid sequence and Human Leukocyte Antigen restriction. These epitopes are identified based on their ability to induce... Agent:

20110293649 - In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles: The invention relates to the finding that stimulation of antigen presenting cell (APC) activation using substances such as anti-CD40 antibodies or DNA oligomers rich in non-methylated C and G (CpGs) can dramatically enhance the specific T cell response obtained after vaccination with recombinant virus like particles (VLPs) coupled, fused or... Agent: Cytos Biotechnology Ag

20110293650 - Influenza virus-like particles (vlps) comprising hemagglutinin: A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA of type A/California/04/09 in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP comprising influenza HA protein... Agent: Medicago Inc.

20110293652 - Chimeric ospa genes, proteins, and methods of use thereof: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides.... Agent: Baxter International Inc.

20110293653 - Antagonists of mir-155 for the treatment of inflammatory liver disease: Provided herein are methods of treating or preventing an inflammatory liver disease in a subject, such as alcoholic liver disease (ALD), by administering to said subject an miR-155 antagonist.... Agent: University Of Massachusetts

20110293654 - Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds: Substituted fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—R1)— group in the fused ring at the 1-position of the imidazo ring, wherein R1 includes a functional group, for example, an amide, sulfonamide, urea, carbamate, ester, ketone, ether, a thio analog of the forgoing, sulfone, oxime,... Agent: 3m Innovative Properties Comany

20110293655 - Porcine adenovirus 3-based prrsv vaccines: The invention relates to a porcine adenovirus 3 based vaccine for the treatment of PRRS virus infection where the PADV3 is a recombinant replication competent PADV3 that comprises a nucleic acid that encodes a novel fusion protein of PRRSV ORF6 and a modified PRRSV ORF5 either alone or in combination... Agent: Imugene Ltd.

20110293656 - Recombinant mva capable of expressing structural hcv antigens: The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form of a vaccine and containing the recombinant MVA according to the invention,... Agent:

20110293657 - Encapsulated vaccines for the oral vaccination and boostering of fish and other animals: The invention relates to a composition comprising a pharmaceutically active agent and a bioadhesive delivery system that provides for the oral delivery of a vaccine to animals, particularly aquatic animals.... Agent:

20110293659 - Method for the oral/mucosal vaccination by means of recombinant yeasts: Recombinant yeast cells are produced which are used for vaccination, among other uses for the oral vaccination by feeding.... Agent:

20110293660 - Novel method: The present invention relates to a method for purifying a virus, or a viral antigen thereof, comprising at least the following steps: a) obtaining a fluid comprising the virus, or a viral antigen thereof, and b) purifying the fluid by at least one density gradient ultracentrifugation step, wherein the ratio... Agent:

20110293658 - Use of inkt or tlr agonists for protecting against or treating a disease such as acute infection or cancer: A method of protecting a mammalian subject against, or treating, a disease, wherein the mammalian subject has elevated numbers and/or activities of MDSC comprising administering to the subject a pharmaceutically acceptable amount of an iNKT agonist, such as alpha galactosylceramide or an analogue thereof, or a TLR agonist, or a... Agent: Ludwig Institute For Cancer Research Ltd.

20110293661 - Vaccine strains of brachyspira hyodysenteriae: The present invention relates generally to vaccine strains of Brachyspira hyodysenteriae. In particular, the present invention relates to isolated live vaccine strains of B. hyodysenteriae lacking one or more virulence factors. The present invention also relates to methods of identifying and preparing vaccine strains, as well as vaccine compositions against... Agent: Boehringer Ingelheim Vetmedica Gmbh

20110293662 - Compositions comprising reduced genome bacteria for use in treatment of sepsis: Methods for prophylaxis or treatment of sepsis in a subject are provided comprising administering to the subject a therapeutically effective dose of multiple deletion strain bacteria.... Agent: Scarab Genomics LLC

20110293663 - Pharmaceutical botulinum toxin compositions: Botulinum toxin, a well know systemic poison, produces favorable therapeutic effect by virtue of regionally attaching to nerves within the myoneural junction and possibly other tissues in a target region of a particular tissue. The present invention provides compositions of botulinum toxin and a sequestration agent that increase sequestration and... Agent:

20110293664 - Chlamydia antigens and uses thereof: Disclosed are novel chlamydia antigens, nucleic acids encoding the antigens, and immunogenic compositions including the antigens. Methods of using the antigens to elicit immune responses (e.g., T cell-mediated and/or B cell-mediated immune responses) comprising administering an immunogenic composition including one or more of the novel antigens may be used for... Agent: Genocea Biosciences, Inc.

20110293665 - Recombinant der p 2 expressed in pichia pastoris as a \"natural-like\" allergen for immunotherapy and diagnostic purposes: The present invention concerns a method for producing a recombinant Dermatophagoides pteronyssinus 2 protein (rDer p 2), comprising the steps of cultivating a Pichia pastoris yeast strain previously transformed with a rDer p 2 coding sequence, and isolating the rDer p 2 protein from said Pichia pastoris yeast strain. The... Agent:

20110293670 - Adhesive material containing 5-methyl-1-phenyl-2-(1h)-pyridone: There is provided an adhesive preparation containing 5-methyl-1-phenyl-2-(1H)-pyridone. The adhesive preparation is a 5-methyl-1-phenyl-2-(1H)-pyridone-containing adhesive preparation including an active medicinal ingredient-containing layer, characterized in that the active medicinal ingredient-containing layer contains an lipophilic base, a dissolving agent (except glycerin and a medium-chain aliphatic acid triglyceride), and 5-methyl-1-phenyl-2-(1H)-pyridone or medically acceptable... Agent: Lead Chemical Co., Ltd.

20110293671 - Bacteriophage compositions for treatment of bacterial infections: A respirable composition for treatment of a bacterial infection includes one or more active bacteriophages in combination with a pharmaceutically acceptable respirable carrier. The composition includes a carbohydrate carrier, and is prepared as fine powder. In another aspect, bacteriophages are provided in a liquid carrier for administration by nebulization. In... Agent:

20110293667 - Bioengineered tissue constructs and methods for producing and using thereof: Bioengineered constructs are formed from cultured cells induced to synthesize and secrete endogenously produced extracellular matrix components without the requirement of exogenous matrix components or network support or scaffold members. The bioengineered constructs of the invention can be produced with multiple cell types that can all contribute to producing the... Agent:

20110293666 - Bioengineered tissue constructs and methods for production and use: Bioengineered constructs are formed from cultured cells induced to synthesize and secrete endogenously produced extracellular matrix components, e.g., without the requirement of exogenous matrix components or network support or scaffold members. The bioengineered constructs of the invention can be treated in various ways such that the cells of the bioengineered... Agent:

20110293675 - Coatings of acrylamide-based copolymers: An implantable device including conjugate formed of an acrylamide-based copolymer and a bioactive agent is provided.... Agent: Advanced Cardiovascular Systems, Inc.

20110293669 - Hydrogel implants with varying degrees of crosslinking: The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with... Agent:

20110293674 - Micro-rnas that modulate smooth muscle proliferation and differentiation: The present invention relates to the identification of microRNAs that regulate smooth muscle cell proliferation and differentiation, including the miR-143/miR-145 cluster. Methods of treating restenosis and neointima formation by increasing expression of miR-143 and/or miR-145 are disclosed. The present invention also relates to the identification of two microRNAs, miR-486 and... Agent: Board Of Regents, The University Of Texas System

20110293676 - Oral cephalotaxine dosage forms: The present disclosure provides oral dosage forms comprising a cephalotaxine and a pharmaceutically acceptable carrier selected from protein, carbohydrate and lipid, an oral dosage form comprising cephalotaxine and a second active agent, as well as methods of treating subjects with such oral formulations.... Agent: Chemgenex Pharmaceuticals, Inc.

20110293673 - Oral film-form base and oral film-form preparation: The present invention provides a film-form base having one or more sugars or sugar alcohols dispersed as fine particles therein, and also provides a film-form preparation containing the base and a drug. The base is produced by dispersing, in an organic solvent having a solubility parameter of 9.7 or higher,... Agent: Nitto Denko Corporation

20110293668 - Oral odor control method and product: A product and method for controlling mouth odor and bad breath using an oral care product containing an odor neutralizer. The product for use in oral care or for use in the mouth to control mouth odors includes an odor neutralizer compound. In a preferred method of manufacture, the O.M.... Agent:

20110293672 - Pancreatic tumour treatment: There is provided a composition comprising microspheres which comprise a water-insoluble, water-swellable polymer and associated with the polymer, in releasable form, a chemotherapeutic agent, for use in the treatment of a pancreatic tumour or cyst, wherein the microspheres, when equilibrated in water at 37° C., comprise at least 40 wt... Agent: Biocompatibles Uk Limited

20110293680 - Composition of a temporary hair thickener: The present invention relates to a composition of a temporary hair thickener. In particular, the present invention relates to a composition of a temporary hair thickener comprising bamboo charcoal powder, a hydrophobic waterproof coating agent, a low grade alcohol and a propellant in a specific amount. The composition of a... Agent: Dong Sung Pharm. Co., Ltd.

20110293677 - Fabric and fibre conditioning additives: A fabric, fibre, hair or skin conditioning additive for use in a liquid cleaning product is encapsulated within a shell comprising a silicon-containing polymer network.... Agent:

20110293679 - Method for coating microspheres onto a flexible material: The invention relates to a method for coating polymer microspheres laden with one or more active substances onto a flexible material without melting, comprising the following steps: a) selecting a porous crosslinked polymer; b) incorporating a liquid lipophilic composition at room temperature and containing at least one active substance into... Agent:

20110293678 - Micellarly integrated oxidation protection for natural dyes: In order to formulate natural dyes, which are insoluble or sparingly soluble in water, in such a way that the dye is protected against oxidation, also and in particular after being incorporated into the end product with dilution, and which as a replacement for azo dyes in a beverage result... Agent: Aquanova Ag

20110293681 - Hand sanitizing patch having an integrally bonded antimicrobial: The present invention provides for topical adhesive patch that includes a backing having a front side and a back side; a formulation in contact with the front side of the backing, the formulation including an adhesive; and at least one antimicrobial. The antimicrobial is integrally bonded to the back side... Agent: Lectec Corporation

20110293682 - Self-triggered microencapsulated biocides and/or fungicides: One embodiment includes a biocide-containing and/or fungicide-containing microcapsule wherein the microcapsule may be capable of degradation due to the presence of byproducts that are released by a fungi or biological organism. Upon release, the biocide and/or fungicide may then be utilized to eliminate the fungi or biological organism.... Agent: Gm Global Technology Operations, Inc.

20110293683 - Silver antimicrobial composition with extended shelf-life: A method for extending the shelf-life of an aqueous dispersion comprising silver halide particles and gelatin, comprises adding adenine to the aqueous dispersion in an amount effective to improve the redispersibility and the colloidal stability thereafter of the aqueous dispersion following extended storage. The extended storage time consisted of 5... Agent: Cerion Technology, Inc.

20110293685 - Scaffolds for tissue engineering and regenerative medicine: The methods and compositions described herein relate to novel 3-dimensional porous scaffolds useful for tissue re-generation, enhancement, or tissue repair. Electrospinning or other methods are used to create mats comprised of fibers that can be seeded with cells and subsequently rolled into a desired shape/form to replace a desired tissue.... Agent: Trustees Of Tufts College

20110293684 - Surface-coated structures and methods: The present invention relates to a methods and composition in which a D-form or retro-inverso Pseudomonas pilin peptide is bound to a substrate. The disclosed methods and composition are useful for inhibiting biofilm formation by non-Pseudomonas bacteria, for reducing the inflammatory response to a material, for reducing corrosion of metals,... Agent: Arch Biophysics, Inc.

20110293686 - Anti-viral compositions and methods for administration: Certain embodiments disclosed relate to compositions, including therapeutic compositions, methods, articles of manufacture, systems, and devices. Certain embodiments relate to anti-viral compositions, methods, articles of manufacture, systems and devices.... Agent: Searete LLC, A Limited Liability Corporation Of The State Of Delaware

20110293687 - Hydrogel implants with varying degrees of crosslinking: The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with... Agent:

20110293688 - Hydrogel implants with varying degrees of crosslinking: The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with... Agent:

20110293689 - Immobilized biologically active entities having a high degree of biological activity: The present invention relates to immobilized biologically active entities having heparin cofactor II binding activity.... Agent:

20110293690 - Biodegradable polymer encapsulated microsphere particulate film and method of making thereof: Films containing microsphere particles and processes for forming thereof are disclosed. The microsphere particles encapsulate one or more bioactive agents and may be deposited on a surface of medical devices or be used to form a medical device.... Agent: Tyco Healthcare Group Lp

20110293691 - Multimodal adhesion barrier: Provided herein are multimodal barrier materials useful for preventing adhesions in a subject, which may include a collagen, a collagen deposition inhibitor and/or a chitosan.... Agent:

20110293692 - Hydrogel implants with varying degrees of crosslinking: The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with... Agent:

20110293703 - Aminoalcohol lipidoids and uses thereof: Aminoalcohol lipidoids are prepared by reacting an amine with an epoxide-terminated compound are described. Methods of preparing aminoalcohol lipidoids from commercially available starting materials are also provided. Aminoalcohol lipidoids may be prepared from racemic or stereochemically pure epoxides. Aminoalcohol lipidoids or salts forms thereof are preferably biodegradable and biocompatible and... Agent: Massachusetts Institute Of Technology

20110293695 - Amphoteric liposomes: Amphoteric liposomes are proposed, which comprise positive and negative membrane-based or membrane-forming charge carriers as well as the use of these liposomes.... Agent: Novosom Ag

20110293696 - Compositions and methods for treating bruises: A composition for the treatment of bruising is disclosed. The composition can include an antioxidant, one or more citrus flavanoids, as active agents along with a pharmaceutically acceptable excipient or filler. The compositions are nutriceutical formulations having the capacity to reduce the number of bruises that occur over time and... Agent:

20110293702 - Compounds and methods for the treatment of inflammatory diseases of the cns: Inflammatory diseases in the CNS can be treated or alleviated by the administration of an oligonucleotide in an amount sufficient to reduce the influx of mononuclear cells to the central nervous system by down-regulating the expression of at least one cell surface marker. For example multiple sclerosis can be treated... Agent:

20110293697 - Hiv-1 immunogenic compositions: The present invention encompasses vaccine and/or immunogenic compositions against HIV and their methods of use for the prevention and/or treatment of HIV infection and/or AIDS. The vaccine and/or immunogenic compositions may contain an isolated HIV protein or fragment thereof, an adjuvant comprising a Toll like receptor (TLR) 4 ligand, in... Agent:

20110293699 - Hydrogel implants with varying degrees of crosslinking: The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with... Agent:

20110293705 - Methods and compositions for localized agent delivery: The invention provides compositions and methods for delivering agents to localized regions, tissues, or organs in vivo by conjugating agent-loaded nanoparticles to cells having homing capability. The agents may be therapeutic or diagnostic agents such as cancer chemotherapeutic agents and imaging agents respectively.... Agent: Massachusetts Institute Of Technology

20110293701 - Multivalent synthetic nanocarrier vaccines: The invention relates, at least in part, to compositions comprising populations of synthetic nanocarriers that comprise different sets of antigens as well as related methods.... Agent: Selecta Biosciences, Inc.

20110293700 - Nanocarrier compositions with uncoupled adjuvant: Disclosed are synthetic nanocarrier compositions with separate adjuvant compositions as well as related methods.... Agent: Selecta Biosciences, Inc.

20110293706 - Nanoshells on polymers: Nano-constructscomprising nanoshells and methods of using the nano-constructs for treating or ameliorating a medical condition are provided.... Agent:

20110293709 - Peptide tyrosinase inhibitors and uses thereof: Disclosed are peptides which inhibit the enzymatic activity of tyrosinase as well as formulations and methods for their use in the reduction of skin pigmentation, and methods of administering the inhibitory peptides in a topical formulation. Methods of skin treatment are also provided, the methods further including use of a... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20110293704 - Priming of an immune response: The present invention relates to a technology and method of priming of an immune response using invariant chain linked antigen, when these are used to prime a subsequent booster immunization using any suitable vacci.... Agent: University Of Copenhagen

20110293708 - Process for preparing purified nucleic acid and the use thereof: The invention relates to a nucleic acid preparation with a content of below 1% protein, preferably below 0.1% protein, free of ethidium bromide, phenol, cesium chloride and detergents based on octyl phenol poly(ethylene glycol ether)n and with a content of below 1 EU/mg DNA of endotoxins. Said preparation is suitable... Agent: Roche Diagnostics Gmbh

20110293693 - Quantum unit of inheritance vector therapy: The innovative treatment strategy described here utilizes configurable microscopic medical payload delivery devices to act as a transport vector to deliver quantum genes to specific type of cells in the body. Utilizing probes on the exterior of the transport device, transport device locate specific target cell types in the body.... Agent:

20110293694 - Quantum unit of inheritance vector therapy method: The innovative treatment method described here utilizes configurable microscopic medical payload delivery devices to act as a transport vector to deliver quantum genes to specific type of cells in the body. Utilizing probes on the exterior of the transport device, transport device locate specific target cell types in the body.... Agent:

20110293698 - Reagents and methods for treating cancer: This invention describes a genetic system for targeting the EVI1 gene in mammalian cells. The EVI1 gene is an oncogenic transcription factor that, when expressed, accelerates cell division and inhibits death of cells. Nucleotide sequences that block the expression of EVI1 and drug delivery systems for them are described. These... Agent: Nanooncology, Inc.

20110293707 - Use of the cathelicidin ll-37 and derivatives thereof for wound healing: Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by... Agent:

20110293712 - Coaxially encapsulated cell suspensions and microtissues: The present invention provides for the coaxial encapsulation of a plurality of cells in a single elongated compartment. By this encapsulation, the cells are protected by at least one layer of separation material and kept in close contact, which leads to a better vitality of the encapsulated cells and consequently... Agent: Koninklijke Philips Electronics N.v.

20110293710 - Immunomodulatory properties of lactobacillus strains: A specific method is provided of improving immunomodulatory properties of Lactobacillus strains using growth media with a specific primary carbon source, including a method of increasing the anti-inflammatory effect of non-pathogenic anti-inflammatory bacterial strains, by the use of specific growth conditions.... Agent:

20110293713 - Pharmaceutical formulations comprising nsaid and proton pump inhibitor drugs: Aspects of the present application relate to pharmaceutical formulations comprising a nonsteroidal anti-inflammatory drug, together with a proton pump inhibitor drug, to reduce the incidence of gastrointestinal complications associated with chronic therapy with a nonsteroidal anti-inflammatory drug. Specific aspects of the application relate to fixed dose combinations comprising aspirin, or... Agent:

20110293711 - Utilization of dialkylfumarates: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in... Agent: Biogen Idec International Gmbh

20110293714 - Pharmaceutical compositions suitable for oral administration of derivatized insulin peptides: The invention is related to a water-free liquid or semisolid pharmaceutical composition comprising a derivatized insulin peptide, at least one polar organic solvent and at least one lipophilic component and a method of treatment using such.... Agent: Novo Nordisk A/s

20110293717 - Compacted moxifloxacin: The invention relates to a process for the preparation of tablets containing moxifloxacin, comprising the steps of (i) providing moxifloxacin, pharmaceutically acceptable salts, solvates or hydrates thereof, optionally mixed with one or more pharmaceutical excipients; (ii) compacting it into a slug; (iii) granulating the slug; and (iv) compressing the resulting... Agent: Ratiopharm Gmbh

20110293715 - Pharmaceutical formulation and process for its preparation: The present invention relates to a multiparticulate tablet with improved gastro-protection comprising at least a pharmaceutically active substance in the form of enteric coated particles, and a mixture of tableting excipients, wherein the said mixture of excipients comprising xylitol and/or maltitol, each in a directly compressible form, a disintegrating agent,... Agent:

20110293716 - Pharmaceutical formulation containing ibuprofen and codeine: The invention consists of a new formulation of ibuprofen and codeine in the form of a tablet, which comprises L-leucine in a concentration ranging between 4%-15% as a lubricant, in order to prevent the formulation mixture from adhering to the punches and to other elements of the compression machine during... Agent: Farmasierra Manufacturing, S.l.

20110293718 - Compositions of r(+) and s(-) pramipexole and methods of using the same: Compositions of predetermined amounts of R(+) pramipexole and S(−) pramipexole and methods of using the same, including for the treatment and prevention of Parkinson's disease, are provided.... Agent: Knopp Neurosciences, Inc.

20110293719 - Novel compounds and compositions and methods of use: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.... Agent: Ardea Biosciences, Inc.

20110293720 - Progestin-containing drug delivery system: The present invention relates to drug delivery compositions in the form of thin water-soluble films (wafers), which contain small particles that comprise at least one progestin and at least one protective agent. The protective agent provides effective taste-masking of the progestin due to limited release of the progestin in the... Agent: Bayer Schering Pharma Aktiengesellschaft

20110293721 - Piroxicam-containing matrix patches and methods for the topical treatment of acute and chronic pain and inflammation therewith: This invention relates to matrix patches for the topical (i.e., transdermal) delivery of piroxicam and methods for the treatment of acute and chronic pain and inflammation therewith, particularly pain and inflammation caused by sports injuries or other muscle aches or injuries requiring the application of analgesic and/or anti-inflammation medication, in... Agent: Absize, Inc.

20110293722 - Hydrogel sponges, methods of producing them and uses thereof: A macroporous hydrogel sponge is provided selected from: (i) a synthetic polymer hydrogel sponge, and (ii) a synthetic polymer-polypeptide conjugate hydrogel sponge, the macroporous hydrogel sponge being at least 20% porous and having a pore diameter of 50-1000 μm, wherein said synthetic polymer is crosslinked to an extent determined by... Agent: Techion Research And Development Foundation Ltd.

20110293723 - Synthetic nanocarrier combination vaccines: Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically acceptable excipient.... Agent: Selecta Biosciences, Inc.

20110293725 - Chimeric therapeutics, compositions, and methods for using same: Chimeric therapeutics are disclosed that include a modified viral core protein and a nucleic acid bound to the modified viral core protein. The nucleic acid may be substantially homologous to a specific gene target. In some embodiments, the nucleic acid bound to the modified viral core protein is substantially non-immunogenic.... Agent:

20110293726 - Chimeric therapeutics, compositions, and methods for using same: Chimeric therapeutics are disclosed that include a modified viral core protein and a nucleic acid bound to the modified viral core protein. The nucleic acid may be substantially homologous to a specific gene target. In some embodiments, the nucleic acid bound to the modified viral core protein is substantially non-immunogenic.... Agent:

20110293727 - Chimeric therapeutics, compositions, and methods for using same: Chimeric therapeutics are disclosed that include a modified viral core protein and a nucleic acid bound to the modified viral core protein. The nucleic acid may be substantially homologous to a specific gene target. In some embodiments, the nucleic acid bound to the modified viral core protein is substantially non-immunogenic.... Agent:

20110293724 - Enzyme treatment of foodstuffs for celiac sprue: Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.... Agent:

20110293728 - Photosensitizer-metal nanoparticle complex and composition containing the complex for photodynamic therapy or diagnosis: Provided are a photosensitizer-metal nanoparticle complex and a composition for photodynamic therapy or diagnosis having the same. The complex includes a photosensitizer, a metal nanoparticle, and a backbone linking the photosensitizer with the metal nanoparticle. The backbone has a polypeptide substrate capable of being specifically degraded by a protease. When... Agent: National Cancer Center

20110293729 - Novel composition based on gamma-hydroxybutyric acid: The present invention relates to a granule of gamma-hydroxybutyric acid or of one of its pharmaceutically acceptable salts, characterized in that it comprises a solid core on which the gamma-hydroxybutyric acid or one of its salts is supported.... Agent: Debregeas Et Associes Pharma

20110293731 - Loading of hydrophobic drugs into hydrophilic polymer delivery systems: A process is described for loading hydrophilic polymer particles with a water-insoluble solvent-soluble drug. The particles are preferably embolic agents. The method provides particles having little or no drug at the surface and in a surface layer, whereby the burst effect is minimised. The drug is precipitated in the core... Agent: Biocompatibles Uk Limited

20110293730 - Polylactide nanoparticles: A drug targeting system for administering a pharmacologically active substance to the central nervous system of a mammal across the animal's blood brain barrier. The drug targeting system comprises nanoparticles made of poly(DL-lactide) and/or poly(DL-lactide-co-glycolide), a pharmacologically active substance which is absorbed to, adsorbed to, and/or incorporated into the nanoparticles,... Agent: Lts Lohmann Therapie-systeme Ag

20110293732 - Nanoparticles made of amorphous cellulose: The present invention provides novel nanoscale cellulose particles and also a process for their production. The cellulose-based particles obtained have volume -averaged particle sizes of less than 300 nm. These nanoparticles are produced from amorphous cellulose or by amorphization of cellulose, optional subsequent hydrolysis and by input of energy into... Agent:

20110293733 - Self-assembling nanoparticle drug delivery system: A self-assembling nanoparticle drug delivery system for the delivery of drugs including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the drug, a lipid bi-layer envelope and targeting... Agent:

20110293734 - New plant derived seed extract rich in essentially fatty acids derived from salvia hispanica l. seed: composition of matter, manufacturing process and use: A Salvia hispanica L. derived seed oil extract composition of matter containing from 60-88% PUFAS in a ratio of from 3.1:1-3.3:1 of ALA to LA, 4-10% of C-18 mono-unsaturated fatty acid, 1-5% of C-18 saturated fatty acid and 4-8% of C-16 saturated fatty acid in a mixed triglyceride form stable... Agent: U.s. Nutraceuticals, LLC, D/b/a Valensa International

20110293735 - Composition of pesticide: A composition of pesticide is a composed of banana oil, pepper powder, urea, and milk powder. Banana oil is composed of ethyl acetate, n-butyl acetate, n-butanol, ketone, benzol, and xylene. Banana oil is diluted with water at a proper ratio. Pepper powder is added to banana oil to provide an... Agent:

20110293736 - Feed composition comprising a mineral complex and methods of using the mineral complex: The invention provides a mineral complex comprising about 40 wt. % to about 60 wt. % SiO2, about 6 wt. % to about 16 wt. % Fe2O3, about 4 wt. % to about 12 wt. %. CaO, and about 2 wt. % to about 8 wt. % MgO. The invention... Agent:

20110293737 - Feed composition comprising a mineral complex and methods of using the mineral complex: The invention provides a mineral complex comprising about 40 wt. % to about 60 wt. % SiO2, about 6 wt. % to about 16 wt. % Fe2O3, about 4 wt. % to about 12 wt. %. CaO, and about 2 wt. % to about 8 wt. % MgO. The invention... Agent:

20110293738 - Feed composition comprising a mineral complex and methods of using the mineral complex: The invention provides a mineral complex comprising about 40 wt. % to about 60 wt. % SiO2, about 6 wt. % to about 16 wt. % Fe2O3, about 4 wt. % to about 12 wt. %. CaO, and about 2 wt. % to about 8 wt. % MgO. The invention... Agent:

20110293739 - Feed composition comprising a mineral complex and methods of using the mineral complex: The invention provides a mineral complex comprising about 40 wt. % to about 60 wt. % SiO2, about 6 wt. % to about 16 wt. % Fe2O3, about 4 wt. % to about 12 wt. %. CaO, and about 2 wt. % to about 8 wt. % MgO. The invention... Agent:

20110293740 - Treatment system and method for osteopenia and osteoporosis using non-synthetic bio-available compounds: A treatment system and method for osteopenia and osteoporosis using non-synthetic bio-available hormones, vitamins, minerals, and agents may be customized by varying the dosage and formulation of the components to maximize therapeutic effect, bioavailability, and patient comfort and compliance with their treatment method, the treatment system including a storage unit... Agent:

20110293741 - Acidic oxidant-containing composition having aluminum corrosion-suppressing effect and use thereof: The invention provides a liquid composition containing (a) an acidic oxidant, (b) nitric acid or a salt thereof, and (c) at least one carboxylic acid selected from the group consisting of monocarboxylic acids, dicarboxylic acids, and tricarboxylic acids, or a salt thereof. The liquid composition can be used to disinfect... Agent: Saraya Co., Ltd.

20110293742 - Antibacterial alloy coating composition: An antibacterial alloy coating composition is applied to a surface of a device. The composition comprises an antibacterial material and an alloy. The alloy consists of more than four metallic elements and at least one non-metallic element. The antibacterial material is, for example, copper, silver, or a combination thereof, and... Agent: Industrial Technology Research Institute

20110293743 - Topical acyl glutathione formulations: A method of preventing or treating conditions of peri-menopausal, menopausal, or post-menopausal skin comprising applying to the skin tissue, a safe and effective amount of a composition comprising between 1.0% to 3% by weight of S-palmitoyl glutathione and a dermatologically acceptable carrier.... Agent:

20110293745 - Aurora kinase inhibitors: The present invention provides Compound 1, solid forms thereof, compositions thereof, as Aurora kinase inhibitor for use as an oncology agent. The present invention also provides synthetic methods of preparing Compound 1 and intermediates thereto.... Agent: Sunesis Pharmaceuticals, Inc.

20110293744 - Benzoxazole inhibitors of poly(adp-ribose)polymerase: Inhibitors of poly(ADP-ribose)polymerase having a structure of Formula (I), ways to make them and methods of treating patients using them are disclosed.... Agent: Abbott Laboratories

20110293746 - Modulation of gsk-3beta and method of treating proliferative disorders: There is provided methods and uses for promoting cell death, when combined with chemotherapeutic agents, in an abnormally proliferating cell, and for treating a proliferative disorder in a subject, which methods and uses involve contacting a cell with, or administering to a subject, an agent that modulates glycogen synthase kinase-3β... Agent: Agency For Science, Technology And Research

20110293747 - Colon cleansing solution: The field of colonic diagnostic and surgical procedures is hampered by the lack of optimal means available to cleanse the colon. A compromise between convenient, distasteful, solid or low volume, hyperosmotic solutions which cause considerable fluid and electrolyte imbalances in patients and large volume, difficult to consume, iso-osmotic solutions has... Agent: Braintree Laboratories, Inc.

20110293748 - Combined preparation for treating sepsis: The present invention relates to a method of treating sepsis, systemic inflammatory response syndrome (SIRS), and/or septic shock in a patient. The method comprises administering (a) a pharmaceutical composition comprising a selenium-containing active substance, (b) a pharmaceutical composition comprising a corticoid-containing active substance, and (c) a pharmaceutical composition comprising insulin.... Agent: Biosyn Arzneimittel Gmbh

20110293750 - Activated wnt-beta-catenin signaling in melanoma: The present invention is directed to a method of determining the prospects for survival of a melanoma patient. This method involves providing a biological sample from a patient diagnosed with melanoma, determining the level of an indicator of Wnt/β-catenin activation in the sample, comparing the level of the indicator of... Agent: University Of Washington

20110293749 - Surgical adjuvant composition and associated methods of use: Disclosed herein are surgical adjuvant compositions for ameliorating tissue and cellular necrosis and/or apoptosis. In addition, surgical methods are described which include the use of the adjuvant of the composition to reduce tissue and cellular necrosis and/or apoptosis.... Agent:

20110293751 - Composition for treatment of skin: The present invention provides a composition comprising stearidonic acid (or an ester thereof) derived for example from Echium oil, and an additional lipid (derived for example from calendula oil) which enhances the pro-collagen effects of stearidonic acid. The composition is useful in reducing visible signs of aging of human or... Agent:

20110293752 - Inhibition of angiogenesis and destruction of angiogenic vessels with extracts of noni juice (morinda citrifolia): Noni juice and a protein-free, alcohol precipitate of Noni juice inhibited angiogenesis in in vitro human angiogenesis models. When growth medium contained Noni juice at least over the range from about 2.5% to about 33% (by volume), angiogenesis was blocked. Moreover, Noni juice and an ethanol precipitate were able to... Agent:

20110293753 - Tocotrienol compositions: Compositional formulations are provided that comprise at least one tocotrienol or a derivative thereof, in combination with compounds derived from plant extracts. The compositions can be provided in a functionally acceptable carrier, or separately in a combined regimen. In some examples, the compositions can be effective for reducing, preventing or... Agent:

20110293754 - Anticancer composition containing herbal extract: The present invention relates to the anticancer composition containing an effective amount of herbal extract, and more particularly to the anticancer composition containing an effective amount of extract of Salviae Miltiorrhizae Radix, Chrysanthemum indicum, Acanthopanax senticosus, Cinnamomum cassia Blume, Eucommia ulmoides Oliv., Glycyrrhiza uralensis Fisch, Pueraria thunbergiana Benth, Crataegus pinnatifida... Agent: Dong-a University Research Foundation For Industry-academy Cooperation

20110293755 - Stabilized formulation comprising omega-3 fatty acids and use of the fatty acids for skin care and/or wound care: A stabilized formulation for skin care, wound care and/or other tissue healing applications and methods for making the same is described. The stabilized formulation stabilizes omega-3 polyunsaturated fatty acids and is constituted of the omega-3 polyunsaturated fatty acids in combination with tocopherol (Vitamin E), ascorbic acid (Vitamin C), herb extract,... Agent:

20110293756 - Preventives or remedies for tumor or human papillomaviral disease: A composition for foods or medicaments, containing a fermentation product or an enzyme-treated product that is either obtained by fermenting or treating with an enzyme at least one type of component selected from the husks, pellicles and astringent skin of Coix seeds.... Agent: Kunihide Beppu

20110293757 - Compositions comprising tea tree oil and methods for the prevention and treatment of cancer: Compositions for the treatment and/or prevention of cancer are described. Preferably the composition comprises a therapeutically effective amount of tea tree oil from Melaleuca alternifolia, together with a pharmaceutically or therapeutically acceptable carrier and/or diluent. Methods for the treatment and/or prevention of cancer are also described. Preferably the method is... Agent: Novasel Australia Pty. Ltd.

20110293758 - Method for anti-oxidation, inhibiting activity and/or expression of matrix metalloproteinase, and/or promoting expression of collagen using ixora parviflora leaf extract: A method for anti-oxidation, inhibiting the activity of matrix metalloproteinase (MMP), inhibiting the expression of matrix metalloproteinase, and/or promoting the expression of collagen in a mammal is provided, and the method comprises administrating an effective amount of an Ixora parviflora leaf extract to the mammal.... Agent:

20110293760 - Method for extracting substances from soapberry fruit and seed and products made therefrom: An exclusive manufacturing technique for extracting active interface saponin and organic substances from soapberry; organic elements and oleic alcohol products from soapberry seeds through the process of fermentation and end products made therefrom, wherein the manufacturing process includes: 1. Pre-ferment soapberry fruit (1). 2. Processing said fruit (1) by a... Agent:

20110293759 - Nutritional supplement for recovery, repair, and maintenance: The present invention provides dietary supplement formulations that may be beneficial for developing and strengthening bones and joints. Also provided are methods of treating a bone disease, such as osteoporosis, and methods of strengthening bones and joints by administering the dietary supplements to a subject in need thereof.... Agent: Calitoga LLC